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PREVALENCE OF HEARING IMPAIRMENT AND IMPACT 
ON SOCIETY
Sooner or later many of us will experience a certain degree of hearing impairment 
(HI). HI is the most frequent sensory disorder with 360 millions of affected 
individuals in the world.1 HI refers to a loss in the ability of hearing of more 
than 26 decibels (dB) for the average of four frequencies (0.5, 1, 2 and 4 kHz) 
in the better hearing ear.1 Some consequences of suffering from HI in childhood 
are delayed development of speech, language and cognitive skills. Besides that, 
having HI later in life can result in economic and educational disadvantages, 
social isolation and/or even exclusion. Overall, all these negative consequences 
make HI the 10th disease burden worldwide.1 
 In developed countries, one in 750 newborns presents with bilateral permanent 
HI of more than 40 dB.2,3 About half of the cases is assumed to be caused by 
genetic defects whereas the other half is attributed to environmental factors, e.g. 
exposure to ototoxic drugs and/or viral infections. HI can be classified as non-
syndromic (NSHI) or syndromic (SHI) depending on the absence or presence 
of additional clinical manifestations, respectively. NSHI accounts for 70% of 
childhood hereditary prelingual HI, whereas the other 30% is SHI with more 
than 400 syndromes with HI known to date.4 Autosomal recessively inherited 
NSHI (arNSHI) is the most common form accounting for about 77% of the cases 
with 97 loci and 63 genes known to date. Autosomal dominant NSHI (adNSHI) 
accounts for 22% of the cases with 67 loci and 33 genes known. X- and Y-linked 
and mitochondrial NSHI are uncommon, accounting for the remaining 1% of the 
cases (Figure 1).5
 In developing countries, the prevalence of prelingual HI is higher as compared 
to that in developed countries, being inversely proportional to the gross income.1,3 
Among the leading causative factors we find maternal infections (e.g. rubeola), 
meningitis, birth anoxia, chronic ear infections, use of ototoxic drugs and also 
consanguinity. Siblings of consanguineous marriages display a significantly 
higher incidence of autosomal recessive disorders such as arHI.6
THE EAR AND HEARING PROCESS
Anatomy and physiology of the ear
The ear is an organ that captures the sound waves and converts them into 
electrical signals resulting in sound perception in the central auditory system. 
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Three parts of the ear can be distinguished: the outer ear with the pinna and 
the external ear canal, the middle ear with the auditory ossicles and the inner 
ear with the cochlea and vestibular system (Figure 2). The sound waves are 
captured by the pinna and travel to the middle ear through the external ear canal. 
The outer and middle ear sections are separated by the tympanic membrane 
(ear drum) that starts vibrating upon capture of sound waves. This vibration 
is transmitted by three auditory ossicles, the malleus, the incus and the stapes, 
to the oval window by the stapes footplate movement. The pressure created in 
the middle ear is then relieved by the Eustachian tube that connects the inner 
ear with the nasopharynx, the upper part of the pharynx (Figure 2).7 The oval 
window separates the middle and the inner ear. The inner ear consists of bony 
labyrinths that reside within the temporal bone, the hardest bone of the human 
body. Within these bony labyrinths, the cochlea and the vestibular system are 
located (Figure 2). 
Figure 1: Diagram showing the different types of childhood HI, the attributed causes in developed 
countries and the patterns of inheritance.
Congenital or childhood deafness (1:750):
developed at or shortly after birth
~50%
genetic cause
~50%
other e.g. infections,
prematurity, antibiotics...
~30%
syndromic
~70%
non-syndromic
~77%
recessive
97 loci 63 genes 67 loci 33 genes 6 loci 6 genes
~22%
dominant
~1%
mitochondrial/X-/
Y-linked
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Inner ear
The inner ear is formed from the otic placode, a thickening of the ectoderm, 
during embryonic development. This placode invaginates and closes to form the 
otic vesicle (also called “auditory vesicle” or “otocyst”).8 After multiple rounds 
of cell division, rearrangements, differentiation and apoptotic events, the otic 
vesicle gives rise to the inner ear and cochleovestibular ganglion.9,10
Cochlea 
The cochlea spirals around a conical bony structure called the modiolus. The 
cochlea is divided into three parallel chambers, the scala vestibuli, the scala 
media and the scala tympani, by the Reissner and basilar membranes (Figure 
3). The scala vestibuli is the upper chamber with the oval window at its basal 
part and the helicotrema at its apex.11 The helicotrema is a connection between 
the scala vestibuli and the lowermost chamber, the scala tympani (Figure 3). 
Therefore, both are filled with the same type of fluid, the perilymph. At the 
Figure 2: Schematic illustration of the outer, middle and inner ear parts (Figure published with 
permission of M.W.J. Luijendijk).
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basal part of the scala tympani the round window is located. This round window 
is covered by an elastic membrane and bounces in and out in order to equilibrate 
the pressure created by the sound waves. The scala media contains the actual 
sensory epithelium, the organ of Corti (Figure 3). The scala media is filled with 
endolymph, a unique body fluid rich in potassium. In contrast, the perilymph is 
rich in sodium. The difference in ion concentrations between both scalae creates 
an electric potential (“endocochlear potential”) that is the driving force for hair 
cell depolarization ultimately triggering neurotransmitter release at hair cell 
afferent synapse.
 The organ of Corti in mammals consists of one row of inner hair cells, three 
(sometimes four12,13) rows of outer hairs cells and supporting cells (Figure 3). 
The human organ of Corti is less well organized with one or two rows of 
inner hair cells and less defined ranks of outer hair cells.12 The outer hair cells 
enhance the sound sensitivity and selectivity. The inner hair cells perform the 
transduction and initiate the depolarization of the spiral ganglion.14 The spiral 
Figure 3: Schematic representation of the vertebrate cochlea, the organ of Corti and the inner ear hair 
cell (Figure adapted and published with permission of M.W.J. Luijendijk and 16).
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ganglion is the group of afferent and efferent nerves that send the hearing-evoked 
signals from the inner ear to the central nervous system and back. Supporting 
cells are involved in many different processes, such as the development of 
sensory epithelia and in preserving the structural integrity and homeostasis of 
the sensory organ.15 
 The apical part of the hair cells contains an actin-rich cuticular plate from 
which microvilli extend, the stereocilia (Figure 3). Stereocilia are typically 
arranged in a “V” shape staircase-like pattern. During development of the hair 
bundle, one true microtubule-based primary cilium (the kinocilium) is located 
at the vertex of the V-shape and determines the orientation of the hair bundle 
(Figure 3). The hair bundle on top of the hair cells is embedded in the tectorial 
membrane, a collagen rich extracellular matrix. Sound induces vibration of the 
basilar membrane with the hair cells against the tectorial membrane (Figure 3). 
Therefore, stereocilia bend and potassium and calcium from the endolymph 
enter the cell through the apical cation channels that are mechanically opened, 
this process is called mechanotransduction. As a consequence, the hair cells 
are depolarized and neurotransmitter release is triggered at their synaptic end. 
The potassium ions are recycled back to the endolymph via gap junctions and 
pumps located in the stria vascularis, at the lateral wall of the scala media, and 
in supporting cells (Figure 3) with two different purposes: 1) potassium efflux 
from hair cells leads to their repolarization; 2) potassium efflux prevents the 
cytotoxic accumulation of potassium ions inside the hair cells. Therefore, the 
supporting cells and the stria vascularis play an important role in the maintenance 
of the endolymph composition and therefore the endocochlear potential. 
 As presented, the hearing system and process is highly specialized and complex. 
Therefore, any defect in diverse biological processes such as gene regulation, ion 
homeostasis and hair bundle morphogenesis can lead to HI (Table 1).
Vestibular system 
The vestibular system is the balance organ. It detects both rotational and linear 
accelerations by the semicircular canals and the two otolith organs (the utricle 
and the saccule), respectively (Figure 2).17 As in the cochlea, the stereocilia 
of hair cells in the vestibular system deflect upon a stimulus, resulting in 
depolarisation of the cell and neurotransmitter release to the vestibular nerve. 
The clusters of hair cells in the saccule and utricle are embedded in gelatinous 
(otolith) membranes with small, calcium carbonate crystals called otoconia. The 
saccule and utricle are positioned at an angle of 90 degrees from each other. 
Therefore, any change in head position will lead to the deflection of stereocilia 
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by gravity due to the pushing weight of the otoconia.18 In the semicircular canals, 
the hair cells are embedded in a gelatineous cupula. Rotation of the head results 
in the flow of endolymph within the semicircular canals eventually leading to 
bending of the stereocilia and as a consequence hair cell depolarization.18 The 
balance information from the vestibular system converge with signals from 
other sensory and motor organs making central vestibular processing highly 
convergent and strongly multimodal.17
Table 1: Genes involved in HI, Usher syndrome and Waardenburg syndrome (WS) and the function of 
their encoded proteins in the auditory system.
*METCC stands for mechanoelectrical transduction channel complex of hair cells. Adapted and 
completed from 69.
Protein function in auditory system Protein coding genes
Hair bundle morphogenesis
Cytoskeleton proteins ACTG1, DIAPH1, ESPN, RDX, TRIOBP, CCDC50, CLIC519-22, 
FAM65B23, GRXCR124, SYNE425, DCDC226, EPS 27
Adhesion proteins CDH23, GPR98, USH2A, PTPRQ28, PCDH1529
Motor proteins MYO6, MYO7A, MYH9, MYO15A, MYO3A
Scaffolding proteins DFNB31, USH1C, USH1G, PDZD730
METCC* PCDH1529, LHFPL531,TMIE32, TMC133, TRPN34
Others LOXHD135, miR-9636, 
Extracellular matrix TECTA, COL11A2, STRC, OTOA, COCH, OTOG37, OTOGL38, 
CEACAM1639, COL4A640, 
Ion homeostasis
Connexins GJB2, GJB3, GJB6
Ion channels KCNQ4, SLC26A4, SLC26A5, P2RX241, SLC17A842
Tight junctions CLDN14, ILDR143, MARVELD244, TJP245
Others CRYM, WFS1, ADCY146, CaBP247, CIB248, 
Transcription factors EYA4, POU4F3, POU3F4, ESRRB, GRHL249 
Mitochondrial function MTTS1, MTRNR1, DIABLO50, PNPT151
Sensory synapse structure/
function
CLRN152,OTOF53
Transcription initiation BDP154
Cytotoxic protection SERPINB655
Melanocyte development PAX3, MITF, SNAI2, EDN, EDNR, SOX10, KITLG30
Unknown function TMPRSS3, MYH14, DFNA5, PJVK, ELMOD356, GPSM257, 
GRXCR258, HGF59, KARS43, LRTOMT60, MSRB361, PRPS162, 
SMPX63, TBC1D2464, TSPEAR65, OSBPL266, TMEM132E67, 
GIPC368
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CLINICAL EVALUATION AND DESCRIPTION OF 
HEARING IMPAIRMENT
Hearing of an individual is characterized by two important characteristics of the 
detected sounds, the pitch and the loudness. Pitch is discriminated by the location 
of the sound-elicited vibration in the basilar membrane and it is expressed 
in Hertz (Hz). The proximal end of this membrane near the oval window is 
relatively narrow and stiff and resonates at higher frequencies, whereas the 
apical end is wider and more flexible resonating at lower frequencies. The 
loudness depends on the sound pressure and it is expressed in decibels (dB). The 
higher the loudness, the higher the amplitude, the more vigorously the basilar 
membrane vibrates and thus the further the stereocilia bend leading to a larger 
action potential.70 
There are different tests and steps to evaluate hearing: 
 1.  Otoscopic examination is used to evaluate the ear canal and tympanic 
membrane as well as the nose, nasopharynx and upper respiratory tract.
 2.  Pure tone audiometry means the determination of the hearing thresholds in 
dB for a subset of pure tone frequencies based on two types of tests:
 a.  Air conduction tests evaluate the external auditory canal, the middle ear, 
the functional integrity of the inner ear, eighth cranial nerve and central 
auditory pathways by using an air injection.
 b.  Bone conduction tests use vibrating tuning forks which are placed 
against the skull. These vibrations bypass both the external and middle 
ear sections and therefore it is possible to distinguish between problems 
in those and in the inner ear.
	 3.		Acoustic	 reflex	 testing	 measures	 the	 contraction	 of	 a	 tiny	 ear	 muscle,	 the	
stapedius	muscle,	that	responds	to	stimuli.	The	acoustic	reflex	absence	means	
that there is a defect but it does not give a hint of the source of the problem. 
 4. Tympanometry tests the condition of the middle ear and the ear drum.
 5.  Otoacoustic emissions are sounds generated by the outer hair cells. Therefore 
they can indicate an outer hair cell dysfunction. They are especially robust 
in infants. 
 6.  The auditory brainstem response test is a method to pinpoint the site of 
sensorineural HI. Electrodes are placed on the scalp and sounds are 
presented resulting in different wave forms. The wave pattern can reflect 
different conditions such as lesions in the eighth cranial nerve or brainstem.
By using these tests, HI can be well characterized as seen in Table 2.
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Table 2: Characteristics of the clinical description of HI (http://hereditaryhearingloss.org/).
Classification of HI Explanation
Type Conductive Defects in the external and/or middle ear. Characterized 
by an air-bone gap >15 dB HI averaged over 0.5, 1 and 2 
kHz, with normal bone conduction thresholds
Sensorineural Defects in the inner ear structures or cochlear nerve. 
Characterized by bone conduction thresholds > 20 dB HI 
with an absent or <15 dB HI air-bone gap, averaged over 
0.5,1 and 2 kHz
Mixed Conductive and sensorineural. Characterized by bone 
conduction thresholds >20 dB HI and air-bone gap >  
15 dB HI averaged over 0.5, 1 and 2 kHz
Severity of HI in the better 
hearing ear, averaged over 
0.5, 1, 2 and 4 kHz
Mild 20-40 dB HI 
Moderate 41-70 dB HI 
Severe 71-95 dB HI
Profound >95 dB HI
Frequency ranges Low ≤ 0.5 kHz
Mid >0.5 kHz and ≤ 2 kHz
High >2 kHz and ≤ 8 kHz
Symmetry of HI Bilateral The average of 0.5, 1 and 2 kHz of both ears > 20 dB HI
Asymmetrical >10 dB HI difference between the ears in at least two 
frequencies
Age of onset Prelingual HI presents before speech develops
Postlingual HI presents after the normal speech has developed
Table adapted and published with permission of E. Van Beelen.
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NON-SYNDROMIC HEARING IMPAIRMENT 
HI is called non-syndromic when it is not associated with additional symptoms 
other than vestibular problems.71 NSHI accounts for around 70% of the inherited 
childhood cases. It is mostly sensorineural and shows different modes of 
inheritance as shown in Figure 1. Loci are designated with a DFN (DeaFNess) 
number which indicates the order of discovery. DFN is followed by an “A” for 
autosomal dominant, “B” for autosomal recessive, “X” for X-linked, and “Y” 
for Y-linked inheritance. “DFN” only is employed for mitochondrial inheritance. 
As shown in Figure 1, NSHI is genetically very heterogeneous which can be 
explained by the complexity of the auditory system (Table 1 and Figure 2). 
 ArNSHI is the most common form of HI accounting for 77% of the 
inherited non-syndromic cases. ArNSHI is typically congenital/prelingual, 
non-progressive, and mild to profound. Therefore, except for some specific 
phenotypes such as the downsloping progressive audiogram associated with 
TMPRSS3 mutations,71,72 the flat stable audiogram configuration caused by 
mutations in TECTA71 and the late-onset HI with a progressive component in 
some cases,71 it is very difficult to pinpoint a causative gene based on audiogram 
configuration. To date, there are 62 genes known to be associated with arNSHI, 
eight of which can be also associated with adNSHI by allelic variants. Mutations 
in GJB2 are the major cause for arNSHI worldwide.73 The c.35delG mutation 
homozygously accounts for half of the arNSHI cases with southern European 
ancestry.74 As it is reported in chapter 7, mutations in MYO15A and STRC are 
a frequent cause of arNSHI in the Netherlands. Also, mutations in USH2A 
frequently explain the congenital HI of Dutch cases who later in life develop 
retinitis pigmentosa. The involvement of these three genes worldwide might 
be underestimated due to the following reasons: 1) MYO15A (NM_016239, 65 
exons) and USH2A (NM_206933, 72 exons) are very large genes and therefore 
not routinely analysed in non-syndromic early onset cases; 2) Sequencing of 
STRC can be hampered due to the close proximity of a pseudogene of more than 
99% identity.
 AdNSHI accounts for the remaining 22% of the non-syndromic cases. Clinically, 
adNSHI is usually progressive except for mutations in DFNA6/14/38,75-78 part 
of DFNA8/12 cases,79 DFNA23,80,81 DFNA 2482 and DFNA5983 which result in a 
prelingual phenotype. DFNX, DFNY84 and DFN types are very rare and account 
for around 1%. 
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SYNDROMIC HEARING IMPAIRMENT
 
SHI accounts for about 30% of the cases of congenital inherited HI with more 
than 400 syndromes characterized to date.4 In this thesis, the most prevalent 
autosomal dominant and recessive syndromes, Waardenburg and Usher 
syndromes, respectively, are discussed. 
Usher syndrome
Usher syndrome is a dual sensory impairment since affected individuals are 
born with sensorineural HI and develop retinitis pigmentosa later in life, which 
is often not apparent till adolescence. Visual symptoms are initially night 
blindness and loss of peripheral vision. Three clinical types of Usher syndrome 
are distinguished based on the severity of the HI and on the presence or absence 
of vestibular dysfunction. Type 1 is characterized by congenital severe to 
profound HI with vestibular areflexia; type 2 presents with congenital moderate 
to severe HI and normal vestibular function; and type 3 is characterized by 
progressive HI as well as, occasionally, progressive deterioration of the 
vestibular system.85 Usher syndrome is genetically very heterogeneous as well 
with 13 loci known for which 10 genes have been identified to be involved 
in the three clinical types of the syndrome.86 Mutations in six of these genes, 
MYO7A,87-90 CDH23,91,92 PCDH15,93,94 DFNB31,95,96 USH1G97 and CIB2,48 can 
lead to either Usher syndrome or NSHI. Mutations in USH2A can lead to either 
Usher syndrome or non-syndromic retinitis pigmentosa.98,99
Waardenburg syndrome 
Waardenburg syndrome (WS) is a dominantly inherited auditory-pigmentary 
syndrome caused by partial absence of melanocytes in the skin, hair, eyes 
and stria vascularis of the cochlea.100 Four clinical types are recognized based 
on the presence of specific features in addition to pigmentary abnormalities 
of hair, skin, eyes and congenital HL as in WS II. WS I is characterized by 
the presence of dystopia canthorum. WS I and II account for the majority of 
the cases, with an estimated prevalence of 5-10:100,000. Whereas 90% of WS 
I cases are explained by mutations in PAX3,101 only 15% of WS II cases are 
explained by mutations in MITF, SOX10 and SNAI2. 100,102-104 Rarely, upper 
limb abnormalities and Hirschsprung disease can be part of the syndrome for WS 
III and IV, respectively. So far, mutations in PAX3 can explain WS III105 whereas 
mutations in EDN, EDNR and SOX10 can be causative of WS IV.106-108 All WS 
genes are involved in neural crest stem cell-derived melanocyte development.109 
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 STRATEGIES FOR DISEASE GENE IDENTIFICATION
 
HI is a genetically very heterogeneous disorder. Before the era of Next Generation 
Sequencing (NGS) technologies, a popular gene identification approach was to 
combine linkage analysis or homozygosity mapping with Sanger sequencing 
of the most promising candidate genes in the linkage interval. This approach 
has been successfully followed in chapters 2, 3 and 4. However, the size of 
the linkage region can hamper disease gene identification by this approach 
(as we see in chapters 5 and 6) and, therefore, we combined linkage analysis 
with Whole Exome Sequencing (WES). 
 In the following paragraphs the strategies for disease gene identification that 
were employed for the research described in this thesis will be discussed.
Single Nucleotide Polymorphism (SNP) arrays 
SNP arrays are powerful tools to identify regions in the genome that segregate 
with the disease according to a certain mode of inheritance.110 Therefore, with 
SNP genotyping the chromosomal region which contains the genetic defect and 
co-segregates with the disease in the family relative to a SNP, whose the genomic 
position is already known, will be identified. SNPs are genomic variations 
presenting in two distinct alleles, each being common in the population 
(> 1%). After the disease haplotypes are determined, evaluation and sequencing 
of the plausible candidate genes within the candidate genomic regions will 
be performed in order to find the genetic cause underlying the disease.111 
The size of these candidate regions is inversely proportional to the number of 
meiosis available (Figure 4).
Homozygosity mapping and shared genotype determination
In autosomal recessive disorders, an affected individual carries mutations in both 
alleles of a single gene located on an autosome in order to be affected. If these 
mutations are identical, they are called homozygous.111 When they are different, 
they are called compound heterozygous.38 Homozygosity mapping and shared 
genotype calculations are based on the same principle: identification of shared 
genotypes in affected individuals, which are different in unaffected individuals 
within the same family. Therefore, the higher the resolution of the SNP array is, 
the more precise the determination of the disease haplotype will be. 
 When a homozygosity mapping strategy is used, the assumption is that 
the disease haplotypes are homozygous. This strategy has been proven to be 
successful in more than 50% of the cases in a population with high consanguinity 
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Figure 4: Schematic representation of the inheritance of recessive mutations. A. In consanguineous 
families, a recent common ancestor likely spreads the mutation. Due to the limited number of 
generations between the ancestor and the affected individual, a large fraction of the ancestral haplotype 
is inherited. B. When the number of generations between the ancestor and the affected individual, and 
thus the number of meiosis and recombination events, increases, a smaller fraction of this haplotype 
is inherited. C. In mixed populations, the patient often inherits two different heterozygous recessive 
alleles at a particular locus. The “cM” abbreviation stands for centiMorgans (Figure adapted and 
published with permission of K.L. Littink).
Homozygous region 20-40 cM
Homozygous region 1-7 cM
Ancestor
Year
1650
1750
1800
1900
2014
Patient
Patient
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C
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rates (Figure 4).112 In presumably mixed populations, e.g. in the Netherlands, 
homozygosity mapping can also determine disease haplotypes inherited from a 
(distant) common ancestor (Figure 4).113 
 Determination of shared genotypes should be especially considered in mixed 
populations where individuals can move easily or choose a partner freely. In 
this case, the assumption is that the disease haplotypes segregating with 
the recessive disease are not necessarily homozygous, but it could also be 
heterozygous (Figure 4).
Linkage analysis 
Linkage analysis has been very successful in localization of (novel) disease 
genes in autosomal dominant (chapter 5), recessive (chapter 6) and X-linked 
disorders.114 In autosomal dominant disorders, an affected individual carries 
a mutation in one of the two alleles of the disease gene. This mutation can 
show full or reduced penetrance. Linkage analysis is a statistical method for 
identification of haplotypes segregating with the disease in a family. In contrast 
to homozygosity mapping and ‘shared genotyping’, linkage analysis does 
not require high density SNP arrays, but it requires SNPs that are in linkage 
disequilibrium. Linkage analysis also requires the availability of accurate 
pedigrees and SNP allele frequencies, which can be difficult to infer from the 
general population. Besides, linkage analysis can also be handicapped by the 
size of the families. When the family is small, the chromosomal regions that 
segregate with the disease are usually numerous and they will not reach genome-
wide significance. When the family is large, the linkage region is likely to reach 
genome-wide significance however powerful computers are essential for the 
LOD score calculations. In order to circumvent these problems, several methods 
such as approximate linkage and haplotyping have been developed and shown to 
be successful as well as more user-friendly.115,116 
Next generation sequencing technologies
DNA sequencing has evolved tremendously since 1977, when the enzymatic 
dideoxy Sanger sequencing technique was introduced.117 Sanger sequencing 
technology provides the ultimate resolution for detecting genetic variation, 
however, it is difficult to scale-up, generally allowing only 96 or 384 analyses 
in parallel. This makes the technique time-consuming as well as expensive, 
at a cost of roughly $500 per Mega base (Mb).118,119 In 2010, NGS or massive 
parallel sequencing revolutionized the genetics field allowing the detection of 
any kind of genetic variation by sequencing millions of DNA fragments in a 
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single experiment.120-122 One NGS application is WES. The exome comprises 
only 1% of the human genome. Despite this, the exome harbours 85% of the 
disease causing mutations known to date.123 Therefore, WES has the potential 
to unravel the causes in large numbers of rare as well as common genetic 
disorders.124 As previously described, HI is genetically very heterogeneous and 
complex, not only because numerous genes and loci are described but also due to 
the presence of modifier alleles.125,126 In the past years, research towards HI gene 
identification has benefited significantly from WES; however, for about 40% 
of the known loci, the causative gene is still elusive. On the other hand, WES 
does not cover non-coding parts of the genome and parts of the exome that are 
not targeted by the enrichment kits. WES also fails to define the boundaries of 
complex insertions, deletions, translocations and inversions. With whole genome 
sequencing (WGS) technologies, these drawbacks are expected to be relieved. 
Thus, WGS is considered to be the most accurate method to date.123,127 
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SCOPE AND OUTLINE OF THIS THESIS
HI is the most common sensory disorder that has a very negative impact 
on the quality of life of patients in our current society that relies on rapid 
communication. To date, many different genetic factors have been associated 
with HI, however, for a significant proportion of cases the genetic defects are 
still elusive. Therefore, the goal of my thesis was to contribute to the genetics 
of HI by the identification of mutations in known and novel genes involved in 
HI by using SNP array genotyping, WES and Sanger sequencing. Results are 
presented in the following chapters:
	 •		Chapter 2 describes the identification of a novel arNSHI gene, OTOGL, 
which is involved in congenital mid frequency HI.
	 •		Chapter 3 describes a homozygous nonsense mutation in CLIC5 as a novel 
cause of congenital and progressive arNSHI accompanied by vestibular 
dysfunction.
	 •		Chapter 4 reports on novel and known mutations in CIB2 causative of 
arNSHI and addresses their functional effects.
	 •		Chapter 5 describes the first gene involved in familial NS-unilateral and 
asymmetric HI (NS-UHI/AHI) and establishes a new phenotype-genotype 
correlation for mutations in KITLG in NS-UHI/AHI and WS II.
	 •		Chapter 6 describes a new syndrome characterized by HI, dystonia and 
sensory neuropathy caused by a homozygous nonsense mutation in FITM2. 
Besides, it provides the results of modeling the disease in Drosophila 
melanogaster by using the UAS-Gal4 system which recapitulated the human 
phenotype.
	 •	 Chapter 7 reports on the clinical characterization and results of WES of 200 
cases with HI.
	 •		Chapter 8 presents the general discussion of this thesis.
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ABSTRACT
Hereditary hearing loss is characterized by a high degree of genetic heterogeneity. 
Here we present OTOGL mutations, a homozygous one base pair deletion 
(c.1430delT) causing a frameshift (p.Val477Glufs*25) in a large consanguineous 
family and two compound heterozygous mutations, c.547C>T (p.Arg183*) and 
c.5238+5G>A, in a non-consanguineous family with moderate non-syndromic 
sensorineural hearing loss. OTOGL maps to the DFNB84 locus at 12q21.31 and 
encodes otogelin-like, which has structural similarities to the epithelial-secreted 
mucin protein family. We demonstrate that Otogl is expressed in the inner 
ear of vertebrates with a transcription level that is high in embryonic, lower 
in neonatal and much lower in adult stages. Otogelin-like is localized to the 
acellular membranes of the cochlea and the vestibular system and to a variety 
of inner ear cells located underneath these membranes. Knocking down of otogl 
with morpholinos in zebrafish leads to sensorineural hearing loss and anatomical 
changes in the inner ear, supporting that otogelin-like is essential for normal 
inner ear function. We propose that OTOGL mutations affect the production 
and/or function of acellular structures of the inner ear, which ultimately leads to 
sensorineural hearing loss. 
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INTRODUCTION
Hereditary hearing loss is characterized by genetic heterogeneity with mutations 
in several hundreds of genes encoding a variety of proteins1-3. Mutations in these 
genes lead to various clinical scenarios ranging from non-syndromic hearing 
loss to one of the more than 400 syndromes that include hearing loss and 
from mild adult onset hearing loss to profound congenital deafness spanning 
a full-spectrum of Mendelian inheritance1,2. The autosomal recessive pattern 
of inheritance occurs in the majority of families with Non-Syndromic Hearing 
Loss (arNSHL) and is typically congenital or prelingual-onset2. Mutations in 
40 genes have thus far been shown to cause arNSHL, which can account for 
more than 60% of families with this type of inheritance pattern3. Hearing loss 
is usually severe or profound in cases with arNSHL, although varying degrees 
of residual hearing are observed in some families. Individuals with mutations 
in STRC (MIM 606440), for example, essentially present with moderate hearing 
loss4 and 22% of the persons with mutations in the DFNB1 locus have moderate 
deafness5.
 In this study we report mutations in OTOGL, encoding otogelin-like, that are 
associated with moderate arNSHL. We demonstrate that OTOGL is expressed 
in the inner ears of humans, mouse, rat, and zebrafish, and its disruption in 
zebrafish leads to hearing loss. 
MATERIALS AND METHODS
Studied Families 
The study on hereditary deafness was approved by the Ethics Committees of 
Ankara University (Turkey) and the Radboud University Nijmegen Medical 
Centre (the Netherlands), and by the IRB at the University of Miami (U.S.A.). 
Informed consents were obtained from all participants, or in the case of minors, 
from the parents. Diagnosis of sensorineural hearing loss was established via 
standard audiometry in a sound-proofed room according to current clinical 
standards. Hearing loss was classified according to the GENDEAF guidelines 
(hereditary hearing loss home page). Evaluation for vestibular function 
included Unterberger, Romberg, head thrust, and head shake tests, oculomotor 
examination, spontaneous nystagmus and positioning tests, and bithermal caloric 
tests via vidoeonystagmography (VNG, Micromedical Technologies, Illinois 
U.S.A.). Slow Component Velocity (SCV) of the nystagmus was measured 
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with a threshold of 6 degree per second. Clinical evaluation of all affected 
individuals by a geneticist and an ENT surgeon included a thorough physical 
examination and otoscopy. A high resolution CT scan of the temporal bone was 
obtained in one affected person in each family. The studies presented here were 
performed in two families: Family 1, a consanguineous Turkish family with 
four children (Figure 1A) and Family 2, a non-consanguineous Dutch family 
with three children having sensorineural hearing loss (Figure 1D). DNA was 
extracted from blood via standard methods. One affected individual from each 
family was prescreened and found not to have common causes of non-syndromic 
deafness including mutations in GJB2 (MIM 121011) and for the m.1555A>G 
mutation in MTRNR1 (MIM 561000). 
Autozygosity Mapping
Genome-wide SNP genotyping was performed via Affymetrix 6.0 and Illumina 
Human Omni Express 700K arrays in Families 1 and 2, respectively. Autozygosity 
mapping was performed as reported previously6,7. The co-segregation of the 
genotypes for each previously reported deafness gene was visually evaluated. 
Multipoint linkage analysis of an autozygous segment was conducted with 
GeneHunter8, assuming a fully penetrant autosomal recessive phenotype with 
population frequency for the hearing loss allele of 0.0001. SNPs spanning 
the autozygous region were chosen for linkage analysis based on tagging and 
heterozygosity in the parents. Copy number variants (CNVs) were assessed by 
determining the relative loss or gain of fluorescent signal intensity from SNP or 
CNV probes on the array as previously described6.
Whole Exome and Sanger Sequencing 
The Agilent SureSelect Human All Exon 50 MB kit was used with an Illumina 
HiSeq 2000 instrument. Adapter sequences for the Illumina HiSeq2000 were 
ligated and the enriched DNA samples were subjected to standard sample 
preparation for the HiSeq2000 instrument (Illumina). Paired-end reads of 100 
bases length were produced. The Illumina CASAVA v1.8 pipeline was used 
to produce 99 bp sequence reads. BWA9 was used to align sequence reads to 
the human reference genome (hg19) and variants were called using the GATK 
software package10. All variants were submitted to SeattleSeq135 for further 
characterization. 
 All 58 exons and exon-intron boundaries of OTOGL (NM_173591.3) were 
screened via Sanger-sequencing (detailed in Supplemental Table S1). To screen 
additional families for linkage to the OTOGL locus, eight SNPs within the gene 
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were chosen, custom TaqMan probes were developed, and assayed according 
to the manufacturer`s protocol Data were analyzed via SDS 2.3 (Applied 
Biosystems) software. 
Minigene Construction and Splicing Assay
For prediction of the effect of the c.5238+5G>A transition on splicing efficiency, 
the following software tools were used: NetGene11, BDGP Splice prediction 
site12 and Human Splice Finder (Alamut; Interactive Biosoftware). 
 The splicing assay for the c.5238+5G>A mutation was performed using the 
pCIneo vector described by Gamundi et al. containing exons 3-5 of RHO13, 
which was adapted for the Gateway cloning system by replacing exon 4 and 
flanking sequences by a Gateway cassette using the EcoNI and PflMI sites of 
the vector. A fragment containing exon 43 and 225 and 126 bp respectively of 
5’and 3’flanking sequences of OTOGL was amplified from genomic DNA of 
one of the parents of Family 2 and clones for the wild type and the mutant alleles 
were selected after sequencing. Primers used for amplification of the fragment 
are provided in Supplemental Table S2. Transfection of HEK293T cells with the 
plasmids, isolation of RNA, and RT-PCR were performed as described14. The 
RHO and OTOGL exons were amplified from the cDNA with forward primer 5’- 
cggaggtcaacaacgagtct-3’ and reverse primer 5’-aggtgtaggggatgggagac-3’, which 
are located in RHO exon 3 and exon 5, respectively. The assay was performed in 
triplo in two independent experiments. The RT-PCR fragments were sequenced 
to verify normal splicing and exon skipping. 
OTOGL Expression Profile by Quantitative PCR in Humans 
RNA derived from various adult tissues as well as from fetal liver was 
purchased from Clontech. In addition, RNA was isolated from fetal inner 
ear, heart, skeletal muscle, and lung as described previously15. cDNA was 
synthesized as previously described15 and purified with NucleoSpin Extract II 
columns (Macherey-Nagel) in accordance with the manufacturer’s protocol. For 
PCR, specific primers (Supplemental Table S2) were designed with Primer3 
Plus and reference sequence NM_173591.3. Amplifications were performed 
with the Applied Biosystem Fast 7900 System in accordance with the 
manufacturer’s protocol. The human beta glucuronidase gene (GUSB; MIM 
611499) was employed as an internal reference. PCR reaction mixtures were 
prepared with the Power SYBR® Green Master Mix (Applied Biosystems) 
in accordance with the manufacturer’s protocol. Temperatures and reaction 
times for PCR were as follows: 10 min at 95°C, followed by 40 cycles of 
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15 sec at 95°C and 30 sec at 60°C. All reactions were performed in 
duplicate. Relative gene expression levels were determined with the delta delta 
Ct method as described previously16.
Otogl Expression by Semi-Quantitative RT-PCR in Mice 
Otogl transcript levels in different developmental stages of mouse inner 
ear were evaluated by semi-quantitative RT-PCR. All the procedures were 
approved by the Institutional Animal Care and Use Committee of the 
Massachusetts Eye and Ear Infirmary. Mouse cochleae were dissected 
from CD1 mice at different stages. RNA extractions were performed using 
Trizol reagent (Life Technologies). Reverse transcriptase reactions were 
performed using SuperScript II (Life Technologies), and PCR reactions 
using Taq polymerase (Life Technologies). The PCR primers are given in 
Supplemental Table S2. PCR conditions were: 94°C, 2 min; 94°C, 30 sec; 62°C, 
1 min; 72°C, 1 min 30 sec for 40 cycles; 72°C, 10 min. Gene expression was 
normalized to GAPDH expression.
Rodent Immunohistochemistry and in situ Hybridization
CD1 mouse inner ear tissues from timed pregnancy were collected following an 
established procedure. The procedure in the use of animals and tissue preparation 
were approved by the Institutional Animal Care and Use Committee of the 
Massachusetts Eye and Ear Infirmary and of the Radboud University Nijmegen. 
Standard immunohistochemical procedures were used for the labeling of 
cryosectioned mouse cochlear slides, with the antibodies against the following 
antigens: OTOGL (1:150, Atlas Antibodies, HPA040364), SOX2 (1:200, Santa 
Cruz, sc-17320), MYO7A (1:1000, Developmental Studies Hybridoma Bank, 
MYO7A 138-1). The nuclei were labeled with DAPI (1X , Molecular Probe).
 For the preadsorption control experiment, the OTOGL antibody was incubated 
with 10-fold excess (relative to antibody concentration) of OTOGL antigen (Atlas 
Antibodies, HPA040364, dissolved in 1M urea and 1x PBS) at room temperature 
for 2 hours. The mixture was spun at 16,000 g for 20’, and the supernatant 
was used for immunofluorescence. The MYO7A antibody was also mixed with 
OTOGL antigen/antibody on the same condition and the MYO7A staining was 
not different from the pattern using the non-treated MYO7A antibody. The 
image acquisition conditions were identical for all immunolabeling results.
 Temporal bones of P10, P20, and P30 Wistar rats were fixed in 2% buffered 
paraformaldehyde, before dissection of the cochlea and vestibular structures. 
For these cryosections, the OTOGL antibody was 1:50 diluted and Alexa Fluor 
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568 labeled phalloidin (1:400; Life Technologies) was added for actin staining. 
The nuclei were labeled with DAPI (1X , Molecular Probe) and for controls, 
the primary antibody was omitted. Sections were examined with a fluorescence 
microscope. In addition, 2% paraformaldehyde fixed whole mount organs of 
Corti of P12 rats were incubated with anti-otogl (1:50), phalloidin (1:400) 
and DAPI (1:8000) as previously described17 and analyzed with a confocal 
microscope. 
 For in situ hybridization the same sample preparation for mouse inner ear 
tissue was used as in immunohistochemistry. The protocol used was identical to 
the one described previously18.
Zebrafish otogl Identification, Cloning, in situ Hybridization and 
Immunohistochemistry
Zebrafish (Danio rerio) were raised and handled following standard techniques19 
approved by the Institutional Animal Care and Use Committee of the University 
of Miami. Embryos from wild-type AB stock were used for gene cloning, 
and enhancer trap transgenic line SqET420 expressing GFP in hair cells for 
expression analysis and physiology. We identified the zebrafish homolog of 
the human OTOGL by sequence similarity and synteny analysis. The human 
OTOGL protein sequence NP_775862.3 was used to query the zebrafish genome 
version-9 by BLAT using VEGA Genome Browser (release 46), the manually 
curated zebrafish genomic database. Two high-scoring genomic loci were 
recovered, dkeyp-27b10.2, a predicted otogl gene (BX321877.7) on chromosome 
18 and (BX842701.1-201) on chromosome 7 that encodes zebrafish otog. 
Separately, linkage analysis of the zebrafish genes to ptprq, a deafness gene 
that in humans is closely linked to OTOGL7,21, showed that only dkeyp-27b10.2 
is closely associated to the zebrafish ptprq. Based on sequence and synteny 
evidence we established the zebrafish gene on chromosome 7 as the ortholog 
of human OTOG on chromosome 11, and dkeyp-27b10.2 on chromosome 18 as 
the ortholog of human OTOGL on chromosome 12. The zebrafish nomenclature 
committee reviewed and approved these name designations, assigning the 
Zebrafish Information Network (ZFIN) number ZDB-GENE-120228-1 to 
otogelin (otog) and ZDB-GENE-050419-93 to otogelin-like (otogl).
 An 800 base pair region of zebrafish otogl near the center of the gene 
that was devoid of repetitive protein domains was cloned using an RT-PCR 
strategy. Nested primers were designed using the zebrafish genome assembly 
version-9. cDNA from 48 hpf embryos was PCR-amplified with Taq polymerase 
(Promega) and primer set 5out-otogl, TGGAGGAAGGAGTCTGCT and 
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3out-otogl, CACGGTCACAGGTGCATT. A second round of amplification 
used inner primers 5in-otogl, GAGTCTGCTGTCCCAAGA and 3in-otogl, 
CAACCGCAGTCTCCATAC. The PCR cycling parameters used for both 
reactions was: 94°C, 2 min, 1 time; 94°C, 30 sec, 60°C, 1 min, 72°C, 2 min, 
35 times; 72°C, 10 min, 4°C, hold, 1 time. PCR product was gel purified, and 
ligated to pGEM-T Easy (Promega) using manufacturer’s instructions. Eight 
clones were sequenced to verify identity of inserts. One plasmid containing the 
correct insert was linearized and in vitro transcribed to generate DIG-labeled 
RNA to use as a probe. Whole mount in situ hybridization was carried out as 
previously described22, with the following modification: prior to developing 
the chromogenic reaction with Fast Red substrate (Roche), embryos were 
immunostained to detect GFP expression in ear hair cells. 
 Immunodetection of GFP and acetylated-tubulin in zebrafish embryos was 
done following a previously described protocol23. Anti-GFP (Anaspec) and Anti-
acetylated tubulin (Santa Cruz Biotechnology) were used as primary antibodies 
and an Anti-rabbit Alexa488-conjugated antibody as a secondary antibody (Life 
Technologies). Actin was detected using Alexa568-conjugated phalloidin (Life 
Technologies). Immunostaining and in situ hybridization were performed via 
standard methods23.
Zebrafish otogl Morpholino Knock-down
To generate zebrafish larvae lacking otogl function, we first identified the 
gene’s intron/exon junctions by comparing Otogl protein sequence XP_683212 
to the otogl genomic region of VEGA. We designed two splice-blocking 
morpholinos against exon/intron junctions 36 and 37 found at the 3’ half of the 
gene because the gene’s 5’ end is poorly annotated. Missplicing events at these 
locations were predicted to generate truncated proteins lacking the last von 
Willebrand Factor (vWF)/cytokine rich paired domains and C-terminal cysteine 
knot domain. The two splice-blocking morpholinos (GeneTools, LLC) are MO1 
GATGCACACACACACTGACCGCAGA against exon/intron junction 36 and 
MO2 CATCCTGAGGAAAGGAGGGTAACAC against exon/intron junctions 
37. The efficacy of otogl knockdown by each morpholino was assessed by RT-
PCR analysis of morpholino-induced intron retention. Total RNA was extracted 
from 3-day old embryos using Trizol (Life Technologies), and treated with Turbo 
DNase (Ambion). 500 ng of purified RNA was reverse transcribed to cDNA 
using an anchored oligodT primer and Superscript III (Life Technologies). 1 
µL of cDNA was then used as template for a PCR reaction with diagnostic 
primers TACCACAGCACTGGCATCAT and TTCCTCCAGCTGAAGCAGAT 
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that span the exon/intron junctions targeted by the morpholinos. Primers 
against an unrelated gene, the glycine receptor β sub-unit (glrbb) serves as a 
loading control. Morpholinos were titrated to determine the lowest dose that 
induced missplicing events. Physiology and molecular biology were carried out 
on embryos injected with 2-5 nL of 0.25 mM otoglMO1 or 2. For phenotypic 
assessment, otogl MO-injected larvae were compared to stage-matched 
larvae injected with the same concentration of a standard control morpholino 
CCTCTTACCTCAGTTACAATTTATA (GeneTools, LLC). Both otogl 
morpholinos produced similar phenotypes that include severe cardiac edema 
and, at higher doses, curvature to the body axis. 
Microphonic Potential Recording in Zebrafish
The microphonic potential recording from larval zebrafish was modified from 
previously described protocols24,25. Morpholino-injected zebrafish at 2 or 3 dpf 
were anaesthetized in 0.01% buffered MS-222 solution and embedded dorsal up 
in 1.8% agarose with 0.01% buffered MS-222 in a low profile 35-mm MatTek 
dish. The MatTek dish was then placed in a QE-1 platform (Warner Instruments, 
Hamden, CT) that was temperature controlled at about 28.5 oC on a Gibraltar 
stage of Zeiss Axioskop 2 FS plus microscope. The Zeiss microscope setup 
rested on an anti-vibration table and enclosed in a Faraday cage (Technical 
Manufacturing Co., Peabody, MA). 
 A stimulus probe with the tip size of 20 µm in diameter was made from a 
glass capillary (OD = 1.50 mm, ID = 0.84 mm, World Precision Instruments, 
Sarasota, FL) using a micropipette puller (P97, Sutter Instrument Co., Novato, 
CA) and a microforge (MF-900, Narishige International USA, East Meadow, 
NY). The stimulus probe was driven by a piezoelectric actuator and calibrated 
using a high-speed camera. The probe tip was placed against the posterior edge 
of the inner ear (pointing to the saccular otolith) and provided linear oscillatory 
motion at 200 Hz along an axis parallel to the longitudinal axis of fish body. 
 The recording electrodes were made from glass capillaries (OD = 1.5, ID = 
1.12 mm, WPI), filled with standard fish saline solution (pH = 7.2) and then 
sharpened with a Sutter BV-10-E micropipette beveler until the electrode 
resistance dropped to about 6 MΩ. The recording electrode tip was advanced to 
penetrate the wall of the inner ear of larval zebrafish using a Narishige MHW-
3 three-dimensional hydraulic micromanipulator. Microphonic responses were 
amplified 1,000x, bandpass filtered between 0.1 and 3000 Hz, averaged up to 200 
times, and recorded at a sampling rate of 25 kHz. The amplitude of microphonic 
responses (RMS) was measured at twice the stimulus frequency in FFT plots. 
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Student’s t-test was performed to determine the significance of differences in 
microphonic amplitude between otogl morphants and larvae injected with a 
control morpholino.
RESULTS 
OTOGL Mutations Cause Moderate Sensorineural Hearing Loss in 
Humans
In Family 1, all four affected individuals had symmetric moderate sensorineural 
hearing loss. Available audiograms did not show progression (Figure 1B). 
Clinical examinations did not reveal additional findings. CT scan of the temporal 
bone of one affected family member was normal as well. Detailed vestibular 
analyses were performed in one individual, II:7, who complained about one 
episode of dizziness lasting for 3 months at age 17. He described it as a blurry 
vision caused by turning his head abruptly to the left and lasting for only a 
few seconds. There were no other symptoms such as vertigo. Vestibular tests 
revealed vestibular hypofunction on the left side via caloric tests. All positional 
tests produced persistent up-left non-torsional nystagmus with the average of 7 
degrees per second without vertigo sensation. 
 Only one autozygous genomic region larger than 1 Mb was shared by all four 
affected members of Family 1. The length of this autozygous region was 15 Mb on 
chromosome 12 (68,804,480 bp-83,923,162 bp) and included the DFNB84 locus 
(Figure 1A). The autozygous region contains 51 RefSeq genes including PTPRQ 
(MIM 603317), which was recently found to be associated with arNSHL7,21. A 
multipoint LOD score of 3.36 was obtained for this region. Sanger-sequencing 
of the exons and intron-exon boundaries of PTPRQ (NM_001145026.1) in 
one affected member did not show a mutation. None of the other previously 
identified deafness genes mapped to an autozygous region suggesting that a 
previously unrecognized human deafness gene was involved in this family.
 We then performed whole exome sequencing in individual II:7, which 
generated 177,257,596 reads. Using a minimum depth of 4x, 84% of the 
targeted regions were covered with an average read depth of 100x. The 
longest autozygous region on chromosome 12 was fully covered by SureSelect 
Human All Exon 50 Mb kit except for PTPRQ which was Sanger-sequenced 
in Family 1. After multiple filters were employed (Table 1), whole exome data 
revealed two novel homozygous variants both located in OTOGL (hg19): a 
one base pair deletion at 80,648,835, c.1430delT (NM_173591.3) predicted to 
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cause a reading frame shift and a premature termination of protein synthesis, 
p.Val477Glufs*25 (NP_775862.3) and 80,717,580T>C corresponding to 
c.4132T>C (NM_173591.3) predicted to lead to the substitution of an Arginine 
for a Cysteine, p.Cys1378Arg (NP_775862.3). Both variants were confirmed via 
Sanger-sequencing (Figure 1C). They both co-segregated with the phenotype in 
the family as an autosomal recessive trait and were absent in 373 ethnicity-
matched control samples. Neither variant has been found in the NHLBI Exome 
Sequencing Project (Exome Variant Server), or in dbSNP databases. The 
p.Cys1378Arg variant affected a highly conserved residue in OTOGL. However, 
since p.Cys1378Arg is located at the C-terminal relative to p.Val477Glufs*25, it 
is unlikely to contribute to the phenotype. Screening for additional mutations in 
OTOGL via linkage analysis followed by Sanger-sequencing in additional 195 
families with severe or profound arNSHL failed to detect a mutation.
 Family 2, presented with three brothers with moderate and stable hearing loss. 
Physical examination and otoscopy revealed no abnormalities. Diagnosis of 
hearing loss was at the neonatal hearing screening for II.3 and can therefore be 
assumed to be congenital. Subsequently, the older brothers where diagnosed at 
the ages of 3 (II.1) and 2 (II.2) years. All three boys performed normally in the 
Unterberger, Romberg, head thrust, and head shake tests and in addition the eye 
tracking movements although a delay in gross motor development was reported. 
A high resolution CT scan in II.3 did not reveal abnormalities. Autozygosity 
mapping in family 2 did not reveal any significant homozygous regions 
(> 1 Mb) shared by all three affected children. As a next step, the data were 
analyzed for the presence of shared genotypes (>3 Mb) in the 3 affected 
children for the previously described autosomal recessive deafness loci; 
a shared region of 10.9 Mb on chromosomal region 12q21.2-q21.32 was 
identified encompassing the DFNB84 locus. Because of the moderate, stable 
nature of the hearing impairment that was also noted in Family 1, we initiated 
mutation analysis of OTOGL. Two variants, which were not present in the NCBI 
dbSNP134 or 135 database, NHLBI Exome Sequencing Project (Exome Variant 
Server) nor in the 1000 Genomes Project, were identified; a nonsense mutation 
c.547C>T (p.Arg183*) and a splice site mutation c.5238+5G>A. All three 
affected children were compound heterozygous for these mutations; father and 
mother were heterozygous for p.Arg183* and c.5238+5G>A, respectively. The 
splice site mutation is predicted to reduce splicing efficiency by ~50% (0.47 vs 
0.98 for the wild-type sequence; BDGP Splice Prediction). Two other prediction 
tools, NetGene Splice site predictions and Human Splice Finder, do not predict 
a splice donor site for the sequence with the G to A transition. A minigene assay 
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Figure 1. Studied Families, Audiograms, and OTOGL Mutations
A) Family 1 and the longest autozygous region on chromosome 12. Parents are first cousins; B) 
Audiograms show moderate sensorineural hearing loss in Family 1; C) Electropherograms showing 
identified mutations in OTOGL in Family 1; D) Pedigree and SNP genotypes in Family 2; E) 
Audiograms of affected subjects in Family 2 show moderate hearing loss; F) Electropherograms of the 
OTOGL mutations identified in Family 2. 
D
E
F
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was performed to test the effect of the mutation on splicing in HEK293T cells 
which demonstrated skipping of exon 43 (Supplemental Figure S1).
 Otogelin-like, the predicted product of Otogl, was recently identified in mouse 
by amplification and sequencing of the transcript. The gene was annotated 
and named because of its structural similarity to otogelin21. Otogelin encoded 
by Otog was first discovered as an extracellular glycoprotein specific to the 
acellular membranes of inner ear26. Otogelin shows structural similarities to the 
epithelial-secreted mucin protein family since it is comprised of an N-terminal 
signal peptide, a central threonine/serine/proline-rich (TSP) region flanked 
by vWF-like cysteine-rich domains and a C-terminal knot motif domain26. 
Otogelin-like similarly contains an N-terminal signal peptide of 22 amino acids 
in the N-terminal (predicted by the SignalP software) as well as vWF and knot 
domains in the mature peptide (Figure 5B). Otogelin and otogelin-like have an 
amino acid identity of 33.3% (56.0% similarity).
Expression Profile of OTOGL 
The expression of OTOGL relative to GUSB standard internal control was 
studied via quantitative PCR (qPCR) in 10 adult and 10 fetal-stage human tissues 
including human fetal inner ear (Figure 2). Because this was performed for adult 
and fetal tissues in two separate experiments, fetal inner ear was included in 
both for comparison. In adult tissues, relatively low OTOGL transcript levels 
as compared to fetal inner ear were seen in lung, spleen, and duodenum, and 
relatively moderate levels in heart, kidney, brain, and retina. In three of the adult 
tissues - skeletal muscle, liver and testis - expression of OTOGL was below the 
detection level. Among the fetal tissues that were tested, the transcript level 
was highest in the inner ear. However, since these tissues were not derived 
from fetuses of the same gestational stage a direct comparison of the transcript 
levels cannot be made. The inner ear was derived from a fetus at 8 weeks of 
gestation and all other fetal tissues from fetuses at 20-21 weeks gestation. At the 
latter stage, OTOGL transcript levels were highest in fetal heart. A low relative 
OTOGL transcript level was observed in skeletal muscle, kidney, spleen and 
colon. In the fetal liver, lung, brain and stomach, expression was below the 
detection level.
Otogelin-like is Present in Several Cell Types and the Acellular 
Membranes of the Inner Ear 
The localization of otogelin-like (OTOGL) in the inner ear was studied 
by immunostaining with an anti-OTOGL antibody in the mouse and rat. 
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Figure 2. OTOGL Expression Profile in Human Tissues 
Relative OTOGL mRNA levels as determined by qPCR in human fetal (A) and adult (B) tissues. The 
relative expression values were determined by using the delta delta Ct method. Relative OTOGL 
transcript levels were highest in fetal inner ear. 
Table 1. The number of variants (SNPs and indels) identified by whole exome sequencing of individual 
II:7 in family 1compared to the reference genome (hg19)
The different filters and annotation categories are shown. 
NA: not available
Region Total Variants Novel Variants
Whole Exome 221,686 77,655
+Homozygous Variants 64,180 2,828
+Chr12:68,804,480-83,923,162 407 38
+Missense, nonsense, splice, frame-shift 16 2
Sanger confirmed NA 2 in OTOGL
A
B
Mutations in OTOGL cause hearing loss
52
53
2
Furthermore, we analyzed the transcription of otogl by in situ hybridization 
in the mouse and zebrafish, and by semi-quantitative RT-PCR in the mouse. 
Overall OTOGL showed a dynamic expression pattern throughout development, 
and immunostaining and in situ results were consistent with each other. At E17.5, 
OTOGL was primarily detected in the spiral prominence and the Claudius cells, 
weakly in hair cells (Figure 3A,B). It was detected in the lumen surface of 
interdental cells in the proximity of Reissner’s membrane (Figure3A, arrowhead) 
and in the base of nascent tectorial membrane (Figure 3A, arrow). A similar 
OTOGL distribution was detected in P0 cochlea (Figure 3C,D), with additional 
detection in some supporting cells. In saccule, OTOGL was detected weakly in 
hair cells and more prominently in the saccular roof (Figure 3E). By P6, OTOGL 
distribution became more restricted. It was detected mainly in the outer hair 
cells, Deiters cells and Claudius cells (Figure 3F). In the tectorial membrane, it 
was localized to the base (Figure 3F, arrow). In the saccule, elevated level was 
detected in the saccule roof with little change in the hair cells (Figure 3H). To 
Figure 3. Otogl Expression and Distribution in the Mouse Inner Ear
A-A’) In E17.5 cochlea, OTOGL was detected by immunohistochemistry on the lumen surface of 
interdental cells close to the Reissner’s membrane (arrowhead), the base of tectorial membrane 
(arrow), hair cells (HC), Claudius cells (Cld) and spiral prominence (SP). Figures in the middle 
column (A’-G’) are merged images that include the 1st column; B) By in situ hybridization, Otogl 
mRNA was detected in the same cell types as shown by immunostaining, with the difference that 
immunolabeling also detected staining on the surface (A, arrowhead and arrow). Scale bars represent 
20 μm; C) in P0 cochlea, a similar OTOGL distribution pattern was detected by immunostaining, with 
clear presence in the Deiters cells (DC). The figure on the 3rd column (C’’) is a merged picture from 
Otogl labeling with a DIC image, to show the tectorial membrane (TM); D) In P0 saccule, OTOGL was 
weakly detected in hair cells, but prominently detected in the saccular roof (SR). The strong labeling 
on the surface of the SR was likely the otolithic membrane. The dashed line represents the base of the 
basilar membrane; E) In situ hybridization showed Otogl expression in the cochlea that was consistent 
with immunolabeling results; F) In P6 cochlea, OTOGL distribution was restricted to outer hair cells 
(OHC), Pillar cells (PC), Deiters cells (DC), and Claudius cells (Cld). In the tectorial membrane, it was 
limited to the base (arrow); G) Preadsorption with a synthetic OTOGL antigen eliminated the signals 
reveled by the OTOGL antibody including TM staining; H) In the P6 saccule, OTOGL distribution 
was similar to that at P0, however with a higher level in the saccular roof; I) the level of Otogl mRNA 
was enhanced in the OHC, Deiters, and Pillar cells; J) Semi-quantitative RT-PCR of whole cochlea 
showed that Otogl transcripts were most abundant at P13, and decreased in towards young adulthood. 
Otogl was also detected in the Cortex (Cor) but not in the Hippocampus (Hip). Gapdh transcript levels 
were used as a control.
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Figure 4. otogl Expression and Loss of Function Analysis in Zebrafish 
A) Expression of otogl (red, in situ hybridization) in ear epithelial cells and its relation to hair cell 
development (green, GPF immunostaining).  Sagittal confocal images of developing otocysts showing, 
at 36 hours post fertilization (hpf), initial otogl expression in the forming macula communis and, at 
56 hpf, in the macula of the utricle.  Throughout larval stages, most hair cells in all maculae express 
otogl, but some otogl-negative hair cells can also be seen (not shown).  Many basal ear epithelial cells 
directly below hair cells also express otogl. Scale bars 25 µm, embryos mounted anterior to the left; B) 
Diagrams comparing the structural organization of human OTOGL and zebrafish Otogl four vWF/C8 
domains (von Willebrand Factor (blue ovals)/cysteine rich (green rectangles) domains), four Trypsin 
Inhibitor Like domains (TIL domains, pink ovals) and one C-terminal cystine knot domain (black 
oval). These diagrams are adapted from the output of SMART.  The location of human mutations 
(1.p.Arg183*; 2.p.Val477Glufs*25; 3.p.Cys1378Arg; 4.c.5238+5G>A) are indicated by asterisks and 
the location of the zebrafish mis-splicing site targeted by the morpholinos is indicated by a red box; 
C) Diagram of zebrafish otogl exons 36, 37, and 38 showing the targeting site of MO1 at exon/
intron junction 36 and the targeting site of MO2 at intron/exon-junction 37 (red bars).  Position of 
diagnostic PCR primers is indicated in exons 36 and 37 (back arrows). Below the diagram, a DNA gel 
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demonstrates efficacy and specificity of otogl morpholinos. The gel shows RT-PCR products generated 
from 500 ng RNA harvested from 56 hpf embryos injected at the one-cell stage either with control 
morpholino (Con MO), otoglMO1, or otoglMO2.  Two primer sets amplify either otogl (top row) 
or glrbb (bottom row; internal control) from cDNA synthesized using anchored oligodT primers. L 
indicates the DNA ladder. A sample without RNA was used as a negative control (no RNA). The faint 
bands at the bottom of the gel are unincorporated primers; D-E) Loss of otogl function by otoglMO2 
causes inner ear and saccular otolith malformations (E, n=3) compared to stage matched, 56 hpf, 
wild type embryos (D, n=5).  Bar is 50 µm.  Embryos mounted anterior to the left; F-G) Confocal 
microscope images of 56 hpf control (F, n=5) and otoglMO2 (G, n=3) embryos show that inner ear 
malformations are due to defects in the development of the tissue pillars that form the semicircular 
canals (arrows in F).  Bars are 20 µm. Embryos were mounted anterior to the left; H) Microphonic 
responses from the inner ear of control (top trace) and otoglMO2 morphants (middle trace) at 56 hpf. 
The bottom trace is the stimulus waveform at 200 Hz and ± 3 µm displacement. I) Histograms showing 
the means ± SD of microphonic responses that were averaged 200 times for control morphants and 
otoglMO2 morphants.  
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study the specificity of the antibody staining, we performed preadsorption with 
a synthesized peptide containing the OTOGL antigen as control. Preadsorption 
abolished the signals revealed by the OTOGL antibody but did not affect Myo7a 
(Figure 3G), demonstrating the specificity of the OTOGL antibody.
 By semi-quantitative RT-PCR, Otogl was upregulated up to P13 in the cochlea, 
and downregulated in the adult. In addition to the inner ear, Otogl transcript was 
detected weakly in the cortex, but not in the hippocampus (Figure 3J). 
 In the rat, OTOGL continued to be present in various inner ear cells, 
particularly in Hensen’s cells in the postnatal period and was present in the 
acellular membranes and basilar membrane (Supplemental Figures S2 and S3). 
 In zebrafish, otogl transcription during the first 5 days of larval development 
was confined to the otic vesicle (Figure 4A, data not shown). Using fluorescent 
in situ hybridization, we first detected otogl transcripts at 36 hours post 
fertilization in the developing macula communis (Figure 4A)22. At later 
developmental stages otogl expression was also detected in the other maculae 
(Figure 4A and not shown). Within the maculae, two different apical epithelial 
cell populations were found to express otogl, hair and non-hair cells (Figure 
4A and data not shown). In older larvae, otogl transcription was also seen in 
many basal epithelial cells directly below hair cells (Figure 4A). Thus, different 
populations of basal and apical cells associated with the maculae express otogl.
Knocking-down otogl in Zebrafish Causes Sensorineural Hearing 
Loss and Anatomical Changes in the Inner Ear
To determine the function of otogl, we knocked down the expression of the 
highly conserved Otogl protein (XP_683212; 73.1% identity over a stretch of 
746 amino acids) in zebrafish by injecting splice-junction blocking morpholinos 
(MOs) into fertilized eggs. Both human and predicted zebrafish Otogl are large 
proteins, 2343 and 2454 aa respectively, consisting of 4 repeats of paired vWF 
/C8 (von Willebrand Factor /cysteine rich) domains with a C-terminal cystine 
knot domain (Figure 5B). Other proteins with this domain structure are mucin 
and otogelin26. We designed two splice-junction blocking morpholinos against 
exon/inton 36 and 37 of the zebrafish gene that result in protein truncations 
(Figure 4B, C). Both otoglMO1 and MO2 morphants significantly knocked down 
the expression of otogl at day 2 (Figure 4C). OtoglMO2 morphants were used 
for inner ear morphological analysis and physiological recordings because MO1 
caused severe cardiac edema. MO2 morphant phenotypes were characterized by 
mild cardiac edema, slight reduction in larvae length (t-test, P = 0.007), failure 
to escape in response to vibration stimuli, a smaller inner ear (P = 0.002) and 
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smaller saccular otolith (P = 0.001) (Figure 5D, E). There was no significant 
difference in size of utricular otolith between the control and morphants (P = 
0.41). Furthermore, loss of otogl function also caused defects in the development 
of the tissue pillars that shape the semicircular canals (Figure 4F,G). It is 
unclear if these misshapen semicircular canals impacted vestibular function, 
as the severe cardiac edema precluded the analysis of circling behaviors at day 
5 post fertilization that are characteristic of vestibular deficits27. Microphonic 
potentials were recorded from controls and otoglMO2 morphants in response to 
oscillatory stimulation at 200 Hz and ± 3 µm in displacement. The microphonic 
waveforms recorded had a characteristic feature of doubling of the stimulus 
frequency (Figure 5H). The average amplitude of microphonic responses that 
were measured at 400 Hz in FFT plots ranged from 14 ± 8 µV (N = 11) for 
control morphlino-injected larvae and 4 ± 5 µV (N = 12) for otogl morphants 
(Figure 4I). Microphonic responses of otogl morphants are significantly smaller 
than those of controls (P = 0.0008).
DISCUSSION
We present mutations in OTOGL as a cause of non-syndromic deafness at the 
DFNB84 locus where mutations in PTPRQ were previously discovered7,21. 
We focused on this genomic region since statistically significant linkage was 
obtained in a genome scan and we found a truncating mutation in OTOGL 
via whole exome sequencing. A second multiplex family was independently 
identified with two compound heterozygous mutations, which provided further 
genetic support for the causative role of OTOGL mutations in hearing loss. We 
subsequently showed that OTOGL is preferentially expressed in the inner ear 
in various species and that knocking-down otogl leads to sensorineural hearing 
loss in zebrafish. We thus present mutations in OTOGL as a cause of hereditary 
deafness. The clinical phenotype is quite similar in the two families with OTOGL 
mutations and is characterized by a stable, moderate sensorineural hearing loss. 
One affected person tested demonstrated vestibular abnormalities, indicating 
that mutations in OTOGL may cause vestibular dysfunction. 
 Sensory epithelia of the vertebrate inner ear consist of highly organized 
arrays of sensory hair cells and supporting cells. The acellular membranes of 
the inner ear form intimate contact with the stereocilia bundles of the hair cells. 
Each neuroepithelium of the inner ear is covered by an acellular gelatinous 
membrane: a voluminous gelatinous substance forming a dome-shaped cupula 
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sits on top of each crista in the ampullae of the semicircular canals. In the utricle 
and saccule, an otoconial membrane loaded with crystal-like structures, the 
otoconia, covers the surface of the macula. In the cochlea, a tectorial membrane 
overlies the auditory epithelia28. These extracellular matrices generally serve to 
either transmit the primary stimulus to the stereocilia bundle, or act as structures 
against which the stereocilia bundles can react. They also serve to load the 
bundles and change their resonance frequency29. Acellular membranes of the 
inner ear contain various collagens and noncollagenous proteins that include 
α-tectorin (TECTA), β-tectorin (TECTB) and otogelin (OTOG)28. In this study 
we show that otogelin-like is an additional component of the inner ear acellular 
membranes that plays important functional roles in hearing. 
 In the mammalian inner ear, the cupula, the otoconial membrane, and the 
tectorial membrane exhibit a progressive increase in molecular and structural 
complexity, with the cupula appearing the least complex and the tectorial 
membrane the most complex28. This increase of complexity may reflect changes 
that occurred in the acellular membranes of the inner ear as a mammalian hearing 
organ arose during evolution from a simple equilibrium receptor28. Otogelin 
was shown to be present in all three membranes suggesting a fundamental and 
ancient role for this protein28. Our study shows that the expression pattern of 
otogelin-like is similar to that of otogelin by its presence in all three acellular 
membranes of the inner ear and in all four species analyzed; zebrafish, mouse, 
rat, and human. 
 Our data show that Otogl is mainly expressed in Claudius cells, Hensen’s cells 
and outer hair cells with a transcription level that is high in embryonic, lower 
in neonatal and much lower in adult stages. The protein product, however, is 
also prominently present in the acellular structures. High levels of transcription 
of Otogl in early and downregulation of the gene in later development strongly 
suggests that otogelin-like, similarly to other acellular structure components 
such as otogelin, is normally involved in the production of the structure, which 
may require relatively low of gene activity for the maintenance on the continuous 
basis30.
 Although a human phenotype of OTOG mutations has not been reported yet, 
targeted disruption of Otog resulted in deafness and severe imbalance in mice31. 
Histological analysis of these mutants demonstrated that in the vestibule, otogelin 
was required for the anchoring of the otoconial membranes and cupulae to the 
neuroepithelia. In the cochlea, ultrastructural analysis of the tectorial membrane 
indicated that otogelin was involved in the organization of its fibrillar network. 
Thus, otogelin is likely to have a role in the resistance of this membrane to 
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sound stimulation31. Because of structural and expressional similarities, it is 
possible that otogelin-like plays a similar role in the inner ear. The clinical 
phenotype in humans with a stable hearing loss and vestibular findings further 
supports this possibility. On the other hand, the functions of otogelin-like and 
otogelin are highly likely to be at least partially non-compensatory, as mutations 
in each of the corresponding genes can cause hearing loss. 
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SUPPLEMENTAL FIGURES AND TABLES
Supplemental Figure S1. Results of minigene assay for the c.5238+5G>A mutation 
(A) Representation of the plasmid used in the minigene assay; (B) Lane 1, RT-PCR after transfection 
with wild type plasmid showing a fragment of 489 bp; lane 2, RT-PCR after transfection with mutant 
plasmid revealing a fragment of 274 bp; M, 100 bp ladder; (C) Electropherograms of wild type and 
mutant cDNA showing the skipping of OTOGL exon 43. 
A
B
C
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Supplemental Figure S2. Immunohistochemical Localization of OTOGL in the Inner Ear of the Rat
(A) In P10 rat cochlea, OTOGL distribution was restricted to the tectorial membrane (arrow) and the 
organ of Corti (C); B) In the control with omission of the first antibody, no staining was observed 
in these structures; (C) The differential interference contrast image is included to show the position 
of the tectorial membrane  (arrow) in the negative control (B); (D) A higher magnification of the 
tectorial membrane demonstrated staining predominantly at the margin and (E) a higher magnification 
of the organ of Corti shows immunostaining in the apical part of the outer hair cells (OHC) and very 
pronounced in Hensen’s cells (H); (F) A whole mount staining of a P12 organ of Corti demonstrated 
the distribution of OTOGL near the lateral cell membrane and/or between Hensen’s cells (H); (G) In 
the P20 rat vestibulum, Otogl was observed in the cupula of the cristae, (I) the gelatinous layer of the 
maculae (H, J) and in the basilar membrane of these sensory patches. Amp = ampulla; Coch = cochlea; 
IHC = Inner Hair Cell; HC = Hair Cell; Sac = Saccule; SC =  Supporting Cell. Scale bars represent 30 
µm in A-C, 3 µm in D, 11 µm in E, 8 µm in F, and 5 µm in G-J.
Supplemental Figure S3. Immunostaining of OTOGL in the Adult Rat 
In P30 rat cochlea, immunostaining was detected in (A) the tectorial membrane and (C) Hensen’s cells 
(H) of the organ of Corti. In the absence of the OTOGL antibody (B, D), no staining was observed in 
these structures. Note the absence of staining in the outer hair cells (OHC) at this age (C). IHC = Inner 
Hear Cell. Scale bars = 5 µm in A, B and 11 µm in C, D.
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Mutations in OTOGL cause hearing loss
Supplemental Table S2. Primers for QPCR and Minigene Assay
Primers for qPCR Human
Forward Primers
(5` to 3`)
Reverse Primers
(5` to 3`)
Size (bp)
OTOGL exon 9-10  
(for qPCR HUMAN)
gattttccaaatccgtgctc ctcatggcagctcagaaaag 99
Primers for Mouse Semiquantitative PCR
Forward Primers  Reverse Primers Size (bp)
Otogl (for RT-PCR):   ggtgctccatgttgtcagag   atttcccagctgccaataaa               547
Otogl (For in situ):      acccctgactattgccctct     cctgtcgaacttgaagcaca              598
GAPDH:                  gatgcctgcttcaccaccttcttg gcagaaggggcggagatgatgac 413
Primers for Minigene Assay
OTOGL intron 42 – intron 43* GGGGACAAGTTTGTACAA
AAAAGCAGGCTTCttctttctt
actgggttaaggc
GGGGACCACTTTGTACAAG
AAAGCTGGGTCatactgacagaa
ggttgggg
624
*the nucleotides in capitals represent the adaptors for the Gateway cloning.
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Mutation in CLIC5 causes deafness and vestibular dysfunction
ABSTRACT
In a consanguineous Turkish family diagnosed with autosomal recessive 
nonsyndromic hearing impairment (arNSHI), a homozygous region of 47.4 Mb 
was shared by the two affected siblings on chromosome 6p21.1-q15. This region 
contains 247 genes including the known deafness gene MYO6. No pathogenic 
variants were found in MYO6 neither with sequence analysis of the coding 
region and splice sites nor with mRNA analysis. Subsequent candidate gene 
evaluation revealed CLIC5 as an excellent candidate gene. The orthologous 
mouse gene is mutated in the jitterbug mutant that exhibits progressive hearing 
impairment and vestibular dysfunction. Mutation analysis of CLIC5 revealed a 
homozygous nonsense mutation c.96T>A (p.(Cys32Ter)) that segregated with 
the hearing loss. Further analysis of CLIC5 in 213 arNSHI patients from mostly 
Dutch and Spanish origin did not reveal any additional pathogenic variants. 
CLIC5 mutations are thus not a common cause of arNSHI in these populations.
 The hearing loss in the present family had an onset in early childhood and 
progressed from mild to severe or even profound before the second decade. 
Impaired hearing is accompanied by vestibular areflexia and in one of the 
patients with mild renal dysfunction. Although we demonstrate that CLIC5 is 
expressed in many other human tissues no additional symptoms were observed 
in these patients. 
 In conclusion, our results show that CLIC5 is a novel arNSHI gene involved in 
progressive hearing impairment, vestibular and possibly mild renal dysfunction 
in a family of Turkish origin.
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INTRODUCTION
Hearing impairment is the most common sensory disorder worldwide and it 
is clinically and genetically very heterogeneous.1 Approximately 80% of early 
onset hereditary non-syndromic hearing impairment inherits in an autosomal 
recessive pattern. Currently, 80 loci and 49 genes have been identified for 
autosomal recessive non-syndromic hearing impairment (arNSHI), showing 
the great genetic heterogeneity (Hereditary Hearing Loss Homepage, http://
hereditaryhearingloss.org/). This heterogeneity might well be explained 
by the complexity of the auditory system. Defects in a large variety of 
biological processes such as gene regulation, ion homeostasis and hair bundle 
morphogenesis can lead to hearing impairment.2
 In the last decade, homozygosity mapping using genome-wide SNP genotyping 
has been a powerful tool in the identification of arNSHI loci and genes.3 Lately, 
next generation sequencing technologies have revolutionized the genetics field 
and also led to the identification of novel arNSHI genes at fast pace.4 The most 
powerful evidence to assign a candidate gene as a novel deafness gene is to 
discover pathogenic variants in several families and not in controls. However, 
due to the large genetic heterogeneity of hearing impairment this can be very 
difficult even with the current technologies. This is also evident from three 
recently identified arNSHI genes, PNPT1, SERPINB6 and TSPEAR, for which 
mutations have only been described in a single family each.5-7 Further evidence 
to assign a candidate gene as a deafness gene can come from animal models, 
especially mouse models with hearing loss. Several genes essential for hearing 
in humans were identified after they had already been demonstrated to be 
associated with deafness in mice.8
 Using homozygosity mapping and candidate gene analysis we identified a 
homozygous nonsense mutation in CLIC5 in a consanguineous Turkish family 
(W05-009). The orthologous mouse gene, Clic5, was described to be mutated in 
the jitterbug (jbg) mouse exhibiting congenital progressive hearing impairment 
and vestibular dysfunction due to progressive hair cell degeneration.9 
MATERIALS AND METHODS
Subjects and clinical evaluations
This study was approved by the local medical ethics committee of the Radboud 
university medical center and Hospital Universitario Ramon y Cajal. Signed 
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informed consent was obtained from the parents, since all patients are minors. 
In addition, a signed form was used to retrieve relevant data from other medical 
centers.
 For the affected individuals of family W05-009 general physical examination 
was performed by a pediatrician. Blood and urine samples were analyzed to 
evaluate renal and thyroid function. ENT examination was executed to exclude 
other possible causes of hearing impairment like previous ear surgery and 
external ear deformities. A computed tomography (CT) scan of the temporal 
bone was performed in order to exclude possible anatomical causes of hearing 
loss. Pure tone audiometry was performed according to current standards 
to determine hearing thresholds at 0.25, 0.5, 1, 2, 4 and 8 kHz. To exclude 
conductive hearing loss both air conduction and bone conduction thresholds were 
obtained. Classification of the hearing loss is in accordance with the GENDEAF 
guidelines (Hereditary Hearing Loss Homepage, http://hereditaryhearingloss.
org/). In addition, otoacoustic emissions (OAEs) were measured in individual 
II.3. Vestibular function was evaluated by electronystagmography and rotatory 
tests.10 GraphPad Prism 5.00 (GraphPad, San Diego, CA, USA) was used to 
perform linear regression analysis to evaluate progression of the hearing 
impairment.
 Three panels of arNSHI patients were analyzed for involvement of CLIC5. 
GJB2 mutations or GJB6 deletions were excluded by routine analysis in most of 
these patients. The first panel consisted of 76 arNSHI index patients, mostly of 
Dutch origin, and these were selected based on the hearing loss phenotype. They 
presented either with a downsloping audiogram configuration and progression of 
hearing loss or early onset progressive hearing loss accompanied by vestibular 
areflexia or hyporeflexia. The second panel consisted of 69 unrelated arNSHI 
sibships of Spanish origin which were not preselected based on type or severity 
of their hearing impairment. The third panel contained 18 arNSHI index patients 
of Spanish origin selected based on the hearing loss phenotype. In most of the 
cases, the hearing loss was postlingual (16 in childhood, at school age; two 
in the second decade of life) and progressive with a downsloping audiogram 
configuration.
Homozygosity Mapping
Genomic DNA was isolated from peripheral-blood lymphocytes by standard 
procedures. Individuals II.2 and II.3 from family W05-009 were genotyped 
using the Affymetrix mapping 250K NspI SNP array. All SNP array experiments 
were performed and analyzed according to the manufacturer’s protocol 
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(Affymetrix, Santa Clara, CA, USA). Genotype calling and calculation of the 
regions of homozygosity were performed with the Genotyping Console software 
(Affymetrix) with the default settings. The cosegregation of the genotypes for 
each previously reported arNSHI gene was visually evaluated.
Mutation Analysis
Primers for amplification of exons and exon-intron boundaries of 
CLIC5 (NM_016929.4, CLIC5A and NM_001114086.1, CLIC5B), ESPN 
(NM_031475.2), MYO6 (NM_004999.3) and for mRNA analysis of MYO6 
(NM_004999.3) were designed with ExonPrimer (http://ihg.gsf.de/ihg/
ExonPrimer.html). Primer sequences and PCR conditions are provided in 
Supplemental Table S1. Amplification by PCR was performed on 40 ng of 
genomic DNA with Taq DNA polymerase (Roche, Mannheim, Germany). 
For MYO6 mRNA analysis, total RNA was isolated from Epstein-Barr-virus 
(EBV)-transformed lymphoblastoid cells of affected individual II.2 using the 
NucleoSpin RNA II kit (Machery Nagel, Düren, Germany) according to the 
manufacturer’s protocol. Subsequently, cDNA synthesis was performed with 1.5 
µg RNA as starting material by using the iScript cDNA Synthesis Kit (Bio-Rad 
Laboratories, Hercules, CA, USA), according to the manufacturer’s protocol. 
PCR reactions were performed on 2 µl cDNA with the Taq DNA polymerase 
(Invitrogen, Carlsbad, CA, USA). 
 PCR fragments were purified with the use of NucleoFast 96 PCR plates 
(Clontech, Mountain View, CA, USA) or ExoI/FastAP (Fermentas, Vilnius, 
Lithuania) in accordance with the manufacturer’s protocol. Sequence analysis 
was performed with the ABI PRISM BigDye Terminator Cycle Sequencing 
V2.0 Ready Reaction kit and analyzed with the ABI PRISM 3730 DNA analyzer 
(Applied Biosystems Foster City, CA, USA). The presence of the CLIC5 c.96T>A 
transversion was investigated in 111 ethnically matched healthy controls. Exon 
2 of CLIC5 was amplified and PCR products were purified as described above. 
Digestion of the PCR products with HpyCH4III (New England Biolabs, Ipswich, 
MA, USA) was performed in accordance with the manufacturer’s protocol, and 
restriction fragments were analyzed on gels containing 1.5% agarose and 1% 
low-melting agarose. The mutation removes a restriction site.
Nonsense-mediated mRNA decay (NMD) evaluation
EBV-transformed lymphoblastoid cell lines were established from heparin blood 
of individuals II.2 and II.3. Cells were grown with and without cycloheximide, a 
protein synthesis inhibitor, which prevents the nonsense-mediated mRNA decay 
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process as described previously.11 Total RNA was isolated as described above. 
cDNA synthesis was performed with 3 µg RNA as starting material by using 
the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA), 
according to the manufacturer’s protocol. For the quantitative PCR (qPCR), 
specific primers (Supplemental Table S1) were designed with Primer3Plus (http://
www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) and reference 
sequence NM_016929.4. PCRs were performed with the Applied Biosystem Fast 
7900 System in accordance with the manufacturer’s protocol. The human beta 
glucuronidase gene (GUSB [MIM 611499]) was employed as an internal control. 
PCR mixtures were prepared with the Power Syber Green Master Mix (Applied 
Biosystems) in accordance with the manufacturer’s protocol. Temperatures and 
reaction times for PCR were as follows: 10 min at 95°C, followed by 40 cycles 
of 15 s at 95°C and 30 s at 60°C. All reactions were performed in duplicate. 
Relative gene expression levels were determined with the delta delta Ct method 
as described previously.11
CLIC5 Expression Profile
RNA derived from adult heart, retina, brain and kidney was purchased from 
Clontech (Mountain View, CA, USA). RNA derived from adult skeletal muscle, 
liver, duodenum, testis, spleen, thymus, and placenta were purchased from 
Stratagene (La Jolla, CA, USA) and bone marrow from Bio-chain (Newark, 
CA, USA). RNA derived from fetal brain, colon, kidney, stomach, spleen, heart, 
skeletal muscle, lung and thymus was purchased from Stratagene. In addition, 
RNA was isolated from adult lung, fetal cochlea and fetal liver as described 
previously.12 The inner ear was derived from a fetus at 8 weeks of gestation 
and the other fetal tissues from fetuses at 20 – 21 weeks of gestation. cDNA 
synthesis, primer design (Supplemental Table S1) and qPCR analysis were 
performed as described above. The forward primer was located on the boundary 
of exons 2 and 3, and the reverse primer in exon 3. This enabled detection of 
all CLIC5 isoforms affected by the nonsense mutation that is located in exon 2. 
Relative gene expression levels were determined with the comparative delta Ct 
method as described previously.13
RESULTS 
Hearing loss and vestibular dysfunction in family W05-009
ENT examination and CT scanning did not reveal an apparent cause of hearing 
81
3
impairment in the two affected children of family W05-009. The parents have 
normal hearing and are first cousins of Turkish ancestry (Figure 1A). The 
patients presented with an early onset sensorineural hearing loss since the bone 
conduction thresholds did not differ from the air conduction thresholds. The 
hearing impairment probably was not congenital since individual II.2 passed 
a behavioural reflex audiometry test which is performed between 7 and 9 
months of age (Ewing test) and individual II.3 had normal hearing at the age 
Figure 1. A) Pedigree of family W05-009 and segregation of the CLIC5 c.96T>A variant
B) Longitudinal binaural mean air-conduction pure tone thresholds are shown of affected 
members of family W05-009
Age (years) is shown with a symbol key. The p95 line, matched for age and sex, indicates that 95% of 
the population has thresholds lower than these.
C) Regression analysis of longitudinal binaural mean air conduction threshold data for each 
frequency separately
Circles indicate individual II.2, squares indicate individual II.3. Annual threshold deterioration is 
shown behind the symbol key for each frequency.
A
C
B
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of 3 months during brainstem evoked response audiometry. The hearing loss 
started mildly, affecting the mid and high frequencies mostly. It progressed 
to a severe-to-profound hearing loss with a gently to steeply downsloping 
audiogram configuration as is shown in Figure 1B. linear regression analysis 
indicated significant progression in all frequencies (Figure 1C). OAEs were 
not present in individual II.3 at the age of 4 months. Individual II.2 received 
a cochlear implant at the age of 11 years. Five years post-implantation, the 
speech recognition scores were 88% (using the standard Dutch phonetically 
balanced consonant-vocal-consonant word lists).14 Initial motor milestones 
were reported to be normal, but later in life balance problems did occur e.g. 
difficulties with walking in the dark and cycling. Vestibular areflexia was found 
in both individuals during the rotatory test at the age of 16 years (II.2) and 11 
years (II.3).
 General physical examination showed that both children had a normal height 
and weight. No other abnormalities besides the hearing impairment were noted 
in individual II.2. On history, there were no signs of any other abnormalities 
in individual II.3. Thyroid function was also normal in individuals II.2 and 
II.3. Renal function was normal in II.2. However, in individual II.3 a blood 
pressure of 127/73 to 129/88 mmHg (90% value for this age and length: 120/76 
mmHg) was measured and an elevated albumin/creatinine ratio was detected at 
the last two visits in the outpatient clinic (9.2 and 3.8 mg/mmol, respectively, 
normal value <2.5 mg/mmol) during urine analysis at the age of 11 years. The 
glomerular filtration rate, calculated with the Schwartz equation, was normal 
with a value of 114 ml/min/1.73 m2 (normal > 90 ml/min/1.73 m2). Since the 
elevated blood pressure and albumin/creatinine ratio were seen in repeated 
measurements, these might be the first signs of a nephropathy. However, no 
other more invasive studies were performed, since the renal function was overall 
only mildly affected. Subsequent renal function follow-up of patient II.3 in the 
future will be needed to determine whether it is indeed a nephropathy.
Homozygosity mapping confines a critical region on chromosome 
6p21.1-q15
To identify genes for arNSHI, homozygosity mapping was performed in some 
large series of familial and isolated arNSHI patients living in the Netherlands. In 
family W05-009 homozygosity mapping revealed a homozygous region of 47.4 
Mb on chromosome 6p21.1-q15 (Figure 2A). This was the largest homozygous 
region shared by the two affected individuals. This region contains the known 
deafness gene MYO6. There were 15 other shared homozygous regions larger 
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than 1 Mb (Supplemental Table S2), and in one of them ESPN is located, which is 
another gene known for arNSHI. Mutation analysis was performed for all exons 
and exon-intron boundaries of ESPN and MYO6, which revealed no putative 
causative variants. Since MYO6 was located in the largest shared homozygous 
region, MYO6 mRNA was analyzed by RT-PCR. No PCR-products of an aberrant 
size were indentified and also sequence analysis of the PCR products did not 
reveal indications for aberrant splicing. To exclude compound heterozygous or 
allozygous mutations in the other known arNSHI genes, cosegregation of the 
genotypes was visually evaluated for each gene. PNPT1, ILDR1, RDX, TECTA, 
OTOGL, PTPRQ and OTOA were present within the genotype shared regions. 
Figure 2. A) Schematic overview of the chromosomal region 6q21.1-q15 showing the homozygous 
regions (black bars) identified in the affected individuals of family W05-009
The homozygous region of individual II.2 delimits the region to 47.4 Mb. Mb positions and 
chromosome bands are according to the UCSC genome browser (GRCh37). 
B) Partial sequences are shown of CLIC5 exon 2 from an affected member, a parent and an 
unaffected sib of family W05-009
 The predicted amino acid changes and the surrounding amino acids are indicated above the sequence. 
Mutated nucleotides are marked by an arrowhead. As reference sequence NM_016929.4 was employed.
A
B
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OTOA could be excluded by short tandem repeat (STR) marker analysis in the 
family. No putative pathogenic variants were identified in the other genes by 
sequence analysis of the exons and exon-intron boundaries.
A nonsense mutation in CLIC5 causes arNSHI
Since no pathogenic variants could be identified in MYO6 or ESPN we 
hypothesized that another gene would be underlying the hearing loss in this 
family. Therefore, we continued with the evaluation of the 247 annotated genes 
in the largest homozygous region, 6p21.1-q15 (http://genome.ucsc.edu/, RefSeq 
genes, hg19; assigned DFNB102). For three of the genes, mutations in the 
orthologous mouse gene cause deafness. Slc17a5 (MGI:1924105)15 and Bmp5 
(MGI:88181) are associated with mixed and conductive hearing loss in the 
mouse, respectively. The third gene, Clic5, was described to underlie progressive 
sensorineural hearing loss and vestibular dysfunction in the jbg mouse mutant.9 
Therefore, CLIC5 represented an excellent candidate gene.
 Mutation analysis of CLIC5 revealed a homozygous nonsense variant c.96T>A 
(p.(Cys32Ter)) (Figure 2B), which segregated with the hearing impairment 
in family W05-009 (Figure 1A). This variant was not present in 222 Turkish 
control alleles, the Exome Variant Server (http://evs.gs.washington.edu/EVS/) 
and the Nijmegen in-house exome database (1302 exomes). This variant was 
submitted to the Leiden Open Variant Database (http://databases.lovd.nl/shared/
variants/0000022995).
 The homozygous CLIC5 c.96C>T mutation is predicted to result in NMD, since 
it creates a premature stop codon (p.(Cys32Ter)) more than 54 bp upstream of the 
3’-most intron.16 However, we could not confirm NMD. The relative CLIC5 mRNA 
expression is comparable in cycloheximide treated and untreated patient EBV-cell 
lines (157.24% vs 157.89%, respectively) and higher - albeit not significantly - 
than in controls (set at 100%) as shown in Supplemental figure 1. 
 For identification of other families with CLIC5 mutations, sequence analysis 
of the coding region and splice sites of CLIC5 was performed in 76 arNSHI index 
patients, mostly of Dutch origin, and 18 Spanish arNSHI index patients. These 
patients were preselected based on the hearing loss and vestibular phenotype 
as described in the materials and methods section. No putatively causative 
variants were identified in these patients. In a parallel approach, compatibility 
with linkage to DFNB102 was investigated in a panel of 69 unrelated arNSHI 
sibships of Spanish origin. These were genotyped for STR-markers D6S459, 
D6S1920, D6S1632 and D6S1638, which flank CLIC5. Haplotype analysis 
revealed compatibility with linkage of the disease locus to these markers in 18 
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sibships. Sequence analysis of CLIC5 in the index cases of these sibships did 
not reveal any putative pathogenic variants. Finally, data of 50 whole exome 
sequence analysis of arNSHI patients, mainly of Dutch origin were evaluated 
for the presence of variants in CLIC5. These patients were not preselected based 
on the type or severity of the hearing loss. No putatively pathogenic variants 
were identified in this cohort.
Figure 3. CLIC5 expression profile in human tissues 
Relative CLIC5 mRNA levels as determined by qPCR in human fetal (A) and adult (B) tissues. 
The relative expression values were determined by using the comparative delta Ct method.13 The 
expression levels are relative to those in liver, which showed the lowest CLIC5 expression of all the 
tissues that were tested.
Relative CLIC5 expression in fetal tissues
Relative CLIC5 expression in adult tissues
A
B
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CLIC5 is expressed in the human inner ear
The expression of CLIC5 was studied via qPCR in human fetal inner ear 
and compared to that in additional 13 adult and 10 fetal-stage human tissues 
(Figure 3). Since this was performed in two separate experiments for adult and 
fetal tissues, fetal inner ear was included in both for comparison. The tissues 
were not derived from fetuses of the same gestational stage; therefore, a direct 
comparison of the transcript levels cannot be made. In fetal tissues, CLIC5 
transcript levels were highest in skeletal muscle, kidney, spleen, heart and colon. 
A lower expression level was found in fetal brain, thymus, lung and stomach. 
Expression in the fetal inner ear was 26 fold higher than in fetal liver in which 
the expression level was the lowest. In adult tissues, the highest expression levels 
were found in heart, lung, skeletal muscle and kidney and there was a gradual 
decrease through retina, spleen, brain, placenta, duodenum and thymus. Finally, 
the lowest expression levels were found in bone marrow, testis and liver. We can 
conclude that CLIC5 is widely expressed in both fetal and adult human tissues.
DISCUSSION
We present a homozygous nonsense mutation, c.96T>A (p.(Cys32Ter)) in CLIC5 
(DFNB102) as a cause of sensorineural hearing impairment accompanied by 
vestibular dysfunction. This nonsense variant will lead to an early truncation of 
the protein. Screening a series of arNSHI index patients did not reveal additional 
causative variants, suggesting that mutations in CLIC5 are not a common cause 
of arNSHI neither in the Netherlands nor in Spain. 
 Initially, the hearing loss in the affected individuals of family W05-009 was 
mild, mainly affecting the mid and high frequencies, and then it progressed 
to severe to profound. They also showed vestibular areflexia in the second 
decade of life. The combination of progression to profound hearing loss and 
complete vestibular dysfunction in the patients of family W05-009 resembles 
the phenotype of the jbg mutants. Auditory-evoked brainstem responses (ABRs) 
at 1-5 months of age in jbg mutant mice, which are null for Clic5, were 40-50 
dB above those of wildtype mice. By 7 months of age their hearing loss had 
progressed to complete deafness due to progressive hair bundle degeneration 
and a reduced density of spiral ganglion cells.9 The vestibular hair cells of 
jbg mice also showed a progressive degeneration. In the crista ampullaris, the 
number of vestibular hair cells was reduced at 3 months and hair cells were 
nearly absent at 12 months of age.9 
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Besides inner ear dysfunction, the phenotype in humans and mice with Clic5 
mutations may well overlap with respect to the renal phenotype. The jbg mice 
have abnormalities in the foot processes of the kidney podocytes leading to 
proteinuria.17,18 The elevated albumin/creatinine ratio and pre-hypertension in 
affected individual II.3 indicate mild renal dysfunction and may well be the first 
signs of a nephropathy. Therefore, follow-up of renal function is indicated for 
individual II.3 but also for his hearing impaired sister. 
 In addition to the inner ear and kidney phenotypes, the jbg mutant mice also 
exhibit emphysema-like lung pathology, hyperactivity and resistance to diet-
induced obesity.19 Characteristics of lung emphysema and hyperactivity were 
excluded in family W05-009 by history taking. The affected individuals had 
normal height and weight. No other gross abnormalities in the organs of the jbg 
mutants were detected and no other complaints from the affected siblings were 
reported so far. The lack of symptoms in organs with relatively high CLIC5 
expression (Figure 3) points towards redundancy for CLIC5 function there.
 CLIC5 belongs to a family of chloride intracellular channel proteins, but its 
protein structure differs from other typical ion channel proteins. CLICs (CLIC1-
6) show no sequence homology to any known channel family, but significant 
homology to glutathione S-transferases in the core region.20 Moreover, some of 
the CLIC proteins, including CLIC5, are not only integral membrane proteins, 
but are also found as soluble proteins in the cytoplasm.21 In the inner ear, CLIC5 
localizes to stereocilia of both the cochlear and vestibular hair cells and on the 
surface of Kolliker’s organ during cochlea development in mice.9 Specifically, 
CLIC5 is predominantly present at the base of stereocilia and, to lesser extent, in 
the cell bodies of hair cells in the region surrounding the cuticular plate.9 CLIC5 
was initially identified in placental microvilli as a component of a multimeric 
complex consisting of several known cytoskeletal proteins, including actin and 
ezrin.22 Although the function of CLIC5 is still elusive, there are several facts 
that support its role in stereocilia integrity. Firstly, radixin immunostaining is 
reduced in the hair bundle of jbg mice where it colocalizes with Clic5.9 This 
suggests that Clic5 is needed for proper radixin activity, so when interacting with 
the ERM (ezrin, radixin and moesin) complex, Clic5 may stabilize connections 
between the plasma membrane and the filamentous actin core.9 Secondly, Clic5 
functions as an adapter between the plasma membrane of podocytes and the actin 
cytoskeleton by facilitating the interaction between ezrin and podocalyxin.17,18,23 
Thirdly, a recent study proposes that Clic5 functions as part of a multiprotein 
linker complex in companion with radixin, ezrin and taperin.24 Protein tyrosine 
phosphatase receptor Q (Ptprq), which is mislocalized as radixin in the jbg 
88
Mutation in CLIC5 causes deafness and vestibular dysfunction
mice, and Myosin VI, key regulator of the proper localization of Ptprq25, might 
well participate in this complex too. Radixin26, Ptprq25,27 Myosin VI28 and 
Clic5 deficient mice9 show loss of stereocilia at the bundle vertex and fusion 
of stereocilia in postnatal stage. This suggests that this multiprotein complex is 
essential for stable membrane-cytoskeletal attachments at the stereocilia base. 
In conclusion, we show that a homozygous nonsense mutation in CLIC5 
(p.(Cys32Ter)) underlies the progressive hearing impairment, vestibular and 
possibly mild renal dysfunction in a family of Turkish origin. CLIC5 mutations 
do not seem to be a common cause of arNSHI in the Dutch and Spanish 
populations. Further screening of CLIC5 in other populations will provide 
important information about the frequency of CLIC5 mutations and may aid to 
further define the phenotype associated with CLIC5 mutations.
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Supplemental Figure 1. The homozygous mutation CLIC5 c.96T>A (p.(Cys32Ter)) in family 
W05-009 does not result in nonsense mediated mRNA decay (NMD)
Shown is the mean expression of CLIC5 in Epstein-Barr-virus (EBV)-transformed lymphoblastoid 
cells of affected individuals II.2 and II.3 (n=2) and controls (n=10) treated with (+CH) and without 
(-CH) cycloheximide. Quantifications were normalized against GUSB expression. Differences in 
expression between the affected individuals and 10 controls were calculated by using the delta delta Ct 
method.11 The p-value was derived from the standard score (Z-value) calculated for untreated samples 
(-CH) as compared to the normal distribution of the 10 controls. Since we assume a lower expression 
level as a result of NMD, a one-sided test was enough to reject the null hypothesis (p=0.376). Also, no 
difference was seen in CLIC5 expression between treated and untreated patient samples. In conclusion, 
occurrence of NMD could not be confirmed.
SUPPLEMENTAL FIGURES AND TABLES
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Supplemental Table S1. Primer sequences and PCR conditions for genomic PCR, sequence 
analysis and QPCR
Target Oligonucleotides Product 
size 
(bps)
Annealing 
Temperature 
(°C)
Primers for genomic PCR and sequence analysis of CLIC5, MYO6 and ESPN
CLIC5 Exon 1 Forward primer CCAGGACCAGCTCTGTCTC 733 56
 Reverse primer AACCTGCCTTCCTCCATTC   
CLIC5 Exon 2 Forward primer TTATTGAGCCCTTACATGCTG 484 56
 Reverse primer ACTTGCCTTTGCAGACTCTC   
CLIC5 Exon 3 Forward primer ACAGGCATGTTGGATAGCAC 653 56
 Reverse primer GTCACTGGGTTACCCTTTCC   
CLIC5 Exon 4 Forward primer GCTGGAAAGGGAAGTATTGC 306 56
 Reverse primer CTCTGGCCCAAGTATTTGAC   
CLIC5 Exon 5 Forward primer TCCAGGTATTCTGCAGTGTG 431 56
 Reverse primer AGGTTCTTGACCAACAGGTG   
CLIC5 Exon 6 Forward primer AAAGAAGACAGCACTGCCAC 427 56
 Reverse primer GCCTCAAGGCAGTGATACAG   
CLIC5 Exon 1a* Forward primer TCCAATGGACTTGTGGTTTG 885 56
 Reverse primer TGACTGATTTAGTCCCTCCG   
MYO6 Exon 1 Forward primer TCCGTAGCCGTGACGTG 532 56
 Reverse primer TCGGGCAGTGAACAGAAG   
MYO6 Exon 2 Forward primer TGGGCAGATGTGTTTGTTAG 388 56
 Reverse primer TGCTTTCCCAAATATCTACCTC   
MYO6 Exon 3 Forward primer GTATGCAACCAATTAAGCCC 262 56
 Reverse primer TAGATTGTTTCTGAACCCGC   
MYO6 Exon 4 Forward primer TAGGGTTTACATCAGCCAGG 337 56
 Reverse primer TCAAGCATGATTTTCTGTTAGAC   
MYO6 Exon 5 Forward primer TGGGTCCCTATAAAGATCAGG 471 56
 Reverse primer CCCTGTGTAAAATACTTGCTCC   
MYO6 Exon 6 Forward primer TGATTTCTTTAAGAGTAAGTGGTCC 322 58
 Reverse primer TACAGTGAGCTGTGGTGGTG   
MYO6 Exon 7 Forward primer TGATGATCTAGGTTTCAGTTTTATATG 238 56
 Reverse primer TGAGAGAAGAACATTCCAGACC   
MYO6 Exon 8 Forward primer GCATGAGCCACTGTGTCC 324 56
 Reverse primer TGCAAATACAGCACCAACTG   
MYO6 Exon 9 Forward primer AACCTCTTTGATAGACAAATGG 651 58
 Reverse primer CAGGCTCAAGCAATCCATC   
MYO6 Exon 10 Forward primer TTCATGGTTGGCACTATTTG 353 56
 Reverse primer CAACAAGAGGTATAAAGTATTACACTG   
MYO6 Exon 11 Forward primer AGTGCATTAATTGACCTGGTG 363 58
 Reverse primer TTTAAGCAAACTGCATATAAAGAGAC   
MYO6 Exon 12 Forward primer AAAAGTTACAAATAAGCCTTGCC 375 56
 Reverse primer TTTTGATCTACCAAGCTCAGG   
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Supplemental Table S1. Continued
Target Oligonucleotides Product 
size 
(bps)
Annealing 
Temperature 
(°C)
Primers for genomic PCR and sequence analysis of CLIC5, MYO6 and ESPN
MYO6 Exon 13 Forward primer GTTTAGGTGCACTCTGTGGC 376 56
 Reverse primer CATATTATGAAATGTGAGTGTGGAC   
MYO6 Exon 14 Forward primer TGAGAACATTTGGGAAGTATAGAAC 351 56
 Reverse primer ATACACCATCCATCCACACC   
MYO6 Exon 15 Forward primer TTCAGAAACAGTGCAAAATTC 295 56
 Reverse primer CTTCCAGGCAGTAATACAGAAG   
MYO6 Exon 16 Forward primer TGTTGTTTCTGATCAGTCCTTG 389 56
 Reverse primer TCCATCTAAGGAAGATACTGTGC   
MYO6 Exon 17 Forward primer CTTACACCTATTTTCTTTCCTAAGAG 500 56
 Reverse primer TCACCACTAGTCAGTGTGGAC   
MYO6 Exon 18 Forward primer AAGTTCCTTTGGACAGAGCC 390 56
 Reverse primer CAAATATCAACAATGCAGGG   
MYO6 Exon 19 Forward primer CCAGGAGGTTGTTAAACTGG 267 56
 Reverse primer CAGGGTTACTATGCCTACTTGC   
MYO6 Exon 20 Forward primer CCCAGCCTTGAGTTCTTTAG 361 56
 Reverse primer AAGATGAAAATTTTATTGCACTG   
MYO6 Exon 21-22 Forward primer TCTCATAAATTGCCCGTTTC 580 56
 Reverse primer TGTTGTTAGTGACCATATAATTCAAG   
MYO6 Exon 23 Forward primer TGCCAAGGCCTATGTAATTG 354 56
 Reverse primer AGCATCACCTCTGAGACAGC   
MYO6 Exon 24 Forward primer GGTCGTCAAGATTTCATGTTTC 307 56
 Reverse primer AAAACCTGAGTATCCAAACTGC   
MYO6 Exon 25 Forward primer TTGAAAACAGAAGTGAAATACCC 375 56
 Reverse primer GTCTCAACACATTTTGTAATTTTG   
MYO6 Exon 26 Forward primer GCTGTATTTGCATATTGGAGTAG 460 56
 Reverse primer TTGTCATTAACCACTGTCAATACC   
MYO6 Exon 27 Forward primer TTCCCAATCTGTTACCTTTG 309 56
 Reverse primer TTGATCTCCTGACCTCGTG   
MYO6 Exon 28 Forward primer GGGGCAGTTATGCTTTCC 336 56
 Reverse primer TTCTGCATGGAAATGAGAGG   
MYO6 Exon 29 Forward primer CACAAATTTGCACAATCCAG 271 56
 Reverse primer AGCACCATACAAGAGCATTAAAC   
MYO6 Exon 30 Forward primer TGTGTTACGGCTAGATTTGTTG 309 56
 Reverse primer TCATGTAACAGGTTCTGGTCC   
MYO6 Exon 31 Forward primer TCCGGTTTTCAAACTTATGC 367 56
 Reverse primer GTGCATTCATGGACCAAAAG   
MYO6 Exon 32 Forward primer GCTTATCCTTATGAATAATTAGCTTAC 431 56
 Reverse primer GCCATCAAGGCTGTATTAGG   
MYO6 Exon 33 Forward primer ACTTTTCAGTCACCACCTCG 296 56
 Reverse primer TCCACTGAAAATTGTAGCAAAAC   
MYO6 Exon 34 Forward primer GGGGTATATTTTAGGATTAAAGGC 438 58
 Reverse primer TGGAAATGTGATTTAACCGC   
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Target Oligonucleotides Product 
size 
(bps)
Annealing 
Temperature 
(°C)
Primers for genomic PCR and sequence analysis of CLIC5, MYO6 and ESPN
MYO6 Exon 35_1 Forward primer ATTGAAAGGGTCCTTGATGG 831 56
 Reverse primer TGCCTTGATCATTTTAAGTGG   
MYO6 Exon 35_2 Forward primer CCGCTGTAATTCCCAAAAC 614 56
 Reverse primer TCCAGTTAAGCCACTATGCC   
MYO6 Exon 35_3 Forward primer GCACAATGTGTGTTGCTGTC 658 56
 Reverse primer CCTAACTGAGGTAATCTTTCTAGGG   
ESPN Exon 1 Forward primer ATTCGAACCCAGTTTTGCTG 1010 58
Reverse primer CCACCCACTTCCAGGACTAC
ESPN Exon 2 Forward primer AGGAAGGGTGGAGAGATC 859 58
Reverse primer ATGTTGAGTGGGAGCCATTT
ESPN Exon 3-5 Forward primer GAGGTCAGACACAGCAGGTG 1954 58
Reverse primer AGCGTGGGTTTCCAGTTATG
ESPN Exon 3-5S# Forward primer AGGTGAGCTGCACCGACGTG NA NA
Reverse primer TGACCTCTAGCTCCCCGTTC
ESPN Exon 6 Forward primer GGAACCTGGGTCCTGCTG 552 58
Reverse primer CCTCCCCATGTTTAAGAGCA
ESPN Exon 7 Forward primer TGGTCTTCCCCCAGTAAGTG 673 58
Reverse primer TACTCTCCTCCCAGTCCAGTG
ESPN Exon 8 Forward primer GCTGCCCACTGTGAGAACC 933 58
Reverse primer GGGAGGCCCTTTCTAGCTG
ESPN Exon 9 Forward primer CCATCCAATCTTGGCTTAGG 377 58
Reverse primer ACTGGTGACAGTGCAGGTGA
ESPN Exon 10 Forward primer CACAGTGTTCTCAGGCATCG 444 58
Reverse primer GATGGGCTGTGCATCCAG
ESPN Exon 11-12 Forward primer TCCCAGCTACTTGTTCTCTGC 691 58
Reverse primer GTGGGGTTAGGTTAACTGAAGG
ESPN Exon 13 Forward primer CTCAGTAACCCACCCCTTG 741 58
Reverse primer ATCTGGGTCAGAGAGGAAGG
Primers for MYO6 mRNA analysis
MYO6 mRNA Ex1-9 Forward primer TTCACCCGTACAGGTAGCC 826 56
Reverse primer TTCCTCTTTGCCTTGAACAC
MYO6 mRNA Ex8-13 Forward primer CTTTGGAAATGCGAAGACTG 787 56
Reverse primer TCCAATAAAATAGGATGATGTTTC
MYO6 mRNA Ex13-19 Forward primer GCAAGCAAACAATGCTCG 738 56
Reverse primer CTTCGAAGTTTATCCAGAAGC
MYO6 mRNA Ex18-26 Forward primer TGAATCCAGAGATAAGTTTATACGG 851 56
Reverse primer GTTCCTGCGTCATCATAGTG
MYO6 mRNA Ex25-31 Forward primer TGATGGTCTGGTTAAGGTGG 750 56
Reverse primer TCACGTAGTTCTGCATATTTCC
MYO6 mRNA Ex30/31-35 Forward primer TTTGAGTAGAGGTCCTGCTG 754 56
Reverse primer GGGCACACACCCTACCTAAG
Supplemental Table S1. Continued
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Target Oligonucleotides Product 
size 
(bps)
Annealing 
Temperature 
(°C)
Primers for genomic PCR and sequence analysis of CLIC5, MYO6 and ESPN
Primer for QPCR
CLIC5 Exon2-3 Forward primer CGGCAACTGTCCTTTCTCTC 115 60
Reverse primer GGCTAGGTTGTGCAGGTCAG
GUSB Exon2-3 Forward primer AGAGTGGTGCTGAGGATTGG 80 60
Reverse primer CCCTCATGCTCTAGCGTGTC
Supplemental Table S1. Continued
Supplemental Table S2. Overview of homozygous regions shared by the affected individuals of family 
W05-009
The reference sequences for exon numbering CLIC5, MYO6 and ESPN were NM_016929.4, 
NM_004999.3 and NM_031475.2, respectively. *This is the first exon of an alternative CLIC5 
transcript (NM_001114086.1) #These primers were only used for sequence analysis.
Genomic position were determined using the UCSC Genome Browser website (http://genome-euro.ucsc.edu/
index.html, hg19).
Start SNP End SNP
Chr.
Start 
position
End 
position
Size 
(Mb)
Known 
arNSHI geneName rsld Name rsld
SNP_A-4193053 rs2477828 SNP_A-2248124 rs2057276 6 41430495 88865821 47.38 MYO6
SNP_A-2227424 rs196004 SNP_A-2061244 rs153219 16 23966086 29215298 5.25 -
SNP_A-1794682 rs10915317 SNP_A-2070006 rs12119878 1 5081066 9218721 4.16 ESPN
SNP_A-2090773 rs11152920 SNP_A-2155415 rs783403 7 48809712 50903934 2.09 -
SNP_A-2152234 rs17238567 SNP_A-1980966 rs1366419 5 20964216 22916852 1.95 -
SNP_A-2013197 rs1912515 SNP_A-4224094 rs11018855 11 88287451 89835267 1.55 -
SNP_A-2303650 rs8105809 SNP_A-2059039 rs3745836 19 55123464 56652592 1.53 -
SNP_A-2194601 rs1447595 SNP_A-1974496 rs10513030 3 135476532 136877493 1.40 -
SNP_A-4212479 rs2159579 SNP_A-2215144 rs7800245 7 84845546 86103733 1.26 -
SNP_A-1993002 rs10503951 SNP_A-4216078 rs6996639 8 33665680 34843712 1.18 -
SNP_A-2146287 rs1124531 SNP_A-1860565 rs891974 5 169773687 170902780 1.13 -
SNP_A-2206226 rs9302387 SNP_A-2138415 rs11642765 16 20478724 21582734 1.10 -
SNP_A-4227577 rs308409 SNP_A-2214677 rs3113377 4 123752692 124834671 1.08 -
SNP_A-4195575 rs16840977 SNP_A-4239672 rs277638 3 99034331 100079447 1.05 -
SNP_A-4203661 rs1631550 SNP_A-2048940 rs2979684 8 23786381 24817441 1.03 -
SNP_A-1826210 rs7118543 SNP_A-2013513 rs4483549 11 89949097 90955972 1.01 -
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Novel and recurrent CIB2 
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affect calcium buffering and 
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CIB2 variants don’t affect Ca2+ and localization
ABSTRACT
Variants in CIB2 can underlie either Usher syndrome type I (USH1J) or 
nonsyndromic hearing impairment (DFNB48). Here, a novel homozygous 
missense variant c.196C>T and compound heterozygous variants, 
c.[97C>T];[196C>T], were found respectively in two unrelated families of Dutch 
origin. Besides, the previously reported c.272T>C functional missense variant 
in CIB2 was identified in two families of Pakistani origin. The missense variants 
are demonstrated not to affect subcellular localization of CIB2 in vestibular 
hair cells in ex vivo expression experiments. Furthermore, these variants do not 
affect the ATP-induced calcium responses in COS-7 cells. However, based on 
the residues affected, the variants are suggested to alter αIIβ integrin binding. 
Hearing impairment was nonsyndromic in all four families. However, deafness 
segregating with the c.272T>C variant in one Pakistani family is remarkably less 
severe than that in all other families with this mutation. Our results contribute to 
the insight in genotype-phenotype correlations of CIB2 mutations.
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INTRODUCTION
Genetic defects are important in the etiology of sensorineural hearing impairment 
(HI) especially in the early onset cases.1 Hereditary sensorineural HI is nonsyndromic 
(NSHI) in the majority of early onset cases but part of these will be diagnosed with 
syndromic HI later in life. Usher syndrome is the most common sensorineural HI 
syndrome with a prevalence of 3-6.2 per 100,000 and the first symptoms of retinitis 
pigmentosa most often in the first or second decade of life.2 Vestibular defects occur 
in part of the subjects with Usher syndrome and lead to delayed motor development.2 
To date, there are 13 loci and 10 genes known to be involved in the three clinical 
types of Usher syndrome.3-6 Mutations in six of these genes, MYO7A7-10, CDH2311,12, 
PCDH1513,14, WHRN15,16, SANS17 and CIB24, can lead to either Usher syndrome or 
autosomal recessive NSHI (arNSHI). Mutations in USH2A can lead to either Usher 
syndrome or nonsyndromic retinitis pigmentosa.18,19
 CIB2 belongs to a family of calcium and integrin-binding proteins. CIB2 contains 
three predicted EF hand domains, of which only the two most C-terminal EF hands 
are able to bind Ca2+.20,21 Upon Ca2+-binding, conformational changes occur which 
create a hydrophobic pocket that mediates the interaction with the C-terminal tail of 
integrin.22,23 CIB2 has a broad expression pattern that includes the inner ear where 
it is immunohistochemically detected in supporting cells and in stereocilia and 
cuticular plate of hair cells in the cochlea and the vestibular system.4 Based on 
the functional impairment of hair cells in Cib2 zebrafish morphants, it has been 
suggested that Cib2 is important for Ca2+ homeostasis in sensory hair cells, and that 
loss of Cib2 function might affect processes like mechanotransduction, adaptation, 
electromotility, and synaptic transmission.4,24 Similarly, through functional studies 
in Drosophila, CIB2 was found to be essential for adequate phototransduction and 
maintenance of photoreceptor cells.4 Furthermore, CIB2 has been demonstrated to 
be integrated into the Usher interactome via the association with whirlin and myosin 
VIIa.4 
 In this study, we present molecular identity of functional variants in CIB2 in NSHI 
affected families of Dutch and Pakistani origin (Figure 1). One is the recurrent 
c.272T>C CIB2 missense variant4 present homozygously in two Pakistani families 
with moderate-to-severe and profound prelingual arNSHI, respectively. The second 
is the novel c.196C>T missense variant found homozygously and in compound 
heterozygous state with the c.97C>T  nonsense variant in two families of Dutch 
origin with profound arNSHI. We analyzed the effect of these deafness-associated 
alleles on the expression, subcellular localization and calcium binding abilities 
of CIB2. 
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MATERIALS AND METHODS
Patients and their clinical and audiological evaluation
The current study conformed to the tenets of the Helsinki declaration. Informed 
consent was obtained from all participating subjects of two families from 
Pakistan W09-1575 and W09-1600 (Figure 1A) and from the Dutch families 
W06-0987 and 07-1069 (Figure 1B and 1C). This study was approved by the 
Department of Biosciences Ethics Review Board of the COMSATS Institute of 
Information Technology, Islamabad, Pakistan and the local ethics committee of 
the Radboud university medical center, Nijmegen, the Netherlands. 
 In all four families, other possible causes of HI, previous ear surgery and 
external ear deformities were excluded by a general ENT examination. 
Additionally, a computed tomography (CT) scan of the temporal bone was 
performed for the affected individual of family W06-0987 and one affected 
member (II.1) of family 07-1069 in order to exclude possible anatomical causes 
of HI. Pure tone audiometry was performed to determine hearing thresholds at 
0.25, 0.5, 1, 2, 4 and 8 kHz. Both air conduction and bone conduction thresholds 
were obtained to exclude a conductive hearing loss. Brainstem evoked response 
audiometry (BERA) was performed for the affected individual of family W06-
0987 and individual II.1 of family 07-1069 according to current standards. 
Visual Reinforcement Audiometry (VRA) was performed before the age of three 
years in the affected individual of family W06-0987.25 GraphPad Prism 5.00 
(GraphPad, San Diego, Ca, USA) was employed for linear regression analysis to 
evaluate whether or not HI in family W06-0987 was progressive. Classification 
of the HI is in accordance with the GENDEAF guidelines (Hereditary Hearing 
Loss Homepage). For families W06-0987 and 07-1069 vestibular function was 
assessed by electronystagmography, rotatory tests and calorisation as previously 
described.26 To evaluate retinal involvement in the disease, fundoscopy was 
performed. In addition, renal, liver and thyroid functions were assessed in 
family W06-0987. 
Genetic studies and functional evaluation of variants
Genomic DNA was isolated from peripheral-blood lymphocytes by standard 
procedures. DNA of individual II.3 from family W06-0987 was genotyped 
with the Affymetrix GeneChip Human Mapping 250K Nsp SNP array 
according to the manufacturer’s protocol. Genotype calling and calculation 
of the regions of homozygosity was performed with the Genotyping Console 
software (Affymetrix) and default settings. For families W09-1575 (IV:2, IV:6, 
C
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Figure 1. Pedigrees and segregation of CIB2 variants 
A) Pedigrees and segregation of the c.272T>C variant in the consanguineous Pakistani families W09-
1575 and W09-1600. “M” represents the mutated allele c.272C and “+” the wild type allele, c.272T.B) 
Pedigree and segregation of c.196C>T variant in family W06-0987 of Dutch origin. “M” represents the 
mutated allele c.196T and “+” the wild type allele, c.196C. C) Pedigree and segregation of c.97C>T, 
indicated as M1, and c.196C>T, indicated as M2, variants in family 07-1069 of Dutch origin. The “+” 
represents the wild type allele, c.97C. Individual II.1 underwent WES.
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IV:8, V:4) and W09-1600 (III:1, III:4, III:8, III:9), genotyping with Illumina 
HumanOmniExpress 700K arrays was performed. Homozygous regions were 
determined using the online tool Homozygosity Mapper with default settings. 
All exons of CIB2 including exon-intron boundaries were analysed for the 
presence of variants as previously described4 employing NM_006383.2 as 
reference sequence. Mutation analysis of TRIOBP was performed by Sanger 
sequencing.27 Primer sequences are available upon request. As a reference 
sequence NM_001039141.2 and NM_138632.2 were employed. 
 For affected member II.1 of family 07-1069, mutations and the common 
deletion in the GJB2 associated with DFNB1 have been excluded by Sanger 
sequencing and allele-specific PCR. Other known mutations in genes associated 
with severe congenital hearing loss i.e. CDH23, MYO7A, PCDH15, USH1C, 
USH1G, USH2A, GPR98, USH3A, DFNB31, were excluded by using the Asper 
biotech array (version 6.0 with 612 variants) for Usher syndrome (Asper biotech, 
Tartu, Estonia). Subsequently, variants in a set of 104 deafness genes (URL Gene 
list) were identified by whole exome sequencing (WES) followed by data filtering 
and interpretation. Library preparation was performed using 3 μg of purified 
DNA of affected member II.1 of family 07-1069. For enrichment the SOLiD 
optimized Sure Select All Human Exon Kit (50 Mb; Agilent Technologies, Santa 
Clara, CA, USA) was employed, followed by sequencing on 5500XL sequencers 
(Life Technologies, Carlsbad, CA, USA). Sequence reads were aligned to the 
human genome (hg19) using Lifescope v2.1 (Life Technologies), followed by 
variant calling on the aligned sequence. Variants were annotated using a custom 
analysis pipeline.28 The criteria to filter and interpret variants in the set of 104 
genes known to be associated with deafness was as described previously.28,29 An 
in-house-developed graphical user interface was used for data visualization and 
filtering within the respective gene set. 
 Molecular modeling, expression of CIB2 in hair cells by Helios gene gun 
transfection and calcium response assays of DsRed-tagged CIB2Phe91Ser, 
CIB2Arg66Trp and CIB2WT were performed as previously described.4
 All variants identified in this study were submitted to the Leiden Open 
Variant Database with the following IDs: c.97C>T, #05182; c.196C>T, #05182; 
c.272T>C, #05182. 
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RESULTS
Patient evaluation
For none of the hearing-impaired individuals additional abnormalities were 
found during ENT examination. Affected individuals of Pakistani family W09-
1575 (Figure 1A) were diagnosed with prelingual, bilateral, moderate-to-severe 
sensorineural HI (Figure 2). In another Pakistani family W09-1600 the HI was 
profound, prelingual, bilateral and sensorineural (Figure 2). There were no 
symptoms of retinal degeneration in the hearing impaired individuals of these 
two families. The ages of the affected individuals at last visit were 5, 13, 24 and 
29 years for family W09-1575 and 11, 15, 25 and 32 years for family W09-1600. 
However, no ophthalmologic examinations could be performed and therefore 
Figure 2. Audiograms of affected individuals of families W06-0987, W09-1575 and W09-1600
Longitudinal binaural mean air-conduction pure tone thresholds are shown of the hearing impaired 
member of family W06-0987. Binaural mean air-conduction pure tone thresholds are shown of 
affected members III.4 and III.9 of family W09-1600, individual V.4 and two unaffected members 
of family W09-1575 (IV:7 at 14 years of age and V:3 at 8 years of age). For individual IV.6 of W09-
1575, the air-conduction thresholds of the left ear are depicted. Age (years) at which measurements are 
performed are indicated with a symbol key.
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subclinical retinal abnormalities cannot be excluded. Individual II.3 of Dutch 
family W06-0987 (Figure 1B) presented with prelingual HI, probably congenital 
but diagnosed by a hearing test at nine months of age. BERA performed before 
the age of one year demonstrated a response at 80 dB Hl. VRA and pure tone 
audiometry revealed bilateral, profound sensorineural HI with a stable character 
and a gently downsloping audiogram configuration (Figure 2). A CT scan did 
not show any structural abnormalities of the temporal bone. Renal, liver and 
thyroid function were found to be normal. Vestibular examination showed a 
slight hyperreflexia. Ophthalmologic examination including fundoscopy at 
the age of 24 years revealed no abnormalities except for bilateral epicanthic 
folds. Both individuals of Dutch family 07-1069 (Figure 1C) were diagnosed 
with congenital, profound sensorineural hearing loss since they both failed the 
neonatal hearing screening. During BERA no responses were found for both 
individuals. Vestibular examination in II.1 displayed excitable vestibules with 
normal responses on the right and an unilateral weakness at the left vestibule. 
This was examined after cochlear implantation at the left ear. A CT scan in 
individual II.1 displayed no temporal bone abnormalities. Also, ophthalmologic 
and renal examination in the same child revealed no abnormalities. Both hearing 
impaired members of family 07-1069 received a cochlear implant with good 
results. At their last visit in the clinic at the ages of 7 (II.1) and 4 years (II.2), 
the affected sibs did not have any signs night blindness as an early symptom of 
retinitis pigmentosa.
Genetic analyses 
As a first step in the genetic analyses of the presented families, functional variants 
in GJB2 were excluded through Sanger sequencing and allele specific PCR was 
employed to exclude the common GJB2/GJB6 deletion. Homozygosity mapping 
was subsequently performed in families W06-0987, W09-1575 and W09-1600 
as part of a larger project directed towards the identification of genetic defects 
underlying sensorineural HI in consanguineous Pakistani families and non-
consanguineous families of the Netherlands.27,30 In the only affected individual 
II.3 of family W06-0987, homozygosity mapping revealed nine homozygous 
regions larger than 1 Mb (Table 1). The second large homozygous region harbored 
TRIOBP, the gene associated with the known arNSHI type DFNB28.31,32 No 
variants with a predicted functional effect were identified in TRIOBP by Sanger 
sequencing of the exons and exon-intron boundaries. The largest homozygous 
region of 16 Mb (SNP_A-1814998 ; SNP_A- A-1821537) contained the CIB2 
gene, associated with DFNB48 and USH1J by allelic functional variants.4 
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Genotyped affected individuals of the consanguineous family W09-1575 shared 
only one homozygous region larger than 3 Mb which overlapped with the only 
shared homozygous region larger than 3 Mb in genotyped affected individuals 
of family W09-1600. CIB2 is located in the overlapping chromosomal 
segment (Table 1). In family W09-1575, an additional homozygous region of 
4 Mb (rs1516570; rs12186082) was identified on chromosome 3. However, 
the affected individuals were homozygous for different alleles. Therefore this 
region was not further analyzed. 
 Mutation analysis of CIB2 in the affected individual of family W06-0987 
revealed a homozygous variant c.196C>T that is predicted to cause a substitution 
of a tryptophan for an arginine (p.(Arg66Trp)) (Supplemental figure 1A). The 
mother and unaffected sibling were carriers of this variant (Figure 1B). CIB2 
c.196C>T affects all known CIB2 protein isoforms except isoform CIB2-006 
as indicated in ENSEMBL (GRCh38) and in the Genome Browser (GRCh37) 
(Supplemental figure 2).4 The c.196C>T variant is not present in the NCBI 
dbSNP138 database, the NHLBI Exome Sequencing Project (Exome Variant 
Server), the 1000 Genomes Project and the Nijmegen exome database (5031 
exomes). In addition, c.196C>T is predicted to have a deleterious effect on 
protein function according to Polymorphism phenotyping version 2 (Polyphen2) 
with a score of 0.98 (range 0-1, 0 being benign and 1 being probably damaging), 
mutation taster with a score of 0.99 (range 0-1, 0 being benign and 1 being 
# Family Start SNP End SNP Chr. Genome Browser (Feb. 2009) Size (Mb) Known 
arNSHI gene
W06-0987 SNP_A-1814998 SNP_A-1821537 15 chr15:68,705,697-84,705,110 16.00 CIB2
 SNP_A-1920225 SNP_A-1945927 22 chr22:36,758,849-40,089,893 3.33 TRIOBP
 SNP_A-2032497 SNP_A-2091266 2 chr2:82,534,958-85,096,481 2.56 -
 SNP_A-2033819 SNP_A-2145805 14 chr14:82,354,342-84,798,493 2.44 -
 SNP_A-2210335 SNP_A-1965012 2 chr2:135,471,415-137,880,893 2.41 -
 SNP_A-2277801 SNP_A-1876469 9 chr9:94,682,964-96,757,868 2.07 -
 SNP_A-2029422 SNP_A-4193502 1 chr1:58,894,050-60,899,424 2.01 -
 SNP_A-1856228 SNP_A-2043311 8 chr8:50,258,845-52,029,738 1.77 -
 SNP_A-1934688 SNP_A-4209616 3 chr3:102,434,617-103,440,905 1.01 -
W09-1575 rs4438265 rs12912915 15 chr15:70,826,268-92,013,118 21.19 CIB2
W09-1600 rs8036698 rs2732151 15 chr15:68,716,776-84,203,685 15.49 CIB2
Table 1. Homozygosity mapping in families W06-0987, W09-1575 and W09-1600
Homozygous regions larger than 1 Mb in the affected individual of family W06-0987 and homozygous 
regions larger than 3 Mb shared by affected individuals in the consanguineous families W09-1575 and 
W09-1600.
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probably damaging) and Sorting Intolerant From Tolerant (SIFT) with a score 
of 0 (≤ 0.05 predicted to be damaging, >0.05 predicted to be tolerated). The 
c.196C>T missense variant affects the codon for amino acid residue Arg66 that 
is moderately conserved with a score of 4 (9; conserved, 1; variable) according 
to the ConSeq online bioinformatic tool. The arginine residue at position 66 
is conserved across the CIB2 orthologs and CIB4 paralogs in a wide range of 
species. In the paralogs CIB1 and CIB3 and several of the CIB2 orthologs, 
lysine is found at this position that is, like arginine, a positively charged amino 
acid (Supplemental figure 1B).
 Sanger sequencing of CIB2 in families W09-1575 and W09-1600 revealed 
a homozygous missense variant c.272T>C (Supplemental figure 1A) which is 
predicted to substitute a serine for a phenylalanine. This functional variant was 
previously described to be a founder mutation and a common cause of arNSHI in 
the Pakistani population.4 However, in contrast to previously reported Pakistani 
families homozygous for the variant c.272T>C, the affected individuals of 
family W09-1575 had moderate-to-severe sensorineural HI (Figure 2). 
 For family 07-1069, DNA diagnostics was requested after the diagnosis 
of profound sensorineural HI. Known functional variants in genes for Usher 
syndrome were excluded. Subsequent analysis of 104 deafness genes in individual 
II.1 of family 07-1069 revealed only two likely functional variants: c.196C>T 
and c.97C>T in CIB2. The latter is a nonsense variant of the codon for Arg33 
(p.(Arg33*)) and the former variant was already detected homozygously in family 
W06-0987). The presence of the variants was confirmed by Sanger sequencing 
in both II.1 and her affected sister, II.2. They inherited c.97C>T from their 
unaffected mother (Figure 1C), indicating that the variants in the two affected 
children are present in the compound heterozygous state (c.[97C>T];[196C>T]). 
Variant c.97C>T is a rare SNP, rs201845656, found three times in 8586 alleles in 
the European American population (allele frequency of 0,03%) in EVS and eight 
times in the Nijmegen exome database (n=5031, allele frequency of 0,08%). 
The c.97C>T variant affects the CIB2 isoforms B and C but not isoforms A and 
CIB2-006 (Supplemental figure 2).4 The c.97C>T variant is predicted to result 
in nonsense-mediated decay, since it introduces a premature termination codon 
more than 54 bp upstream of the last intron.33
The c.196C>T and c.272T>C variants do not affect targeting of CIB2 
to the stereocilia tip of vestibular hair cells
CIB2 is localized along the stereocilia of cochlear and vestibular hair cells as 
well as at the stereocilia tips.4 The mechanism that permits the targeting of 
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Figure 3. The c.196C>T variant does not affect the localization of CIB2 in hair cells of the 
vestibular system
(A,B,C) CIB2WT-GFP, CIB2Arg66Trp-GFP and CIB2Phe91Ser-GFP constructs were overexpressed in the P2 
vestibular system of mouse using the gene gun technology. The CIB2WT-GFP variant is targeted to the 
tip of the stereocilia (green, arrows) and accumulates in the cuticular plate of sensory hair cells (A). 
The localization of CIB2 is not disrupted when c.196C>T and c.272T>C variants were introduced (B, 
C). Phalloidin labeling is in red and DAPI staining in blue. Scale bar: 10µm.
A
B
C
110
CIB2 variants don’t affect Ca2+ and localization
CIB2 to the region of the mechanotransduction machinery is still unclear. We 
transiently overexpressed a CIB2Arg66Trp-GFP and CIB2Phe91Ser-GFP constructs in P2 
vestibular system explants in order to investigate their effect on CIB2 targeting. 
We found that, like wild type control (CIB2WT-GFP), CIB2Arg66Trp-GFP, as well 
as CIB2Phe91Ser-GFP, accumulate in the cuticular plate, along and at the tip of the 
stereocilia of vestibular hair cells (Figure 3). These results suggest that, at least 
ex vivo, the arNSHI associated variants do not affect CIB2 targeting in vestibular 
sensory hair cells (Figure 3).
 
The c.196C>T and c.272T>C variants do not affect the calcium 
buffering property of CIB2
To test the calcium buffering property of CIB2Arg66Trp variant, we performed 
a ratiometric Ca2+ imaging assay on transiently transfected COS-7 cells and 
measured ATP-induced inositol triphosphate (IP3)-dependent calcium responses. 
Cells overexpressing DsRed-CIB2WT had a significant decrease in ATP-induced 
Ca2+ release as compared to mock-transfected cells (Figure 4C). The calcium 
responses of cells transfected with DsRed-CIB2 Phe91Ser or DsRed-CIB2Arg66Trp 
constructs were comparable to cells transfected with a DsRed-CIB2WT construct 
showing that the amino acid substitutions do not affect the calcium-buffering 
ability of CIB2 (Figure 4C).
Molecular modeling suggests impaired interaction of CIB2 with 
effector molecules due to the c.196C>T and c.272T>C variants
When modeled using the known crystal structure of CIB1 as backbone4,21,34 
in CIB2 the p.Arg66 maps to the N-terminal domain of CIB2 within a region 
that has been implicated in the interaction of CIB protein with the carboxy 
terminal, unstructured, negatively charged tail of αIIβ integrin. CIB1 is involved 
in the activation of integrin αIIβ3. It is thought that hydrophobic interactions 
between the αIIβ helix and the C-terminal domain of CIB1 primarily drive the 
interaction, with the N-domain involved in electrostatic stabilizing interactions 
with the negatively charged unstructured C-terminal tail of αIIβ (residues 
P998PLEEDDEEGQ1008). Implicated in this interaction are residues p.Arg33 and 
p.Lys65 of CIB1. By structure-based sequence alignment this corresponds to 
p.Arg33 and p.Arg66 of CIB2. Therefore, an amino acid change at p.Arg66 
would likely destabilize the interaction with integrin and thus attenuate 
integrin activation (Figure 4 A, B).22,34 In consistence with our calcium imaging 
data, Arg66 is located away from the Ca2+ binding pockets20,21, and thus the 
substitution of tryptophan for arginine at position 66 is predicted not to alter 
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calcium buffering abilities of CIB2. Similarly, the substitution of serine for 
phenylalanine at position 91 is also predicted to weaken the interaction of CIB2 
with αIIβ integrin.4
Figure 4. (A, B) Molecular modeling of CIB2
The p.(Arg66Trp) and p.(Phe91Ser) missense mutations in CIB2, associated with arNSHI are predicted 
to alter the interaction of CIB2 with effector molecules. For molecular modeling, we used (A) the 
NMR structure of CIB1 bound to αIIβ integrin peptide and (B) the Protein Data Bank (PDB) 1XO5 
crystal structure of Ca2+-CIB1. Two Ca2+ ions are represented by grey spheres. 
(C) The c.196C>T variant does not affect the calcium buffering ability of CIB2
COS-7 cells were transfected with DsRed-CIB2WT, DsRed-CIB2Arg66Trp and DsRed-CIB2Phe91Ser 
constructs. The increase of cytosolic calcium concentration in response to the application of 1 µM 
of ATP was measured with ratiometric Fura-2 imaging as previously described.4 The ATP-evoked 
calcium responses decreased when DsRed-CIB2WT (Red bar) is overexpressed due to the ability of 
CIB2 to bind and buffer Calcium. The p.(Phe91Ser) and p.(Arg66Trp) substitutions did not alter 
calcium buffering ability of CIB2 (grey bars on the right). Data are normalized to the average response 
of mock-transfected cells and are shown as mean ± s.e.m. ***P < 0.001; **P < 0.01; *P < 0.05.
A C
B
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DISCUSSION
In this study we present a new homozygous functional variant, c.97C>T, and 
a compound heterozygous variants, c.[97C>T];[196C>T] in CIB2 underlying 
DFNB48 arNSHI in an isolated case (W06-0987) and in a family (07-1609), 
respectively, of Dutch origin. Additionally, we report two consanguineous 
families of Pakistani origin (W09-1575 and W09-1600) with arNSHI carrying 
the previously described and recurrent CIB2 variant, c.272T>C. Due to this 
founder variant, defects in CIB2 are the major cause of arNSHI in Pakistan.4 
 DFNB48 and USH1J are caused by allelic CIB2 variants.4 Patients of the 
so far only family with USH1J present with prelingual, bilateral profound HI. 
Retinitis pigmentosa in the USH1J family progressed from mild to complete 
vision loss and was detected as early as 10 years of age. Besides that, vestibular 
dysfunction, later confirmed by ENG, was suspected since there was a delayed 
onset of ambulation.35 The DFNB48 phenotype found in three of the four 
families reported in the present study is consistent with the previously described 
DFNB48 phenotype4,36, severe to profound, prelingual bilateral HI without signs 
of retinitis pigmentosa and vestibular dysfunction. However, the HI in family 
W09-1575 with the recurrent homozygous variant, is less severe. The age at last 
evaluation of affected individuals in this family, who were diagnosed in early 
childhood, varies from 5 to 29 years and there are no signs of progression to 
profound HI. Genetic modifying factors might contribute to the less severe HI 
as compared to that in the previously descriDFNB48 families.4 Therefore, it 
is worthwhile to perform more extensive genotyping in this family in order to 
identify candidate modifying DNA variants for CIB2 defects which may provide 
insight into pathogenic mechanisms.
 Interestingly, the c.196C>T variant associated with arNSHI is located very 
close to the c.192G>C variant associated with the USH1J phenotype.4 At their 
most recent evaluation at the ages of 24 years (family W06-0987) and seven 
and four years (family 07-1069), the hearing impaired individuals with the 
c.196C>T variant in the homozygous or compound heterozygous state did not 
have any symptoms of early retinitis pigmentosa. Since electroretinography 
could not be performed, we cannot exclude an early stage of retinitis pigmentosa 
in these individuals. However, classical Usher syndrome type I as diagnosed 
in the USH1J family with the c.192G>C variant in the homozygous state4,35 
is excluded in the present families because of absence of vestibular areflexia 
and for family W06-0987 in addition because of lack of symptoms of retinal 
degeneration at 24 years of age.2 The difference in phenotypic effect of the 
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c.192G>C (p.(Glu64Asp)) and c.196C>T (p.(Arg66Trp)) variants in CIB2 might 
be the result of a larger negative effect of the former mutation because of loss of 
a salt bridge between residues Arg33 and Glu64 which is formed in the absence 
of integrin.4 The associations of CIB2 with the Usher proteins myosin VIIa 
(USH1B) and whirlin (USH2D)16 are candidates for being affected differently by 
the two mutations but so far the region(s) of CIB2 that mediate(s) these direct or 
indirect interactions is still elusive. The identification of additional USH1J and 
DFNB48 families can shed light on the underlying reasons for the phenotypic 
differences, DFNB48 and USH1J, of mutations that affect neighboring 
amino acid residues. Phenotypes varying from arNSHI, Usher syndrome type 
I and hearing impairment combined with a variable age of onset of retinitis 
pigmentosa or asymptomatic retinitis pigmentosa-like findings has previously 
been described for functional variants in CDH23.37 Screening of CIB2 in more 
families in different populations will add more information on the frequency of 
functional variants of CIB2  and will contribute to define phenotype-genotype 
correlations of CIB2 variants. 
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WEB RESOURCES
1000 Genomes Project: http://www.1000genomes.org/
Conseq: http://conseq.tau.ac.il/
ENSEMBL: http://www.ensembl.org/Homo_sapiens/Info/Index
Exome variant server: EVS, http://evs.gs.washington.edu/EVS/
Genome browser: http://genome-euro.ucsc.edu
Gene list: https://www.radboudumc.nl/Informatievoorverwijzers/
Genoomdiagnostiek/en/Pages/Hearingimpairment.aspx)
Hereditary Hearing Loss Homepage: http://hereditaryhearingloss.org/
Homozygosity Mapper: www.homozygositymapper.org
Interpro: http://www.ebi.ac.uk/interpro/
LOVD: http://databases.lovd.nl/shared/variants/0000053133#05182;  
http://databases.lovd.nl/shared/variants/0000053131#05182; http://databases.
lovd.nl/shared/variants/0000053132#05182
Mutation Taster: www.mutationtaster.org
Polymorphism phenotyping 2: Polyphen2 , http://genetics.bwh.harvard.edu/pph2/
Sorting Intolerant From Tolerant: SIFT, http://sift.jcvi.org/
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SUPPLEMENTAL FIGURES
Supplemental figure 1. CIB2 variants causing arNSHI
A) DNA sequence chromatograms of exon 3 and exon 4 of CIB2 depicting wild type sequences and 
the homozygous mutations c.196C>T and c.272T>C, respectively, and chromatograms of exon 3 with 
the compound heterozygous mutations c.97C>T and c.196C>T and wild type sequences. Nucleotide 
positions are according to human CIB2 isoform A (accession no. NM_006383.2). B) Clustal W 
alignment of CIB family members revealed that the p.Arg66 residue in human CIB2 (accession 
no. EAW99186) is either an arginine or a lysine in orthologs and homologs in a wide variety of 
species. Furthermore, residue phenylalanine at position 91 is highly conserved across homologs and 
orthologous as shown previously.4
A B
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Supplemental figure 2. Schematic representation of the genomic structure of CIB2 and of the 
isoforms of the encoded protein
In blue the exonic parts encoding the predicted EF hands, in red the only CIB2 mutation described 
causing USH1J 4, in bold black the mutations described here to cause DFNB48 and in regular black 
the CIB2 mutations previously described to cause DFNB48.4 The accession numbers for the cDNA 
sequences encoding the respective isoforms are uc002bdc.2 for isoform A, uc002bdb.2 for isoform 
B, uc010ums.2 for isoform C and uc031qta.1 for isoform CIB2-006, according to the UCSC Genome 
Browser (GRCh37/hg19).
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aBStraCt
Linkage analysis combined with whole-exome sequencing in a large family 
with Non-Syndromic, congenital and stable Unilateral and Asymmetric 
Hearing Loss (NS-UHL/AHL) revealed a heterozygous truncating mutation, 
c.286_303delinsT (p.Ser96Ter), in KITLG. This mutation co-segregated with 
the NS-UHL/AHL as a dominant trait with reduced penetrance. By screening 
a panel of probands with NS-UHL/AHL, an additional mutation, c.200_202del 
(p.His67_Cys68delinsArg), was found. In vitro studies revealed that the 
p.His67_Cys68delinsArg transmembrane isoform of KITLG is not detectable 
at the cell membrane supporting pathogenicity. KITLG encodes a ligand for the 
KIT receptor. Also, KITLG-KIT signaling and MITF are suggested to mutually 
interact in melanocyte development. Since mutations in MITF are causative 
of Waardenburg syndrome type II (WS II), we screened KITLG in suspected 
WS II probands. A heterozygous missense mutation, c.310C>G (p.Leu104Val), 
was identified which segregated with WS II in a small family. In vitro studies 
revealed that the p.Leu104Val transmembrane isoform of KITLG is at the cell 
membrane as is wild-type KITLG. However, in culture medium of transfected 
cells, the p.Leu104Val soluble isoform of KITLG was reduced whereas no 
soluble p.His67_Cys68delinsArg and p.Ser96Ter KITLG could be detected. 
These data suggest that mutations in KITLG associated with NS-UHL/AHL 
have a loss-of-function effect. The mechanism of the mutation underlying WS 
II leading to membrane incorporation and reduced secretion of KITLG we 
speculate occurs via a dominant negative or gain-of-function effect. Our study 
unveils different phenotypes associated with KITLG, previously associated with 
pigmentation abnormalities and will thereby improve the genetic counseling of 
individuals with KITLG variants.
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INtrODUCtION
Familial Non-Syndromic sensorineural Unilateral and Asymmetric Hearing 
Loss (NS-UHL/AHL) (MIM 125000) is rare with only a few families described 
in literature and no genes or loci known to date.1-3 Like symmetric hearing 
loss (HL), UHL/AHL can negatively affect the life of individuals because of 
cognitive and social developmental delay. UHL/AHL can also be inherited as 
part of a syndrome, e.g. Waardenburg syndrome (WS) (PS193500) or Pendred 
syndrome (MIM 274600), or it can be induced by environmental factors such as 
prematurity, trauma and meningitis. 
 WS is a dominantly inherited auditory-pigmentary syndrome with an 
estimated prevalence of 5-10:100,000. To date, four types of WS (I to IV) are 
distinguished and seven genes are found to be associated with the syndrome. 
The classification of WS is based on the presence of specific clinical features in 
addition to pigmentary abnormalities of hair, skin, and eyes and congenital HL 
as in WS II.4 These additional clinical features are craniofacial defects in WS 
I, craniofacial and limb defects in WS III and Hirschsprung disease in WS IV. 
All WS genes function in the same pathways involved in development of neural 
crest-derived melanocytes by influencing Mitf expression and/or activity.5-9 
 Besides WS, there are other HL syndromes accompanied by hypopigmentation 
due to melanocyte defects.10 One of these is the piebald trait (MIM 172800). 
Piebaldism is characterized by congenital regional absence of melanocytes in 
the skin and hair caused by heterozygous loss of function mutations in KIT 
(MIM 164920).10 Very occasionally, piebald trait has been found to be associated 
with congenital HL indicating that they might be part of the same disorder.11,12
 By using a combined strategy of linkage analysis and whole-exome 
sequencing (WES) in a large Dutch family with NS-UHL/AHL, a truncating 
mutation, c.286_303delinsT (NM_003994.5 and NM_000899.4, p.Ser96Ter), of 
KITLG (MIM 184745) was identified. Targeted gene testing of a panel of NS-
UHL/AHL affected individuals identified an in-frame deletion, c.200_202del 
(NM_003994.5 and NM_000899.4, p.His67_Cys68delinsArg), in a family of 
Spanish origin. Due to the dual regulation of melanocyte development by KIT-
KITLG signaling and MITF,6,8,13 a cohort of WS II affected individuals was 
tested for mutations in KITLG which revealed a missense mutation, c.310C>G 
(NM_003994.5 and NM_000899.4, p.Leu104Val), that was segregating with 
WS II in another family from the Netherlands. We analyzed the effect of these 
mutations on subcellular localization and secretion of the transmembrane and 
soluble KITLG isoforms, respectively.
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SUBjeCtS aND MethODS
Subject evaluation
The current study was approved by the medical ethics committee of the Radboud 
university medical center, the Hospital Universitario Ramón y Cajal and the 
Institutional Review Board of Baylor College of Medicine. Written informed 
consent was obtained from all participating subjects.
 The medical history was taken from all participants, paying special attention 
to hearing impairment, vestibular symptoms and possible causes of acquired 
deafness. In family W09-1628 (Figure 1A), 26 people participated in the Ear, 
Nose and Throat (ENT) evaluation (II:4, III:1, III:3, III:4, III:5, III:6, III:7, III:9, 
IV:1, IV:3, IV:4, IV:5, IV:6, IV:7, IV:8, V:1, V:2, V:3, V:4, V:5, V:6, V:7, V:8, 
V:9, V:10, V:11). In family S1489, the index case III:1 and his father II:1 took 
part in an ENT examination (Figure 1B). From family 12-01744, two individuals, 
the index II:1 and his mother I:2, both affected with WS II, participated in an 
ENT evaluation (Figure 1C). The affection status of the other family members 
was based information provided by close relatives. 
 Individuals were considered to be affected if at least one ear showed three 
pure tone thresholds below the 95th percentile (P95) at the last evaluation. AHL 
was indicated when the difference between the hearing thresholds of both 
ears was more than 10 dB at three or more frequencies or more than 15 dB at 
two or more frequencies. The HL was indicated as unilateral if three or more 
frequencies were beyond the P95 value in only one ear, with normal hearing in 
the contralateral ear. 
 Audiometric examination comprised conventional pure-tone audiometry 
in a sound-treated room according to the International Organization for 
Standardization (ISO) standards 389 and 8253-1 (ISO 389. 1985; ISO 8253. 
1989). Air conduction thresholds were measured in dB HL at 0.25, 0.5, 1, 2, 4, 
and 8 kHz. Bone conduction thresholds were measured to exclude conductive or 
mixed HL. The P95 threshold values in relation to the person’s age and sex were 
derived for each frequency using the ISO 7029 method (ISO 7029. 1984).14 In 
family W09-1628, speech-audiometry was performed under the above-mentioned 
conditions using standard monosyllabic (consonant-vowel-consonant) Dutch 
word lists. For individual II:1 of family 12-01744 play-audiometry with blocks 
was performed at the age of three years. Thresholds were measured in dB HL at 
0.5, 1, and 4 kHz.
 Six affected members of family W09-1628 (III:5, IV:1, V:1, V:5, V:6, V:7) 
underwent vestibular and ocular motor tests. Ocular motor evaluation comprised 
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saccades, smooth pursuit, optokinetic nystagmus, as well as gaze evoked and 
spontaneous nystagmus. Vestibulo-ocular reflexes (VOR) were evaluated using 
electronystagmography (ENG) with computer analysis. Vestibular stimulation 
comprised rotary and caloric tests.15 The diagnosis of hyporeflexia in the 
rotary test was based on finding parameter values below the 5th percentile of 
normal. When the response parameters had directional preponderance values 
of >25%, VOR asymmetry was considered to be significant. The finding of 
Figure 1. Families affected by KITLG mutations. A) Pedigree of family W09-1628 with NS-UHL/
AHL. Asterisks mark individuals who were genotyped with HumanOmniExpress BeadChip arrays. 
‘M’ represents the mutant allele c.286_303delinsT and ‘+’ the wild-type allele. For privacy reasons, the 
genotype for the c.286_303delinsT has not been indicated for unaffected individuals except for those 
with affected offspring. B) Pedigree of family S1489 with NS-AHL. ‘M’ represents the c.200_202del 
variant and ‘+’ the wild-type allele. C) Pedigree of family 12-01744 with WS II. ’M’ represents the 
variant c.310C>G, ‘+’ the wild-type allele and ‘?’ indicates an unclear affection status.
A
B C
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caloric asymmetry relates to a difference in response levels larger than 20%. 
Caloric hyporeflexia indicates a response level of < 7º/sec for cold and < 10 º/sec 
for warm. According to ANSI (1999) procedures, we have established normative 
laboratory data using the 95% confidence limit for the normal population. To avoid 
underestimation, we have calculated the lower limit of acceptance by using 2.34 
times the standard deviation from the mean to define a hyporeactivity of the caloric 
responses (i.e. 7º/sec and 10 º/sec for cold and warm irrigation, respectively).16
 High resolution spiral computed tomography (CT) images of the temporal bones 
of both ears, with 0.6 mm axial sections and coronal reconstructions, were obtained 
to detect possible inner ear anomalies in one affected individual (V:7) of family 
W09-1628. The images were analyzed by an experienced head and neck radiologist. 
 In the index case III:1 of family S1489 magnetic resonance imaging (MRI) was 
performed to exclude inner ear defects and retrocochlear pathology. 
 To evaluate the presence of pigmentation abnormalities, history was taken and 
physical examination was performed in all three families W09-1628, 12-01744 and 
S1489. Fourteen individuals of family W09-1628 participated in a dermatological 
evaluation, 10 of whom were heterozygous for the mutation underlying the HL 
in the family (eight had HL, in one of whom the HL was not associated with the 
mutation in the family, two did not show HL) and four of whom were controls 
without the mutation. Dermatological evaluation included determination of skin 
type (I - VI), eye color, hair color, poliosis of the head, cilia and eyebrows, skin 
depigmentation, hypopigmentation, hyperpigmentation, number of naevi, allergic 
reactions, other observed skin abnormalities and treatment of skin abnormalities in 
the past. The whole body was examined and a Wood’s lamp was used to analyze the 
hypo-, hyper- and depigmentations. If necessary, skin abnormalities were reviewed 
with a dermatoscope. Examination with a Wood’s lamp was also performed for the 
affected individuals of family 12-01744.
 To evaluate the presence of abnormalities in hematopoiesis, blood samples 
were collected of the 14 individuals that underwent dermatological evaluation. 
Blood samples were evaluated for haemoglobin concentration, mean corpuscular 
haemoglobin concentration (MCHC), erythrocyte-counts, mean corpuscular 
volume (MCV), red blood cell count distribution width (RDW), reticulocyte 
counts, hematocrit, trombocyte counts, leukocyte counts and differentiated 
leukocytes (neutrophilic granulocytes, lymphocytes, eosinophilic granulocytes, 
basophil granulocytes and monocytes) by microscopic analysis and an automated 
protocol. As a reference the Radboud university medical center standard 
was used.17
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Description of subject cohorts
The cohort of 64 probands of Dutch origin, with a clinical suspicion of WS II 
consisted of three classes of affected individuals: (1) 31 subjects with bilateral 
symmetric HI and hair, eye and/or skin pigmentation abnormalities, (2) nine 
subjects with AHI of whom five had additional hair, eye and/or skin pigmentation 
abnormalities and (3) 24 subjects with UHL of whom 15 had pigmentation 
abnormalities of hair, eye, and/or skin. Because AHL is described in WS II, 
MITF testing was requested in routine diagnostics and excluded. In the index 
case of family 12-01744 of this cohort, all genes known to be involved in WS II 
(MITF, SOX10, SNAI2) were analyzed by Sanger sequencing and no potentially 
pathogenic variants were found. The NS-UHL/AHL cohort consisted of 23 index 
cases, 10 with NS-UHL and 13 with NS-AHL. In all subjects of this cohort 
the c.35delG GJB2 (MIM 121011) mutation (NM_004004.5, p.Gly12Valfs*2) 
and the m.1555A>G mutation in MT-RNR1 (MIM 561000, NC_012920.1) were 
excluded. These subjects were not pretested for MITF mutations.
Linkage analysis
Genomic DNA was isolated from peripheral blood lymphocytes by standard 
procedures. The HumanOmniExpress BeadChip arrays (Illumina) with a total of 
733,202 SNPs covering the genome at a median of 2.2 kb intervals were used 
for genotyping DNA from individuals’ blood (Figure 1A). SuperLink online 
SNP 1.1 software was employed for multipoint LOD score calculations using 
a window size of ten SNPs.18 In order to select independent SNPs, pruning 
(r2=0.025) was performed by using PLINK.19 The disease was assumed to be 
an autosomal dominant disorder with a disease allele frequency of 0.001. The 
penetrance of the disease allele was set at 70%.
 In order to confirm the linkage region defined by Superlink, genotyping of 
variable number of tandem repeat (VNTR) genetic markers was performed.20 
Touchdown PCR was used to amplify the VNTR markers. Marker heterozygosity, 
order and genetic location were derived from the Marshfield genetic map. VNTR 
markers were selected to encompass the linkage interval, on chromosome 12, 
region q21.32-q23.1. The alleles were assigned using Gene Mapper v.4.0 
software (Applied Biosystems). 
Whole-exome sequencing
WES was performed at the Human Genome sequencing center (HGSC) at 
Baylor College of Medicine through the Baylor-Hopkins Center for Mendelian 
Genomics initiative. Using 0.5 µg of DNA, an Illumina paired-end pre-capture 
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library was constructed according to the manufacturer’s protocol (Illumina 
Multiplexing_SamplePrep_Guide_1005361_D) with modifications as described 
in the “BCM-HGSC Illumina Barcoded Paired-End Capture Library Preparation” 
protocol. Four pre-captured libraries were pooled and then hybridized in solution 
to the HGSC CORE design (52Mb, NimbleGen) according to the manufacturer’s 
protocol “NimbleGen SeqCap EZ Exome Library SR User’s Guide (Version 
2.2)” with minor revisions.21 The sequencing run was performed in paired-end 
mode using the Illumina HiSeq 2000 platform, with sequencing-by-synthesis 
reactions extended for 101 cycles from each end and an additional seven cycles 
for the index read. With a sequencing yield of 10.4 Gb, the samples achieved 
91% of the targeted exome bases covered to a depth of 20X or greater. The 
overall coverage in the linkage interval was optimal with 97.7% and 94.4% of 
base pairs covered ≥10X for individuals IV:1 and III:9, respectively. Illumina 
sequence analysis was performed using the HGSC Mercury analysis pipeline,22,23 
which moves data through various analysis tools from the initial sequence 
generation on the instrument to annotated variant calls (SNPs and intra-read 
insertions and deletions). 
Sanger sequence analysis
Primers for amplification of exons and exon-intron boundaries of KITLG 
(NM_003994.5 and NM_000899.4) and KITLG rs642742 and rs12821256 were 
designed with ExonPrimer (Table S1). Amplification by PCR was performed on 
40 ng of genomic DNA with Taq DNA polymerase (Roche or Invitrogen). PCR 
fragments were purified with NucleoFast 96 PCR plates (Clontech) or ExoI/
FastAP (Fermentas) in accordance with manufacturer’s protocols. Sequence 
analysis was performed with the ABI PRISM BigDye Terminator Cycle 
Sequencing V2.0 Ready Reaction kit and analyzed with the ABI PRISM 3730 
DNA analyzer (Applied Biosystems). As reference sequence NM_003994.5 and 
NM_000899.4 were employed.
 The presence of the KITLG c.286_303delinsT mutation was determined in 153 
ethnicity matched control individuals. To do so, exon 4 of KITLG was amplified 
and fragments were analyzed by agarose gel electrophoresis. The presence of the 
KITLG c.200_202del variant was investigated in 200 controls of Spanish origin 
by a size-based screening with one primer labeled with a 6-FAM fluorophore. 
Allele size was determined by capillary electrophoresis in an ABI PRISM 3100 
genetic analyzer (Applied Biosystems) and analysis with the GeneScan software 
(Applied Biosystems). For all three KITLG variants absence was verified in 
the following databases: the Exome Variant Server (>200,000 exomes), the 
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Nijmegen WES database (5031 exomes), Exome Aggregation Consortium 
database (ExAC, 65,000 exomes), the “Centro de Investigación Biomédica en 
Red de Enfermedades Raras” (CIBERER) Exome Sever (403 exomes), and the 
WES database of the Baylor-Hopkins Center for Mendelian Genomics (~5000 
exomes). 
 A possible effect of the KITLG variants was predicted with the following 
software tools included in Alamut (Interactive Biosoftware): Sorting Intolerant 
from Tolerant (SIFT), Polymorphism phenotyping version 2 (Polyphen2), 
Mutation Taster, NetGene, BDGP Splice prediction site and Human Splice 
Finder. The conservation of the substituted amino acids was scored by using the 
Conseq online tool. 
pCr4-topo cloning
Exon 4 of KITLG from individual IV:1 in family W09-1628, and index case 
III:1 from family S1489 were amplified (primers as for sequencing) and cloned 
into a pCR4-Topo vector (Invitrogen) according to the manufacturer’s protocol. 
Plasmid DNA was isolated from transformed E. coli DH5α with the NucleoSpin 
Plasmid (NoLid) kit (Machery Nagel) and analyzed by Sanger sequence analysis 
as described above. 
expression of KItLG in NIh3t3 cells
Total RNA was extracted from human control peripheral blood using QIAamp® 
RNA Blood mini Kit (Qiagen) following the manufacturer’s instructions. 
Reverse transcription was carried out using 1μg of RNA and random  hexamers 
with the Transcriptor First Strand cDNA Synthesis Kit (Roche). Full-length 
transcripts encoding the human KITLG transmembrane (NM_003994.5) and 
soluble (NM_000899.4) isoforms were amplified using modified primers; the 
forward primer contains a BamHI site and the reverse primers (R2-XhoI or R1-
XhoI) contain a XhoI restriction site (Table S1). Amplimers were cloned in 
the eukaryotic expression vector pIRES-hrGFP-1a (Stratagene) to obtain two 
different sets of plasmids suitable to generate respectively: 1) the human soluble 
KITLG protein (with the region encoded by exon 6) and 2) the KITLG protein 
(without the region encoded by exon 6) fused to three FLAG epitopes at the 
C-terminal end.
 Plasmids encoding the aberrant KITLG, p.His67_Cys68delinsArg, p.Ser96Ter 
and p.Leu104Val, were generated by direct mutagenesis with the QuickChange 
Site-Directed Mutagenesis Kit (Stratagene) and verified by Sanger sequencing. 
Cell culture, transfection and detection of proteins by immunofluorescence were 
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performed as previously described.24 Cells were transiently transfected with 
500 ng of wild-type or mutated constructs using Lipofectamine 2000 (111668, 
Invitrogen) according to the manufacturer’s protocol. As primary antibodies, 
the monoclonal anti-FLAG M2 mouse antibody (1:500; SIGMA, F1804) or 
with anti-KITLG antibody (1:1000; Abcam, ab52603, anti-SCF) were used and 
as secondary antibodies the Alexa Fluor 488-conjugated goat anti-mouse IgG 
(1:1000; Molecular Probes, A-11017; Invitrogen) or Alexa Fluor 594-conjugated 
goat anti-rabbit (1:500. Molecular Probes, A11037; Invitrogen) were employed. 
Slides were mounted using FluorsaveTM Reagent (Calbiochem). Images were 
acquired and analyzed by confocal microscopy (Nikkon C1 plus ECLIPSE Ti-e 
microscope and an 60X Plan Apo VC OIL objective with NA 1.4).
enzyme-linked immunosorbent assay (eLISa) 
In order to assess the levels of the soluble KITLG isoform, a commercial 
ELISA kit (ab100636 SCF Human ELISA kit) was employed according to 
manufacturer’s instructions (Abcam). NIH3T3 cells were independently 
transfected with plasmids encoding soluble wild- type KITLG or soluble KITLG 
containing the mutations identified in this study (p.Ser96Ter, p.Leu104Val, 
and p.His67_Cys68delinsArg). After cells were cultured for 24 hrs, cell-free 
supernatants were collected by centrifuging at 15000 rpm for 10 min at 4 ºC. 
Samples were stored at -70ºC until the ELISAs were performed. Samples were 
diluted with one volume of 1X assay diluent B. The detection limit was 2 pg/
ml and the mean intra- and inter-assay coefficients of variability were < 10% 
and < 12%, respectively. Samples were assayed in quadruplicate and at least 
four independent transfections were performed. Transfection levels of cells with 
the wild-type and mutant constructs were determined by detection of GFP and 
KITLG by (immuno)fluorescence of permeabilized cells. For detection of the 
latter, the anti-KITLG antibody (Abcam, ab52603, anti-SCF. Figure S1) was 
employed. The dosage of the soluble form detected by ELISA in the medium was 
normalized to the quantity of transfected cells per well in each case. Cells were 
examined with a fluorescence inverted microscope (Olympus IX81) equipped 
with a UPLFLN40X, PLAPON60XO and UPLSAPO100XO objectives. Images 
were recorded with a cooled CCD-F View II (Soft Imaging System) camera 
and processed using Cell R software (Olympus). We verified that the ELISA 
kit allowed the identification of the aberrant KITLG proteins, including the 
truncated form (p.Ser96Ter), by using cellular extracts of permeabilized cells 
transfected with constructs encoding FLAG-tagged transmembrane KITLG 
aberrant isoforms (Figure S2). 
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Clinical characterization of families with NS-UhL/ahL and WS II 
Family W09-1628 A large Dutch family, W09-1628 (Figure 1A), with autosomal 
dominant, congenital, non-syndromic sensorineural HL and a large inter- 
and intra-individual variation of severity and audiogram configuration was 
ascertained. Otoscopy was normal for all but two individuals, V:7 and V:8 (for 
details see the Supplemental Note ). 
 In cases with UHL, either the left or the right ear was affected and severity 
of the HL varied from mild to profound (Figure 2A and Figure S3). Overall, 
five individuals presented with NS-AHL (III:9, V:1, V:5, V:6, V:11) and four 
individuals with NS-UHL (III:1, III:5, IV:1, V:7) (Figure S3). HL was only 
affecting or more pronounced in the lower frequencies (< 2 kHz) in four 
Figure 2. Pure tone audiometry in families affected by KITLG mutations. A) Pure tone audiograms for 
individuals of family W09-1628 with UHL (III:5) and AHL (V:6). B) Pure tone audiograms for family 
S1489 with AHL. C) Pure tone audiograms for family 12-01744 with WS II. R, right ear; L, left ear, 
P95 represents thresholds according to the P95 of presbyacusis (ISO 7029. 1984).
14
A
B
C
134
KITLG mutations in hearing impairment
ears. Interaural differences in audiogram configuration were observed in one 
individual (III:9, Figure S3). Additional information on individual cases is 
provided in the Supplemental Note. 
 Analysis of longitudinal data revealed that HL was stable in all individuals. 
Only minor “negative progression” was seen in individual longitudinal data 
which is likely to be explained by the young age at which first thresholds were 
determined. The genetic defect underlying the NS-UHL/AHL in this family has 
a reduced penetrance since four individuals transmitting the disease to their 
offspring were unaffected (II:4, IV:3, IV:5 and IV:7) (Figure 1A). 
 Vestibular function was evaluated in six of the hearing impaired family 
members (Table S2). Three individuals displayed asymmetry on calorisation, 
corresponding with the side of the worst ear (V:1, IV:1, III:5). One person (V:7) 
displayed a marginal hyporeflexia on both sides while he had UHL; the other 
ear had a dip at 4 kHz only although no history of excessive noise exposure was 
reported. In the remaining two individuals (V:5 and V:6), vestibular function 
was found to be normal (Table S2). Except for individual II:4, none of the 
individuals who carried the mutation reported vestibular symptoms. During 
history taking, individual II:4 indicated a possible Meniére disease. 
 Since KITLG functions in the proliferation, migration and survival of 
hematopoietic stem cells and melanoblasts,25-28 blood cell counts as well as skin, 
hair, and eye color were evaluated in members of family W09-1628 with and 
without the KITLG mutation. All determined hematological parameters were 
within the normal range although individuals IV:1, IV:3 and V:4 were treated in 
the past with ferrofumarate for anemia (Table S3). These findings suggest that 
the KITLG mutation in the present family, in the heterozygous state does not 
affect steady state hematopoiesis. 
 All evaluated individuals had skin type I or II, blond hair and blue eyes (Table 
S4). Heterochromia iridis and dystopia canthorum were not observed. Hypo- and 
depigmentations of the skin were not found in the younger generation (V). In the 
older generations, hypo- and depigmentations were present in individuals with 
and without KITLG mutation (Table S4). These pigmentation characteristics are 
age-related and a common feature in the population.29 Our findings suggest that 
the heterozygous KITLG mutation in this family does not lead to pigmentation 
abnormalities of skin, eyes or hair. 
 Family S1489 The index case of family S1489 (Figure 1B) and his father 
presented with AHL and variability in severity and audiogram configuration 
(Figure 2B) as was observed in family W09-1628. The AHL in the propositus 
(III:1) was reported to be of prelingual onset without progression. The earliest 
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clinical evidence of HL was obtained at the age of four years. HL was profound 
at all frequencies in the right ear and mild in the left ear, affecting the low 
frequencies. The father of the propositus (II:1) presented with moderate bilateral 
AHL. Audiogram configuration was downsloping for the left ear and flat for 
the right ear. No vestibular symptoms were reported by the affected father and 
son. Examination of the skin revealed no hypo- or hyperpigmentation features. 
Additional information is provided in the Supplemental Note.
 Family 12-01744 In family (Figure 1C), otoscopy demonstrated otitis media 
with effusion for the right ear of the index case (II:1) at the age of almost 5 years. 
Therefore, reliable thresholds could only be measured for the left ear which 
were normal. At the age of three years, play audiometry had been performed 
elsewhere which revealed profound HL for the right ear (Figure 2C). The mother 
of the index case (I:2) did not present any abnormalities in otoscopy and her 
hearing was normal with only two frequencies, 4 kHz and 8 kHz, below the P95 
values (Figure 2C). The index case had heterochromia iridis that is suggested to 
be present in his mother as well by small blue spots in the iris (Figure 3A, B). 
Both individuals had skin type III. The index case had brown/blond hair. On the 
thorax and upper arms, he had a hypopigmented partially sharply demarcated 
macule which was already present at birth. Furthermore, a nummular sharply 
demarcated hyperpigmented macule at the back was seen (Figure 3C, D). 
Figure 3. Eye and skin hypopigmentation phenotypes in family 12-01744 with WS II. A) Heterochromia 
iridis in the index case (II:1). B) Signs of heterochromia iridis in his mother (I:2). C) A hypopigmented 
sharply demarcated macule on the thorax of case II:1 and D) on the upper arm and a nummular sharply 
demarcated hyperpigmented macula at the back, detected by a Wood’s lamp.
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Figure 4. Genetic defects underlying UHL and AHL and schematic representation of the genomic 
structure of KITLG and of the encoded KITLG isoforms. A) Electropherograms of pCR4-topo clones 
representing the wild-type and c.286_303delinsT alleles of KITLG exon 4 of individual IV:1 (family 
W09-1628). B) Electropherograms of pCR4-topo clones representing the wild-type and c.200_202del 
alleles of KITLG exon 4 of individual III:1 (family S1489). C) Partial nucleotide sequences of KITLG 
exon 4 of case II:1 of family 12-01744. The mutated nucleotide is marked by an arrowhead. As 
reference sequences NM_003994.5 and NM_000899.4 were used. D) Exon 6 is alternatively spliced. 
The yellow dots represent the gain of function mutations c.98C>T, c.100A>C and c.107A>G, causative 
of familial hyper- and hypopigmentation syndromes. The green and red dots represent the mutations 
identified in the present study to be causative of NS-UHL/AHL. The white dot represents the mutation 
identified in a family with WS II. All depicted variants affect the KIT ligand domain of both the soluble 
and transmembrane isoforms of KITLG. “WT” means wild-type.
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a locus for NS-UhL/ahL on chromosome 12q21.32-q23.1
In family W09-1628 genotyping was performed with high density SNP 
arrays (Figure 1A). Genome-wide multipoint LOD scores were calculated 
using 14,488 independent SNPs which revealed a single linkage interval of 
13.15 Mb on chromosome 12q21.32-q23.1, delimited by rs10459171 and 
rs35723 (chr12:87,808,426-100,960,087; GRCh37/hg19). A maximum LOD 
score of 4.27 was calculated for rs7132875 and rs7309222 (Figure S4). There 
were no other regions with a LOD score suggestive of linkage (≥ 2.0) (Figure S4). 
 As a next step, linkage of the disease to the 12q21.32-q23.1 region was 
confirmed by genotyping of VNTR genetic markers and recombination 
events delimited the linkage interval to a region flanked by markers D12S88 
and D12S346 (12q21.31-q23.1; chr12:86,371,384-99,528,530 GRCh37/hg19) 
(Figure S5). According to the UCSC Genome Browser (GRCh37/hg19), 
82 RefSeq genes were present in the critical region but none was reported to 
be related to deafness in humans before and in mouse, only the ortholog of 
KITLG (Kitl) was associated with sensorineural HI (Mouse Genome Informatics 
database). 
WeS discovers a truncating mutation in KITLG 
Because of the size of the critical region, WES was performed for the affected 
individuals III:9 and IV:1 to identify the genetic defect underlying the NS-UHL/
AHL in family W09-1628. Multiple filter steps of the initial 87,751 variants that 
were shared by individuals III:9 and IV:1 (Table 1) revealed two heterozygous 
candidate variants in exon 4 of KITLG, c.286_303del and c.303insT. Sanger 
sequencing after cloning of KITLG exon 4 amplimers demonstrated that both 
variants are present in cis and thus are likely to represent one mutational event 
(c.286_303delinsT) (Figure 4A). The predicted effect of the c.286_303delinsT 
variant is a shift of the reading frame and a premature termination of protein 
synthesis, p.Ser96Ter. The variant was detected heterozygously in all 
affected individuals of the family, in all unaffected individuals who transmit 
the mutation to their offspring, in one individual with an unknown affection 
status, and in an additional unaffected individual (Figure 1A). The KITLG 
variant c.286_303delinsT was neither present in 153 ethnicity-matched control 
individuals nor in exome databases ( see ‘Subjects and Methods’). CNV analysis 
of WES data did not reveal any CNV in the linkage interval and no CNVs that 
were shared by the two individuals (Table S5).
 Based on the segregation pattern of the c.286_303delinsT variant in KITLG, 
we calculated a penetrance of 60-67%. The SNPs rs642742 and rs12821256 
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are located in KITLG enhancers ~326 kb and ~350 kb upstream of the KITLG 
transcription start site, respectively, and are described to alter enhancer 
activity.30,31 To evaluate a possible contribution of these SNPs to the penetrance 
of HL in the family, they were genotyped in all with the mutation (Figure S5). 
No correlation was observed between the SNP genotypes and the penetrance of 
the mutation in this family. 
KITLG variants in NS-UhL/ahL and WS II
We further addressed involvement of KITLG mutations in both NS-UHL/AHL 
and in WS II. HL in individuals with WS II is variable, being asymmetric and/
or unilateral in some of the cases.32,33 Furthermore, function of MITF (MIM 
156845) that is associated with WS II, is influenced by KITLG-KIT signaling.8 
We selected two panels of affected individuals. The first panel consisted of 
64 probands with a clinical suspicion of WS II. The second panel consisted 
of 23 unrelated probands with autosomal dominant NS-UHL/AHL, mainly of 
Spanish origin. Further details on the panels are provided in ‘Subjects and 
Methods’. Two additional heterozygous KITLG variants were identified, an 
in-frame deletion, c.200_202del (p.His67_Cys68delinsArg) (Figure 4B), in an 
index case of Spanish origin with NS-AHL and a missense variant, c.310C>G 
(p. Leu104Val; Figure 4C) in a WS II case of Dutch origin with UHL.
 The KITLG variant c.200_202del was heterozygously present in the father 
of the proband who also presented with NS-AHL (Figure 1B, Figure 2B). The 
c.200_202del variant was neither detected in 200 ethnicity-matched control 
alleles nor in exome databases (see ‘Subjects and Methods’). The predicted 
effect of the deletion of three nucleotides on the encoded protein is an amino 
Filter steps # Variants
Shared exome 87,751
In linkage region 12q21.31-q23.1 241
≤ 0.5 % dbSNP132-Nijmegen in-house frequency 50
Exonic missense, nonsense,  indels, non- and canonical splice sites 9
Confirmed by Sanger sequecing 2 in KITLG
table 1. Filter steps applied on sequence variants identified in WES of individuals III:9 and IV:1 of 
family W09-1628.
Indicated are the number of variants as compared to reference genome GRCh37 (hg19) after each 
filter step.
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Figure 5. Effect of KITLG mutations on subcellular localization and excretion of the transmembrane and 
soluble KITLG isoforms, respectively. A) WGA staining of NIH3T3 cells transfected with constructs 
encoding the FLAG-tagged wild-type, p.His67_Cys68delinsArg and p.Leu104Val transmembrane 
isoform of KITLG. Cells were incubated with anti-FLAG antibodies and Alexa 488-conjugated goat 
anti mouse (left column), WGA Texas Red-X is visualized in the middle column. In the right column, 
the signals of the left and middle columns are merged. Co-localization of WGA with wild-type and 
p.Leu104Val KITLG was observed at the cell membrane but not with p.His67_Cys68delinsArg 
KITLG. WGA (red) and KITLG (green) fluorescence intensities profiles were plotted as a function of 
distance using ImageJ software. Scale bar = 25 μm. B) The amount of soluble p.Leu104Val KITLG 
is significantly  reduced (p < 10-3, Student’s t-test) in the medium of transfected NIH3T3 cells as 
measured by ELISA. No soluble KITLG was detected for the p.His67_CysdelinsArg and p.Ser96Ter 
mutations. Data are means ±SD of four independent experiments. “WT” means wild-type.
A
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acid deletion and a substitution (p.His67_Cys68delinsArg). Cys68 is highly 
conserved with a score of 9 in the ConSeq online bioinformatic tool (9; conserved, 
1; variable). The Cys68 residue forms an intramolecular Cys-Cys bond with 
Cys163 which is essential for the full biological activity of  KITLG.25,34-36 The 
loop in which Cys68 is located connects a β-sheet to an α-helix. Homology 
modeling of KITLG p.His67_Cys68delinsArg predicts that when residue Cys68 
is not present and the Cys68-Cys163 bond thus cannot be formed, the local 
structure of KITLG around the loop is affected. Also, a reactive Cys (Cys163) 
is left without a binding partner which could lead to even larger structural 
changes than predicted (Figure S6A, B). The interaction with the KIT receptor 
is predicted to be preserved (Figure S6B). In aggregate, these data suggest that 
the cysteine at position 68 has a critical role in maintaining the structural and 
functional integrity of the protein.
 In family 12-01744, KITLG c.310C>G was inherited from the mother (Figure 
1C). The variant is predicted to substitute valine for leucine at position 104 
(p.Leu104Val) and is not present in any of the exome databases (see ‘Subjects 
and Methods) which include at least 4000 exomes of individuals of Dutch origin. 
The amino acid substitution is predicted to be deleterious for protein function 
according to Polyphen2 with a score of 0.998 (range 0-1; 0, benign; 1, probably 
damaging), mutation taster with a score of 1 (range 0-1; 0, benign; 1, probably 
B
142
KITLG mutations in hearing impairment
damaging), and SIFT with a score of 0.04 (≤ 0.05, probably damaging; >0.05 
predicted tolerated). Leu104 is highly conserved with a score of 9 in ConSeq. 
Leu104 is buried inside an α-helix and therefore not interacting with the KIT 
receptor. The substitution Leu104Val is predicted to have a small, local effect on 
the structure since valine is predicted not to be exactly at the same position as 
leucine (Figure S6C, D). Although Leu104 is buried in the protein, neighboring 
residues can contact the KIT receptor. Therefore, a small effect on the position 
of these contacting residues is expected, but since the contact surfaces of KITLG 
and KIT receptor are much larger, the interaction is not predicted to be severely 
impaired by the Leu104Val substitution (Figure S6C, D).
 KITLG encodes two KITLG isoforms through alternative splicing and proteolytic 
processing, a transmembrane isoform and a soluble isoform (Figure 4D). 
In mouse, it appears that soluble KITLG plays a role in melanocyte migration and/
or early survival and transmembrane KITLG in melanocyte survival at or close to 
the destination.26,37 All three KITLG mutations identified in this study affect both 
KITLG isoforms (Figure 4D). 
KITLG variants affect protein localization and/or secretion 
We studied the effect of the p.His67_Cys68delinsArg and p.Leu104Val variants 
on subcellular localization of transmembrane KITLG. NIH3T3 cells were 
transiently transfected with a set of plasmids to express the FLAG-tagged wild-
type or variant human transmembrane KITLG (Figure 5A). The expression of 
wild-type and aberrant variants of KITLG was verified by Western blot analysis 
(Figure S7). Localization of KITLG at the cell membrane was addressed by 
labelling of the membrane with wheat germ agglutinin (WGA), a member of the 
lectin family, which binds to N-acetyl-D-glucosamine and sialic acid residues 
on the surface of cells. Both FLAG-tagged wild-type and p.Leu104Val KITLG 
were detected in the cytoplasm and at the cell membrane, also in lamellipodia 
and filipodia (Figure 5A). In contrast, p.His67_Cys68delinsArg KITLG 
staining did not overlap with the WGA-labeling (Figure 5A). This indicates 
that the transmembrane p.His67_Cys68delinsArg KITLG fails to reach the cell 
membrane and therefore will not or only to a very limited extent in comparison 
to controls, be integrated in the cell membrane which supports functional 
consequences of the mutation and the pathogenic effect of this variant. 
 As a next step, we investigated whether the p.His67_Cys68delinsArg, 
p.Leu104Val, and p.Ser96Ter variants affect proteolytic processing and 
subsequent secretion of soluble KITLG. After expression of wild-type and 
variant soluble KITLG in NIH3T3 cells, secreted KITLG was measured by 
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ELISA of the growth medium. The amount of soluble p.Leu104Val KITLG 
was significantly reduced as compared to wild-type soluble KITLG whereas 
no p.His67_Cys68delinsArg and p.Ser96Ter soluble KITLG could be detected 
(Figure 5B). These findings support a pathogenic effect of all three KITLG 
variants.
 Since KITLG can be detected in human blood,34 we assessed by Western blot 
analysis whether the levels of KITLG were significantly reduced in peripheral 
blood samples of affected individuals with the c.286_303delinsT, c.200_202del 
and c.310C>G mutations as compared to levels in control individuals. No clear 
differences were observed (Figure S8). Moreover, the truncated protein encoded 
by the c.286_303delinsT KITLG allele was not detected. This suggests that 
either the truncated protein is not stable and/or that the transcript is degraded 
by nonsense-mediated decay (NMD). Since the truncating variant is in exon 
4, not in the last or penultimate exon, the transcript is predicted to be subject 
to NMD.38 
Kitl expression in the mouse cochlea
Since expression of KITLG/Kitl in cochlear tissue was not demonstrated 
previously, we assessed transcription of Kitl in mouse cochlea by RT-PCR 
employing as templates cDNA derived from RNA of P2 and P28 mice. Two 
amplification products were obtained that corresponded to Kitl transcripts with 
and without exon 6. Moreover, q-PCR demonstrated that the relative levels of 
both Kitl alternative transcripts were increased at P28 as compared with those 
at P2 (Figure S9). Although blood in cochlear vessels might have contributed to 
the detected Kitl transcripts, our data suggest that Kitl functions postnatally in 
mouse inner ear.
DISCUSSION
Here, we present variant alleles of KITLG, alternatively called SCF (Stem Cell 
Factor) or MGF (Mast Cell Growth Factor), and provide evidence that these 
disease associated alleles underlie dominantly inherited NS-UHL/AHL and WS 
II. A combined strategy of linkage analysis and WES, revealed a heterozygous 
truncating mutation, c.286_303delinsT, in KITLG in a large Dutch pedigree 
(W09-1628) with NS-UHL/AHL. The HL is inherited as a dominant trait with 
incomplete penetrance. By further testing of KITLG, two additional mutations 
were identified in a small family with NS-UHL/AHL and in a family with WS 
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II. The HL in all three families with mutations in KITLG was congenital, stable 
and variable with regard to the affected ear as well as audiogram configuration 
and severity. Based on the variable expression of KITLG mutations, bilateral 
symmetric HI might be seen as a phenotypic outcome. However, no potentially 
pathogenic variants were identified in WES data of 231 cases with bilateral and 
symmetric HI (87 adNSHI and 144 isolated cases). This indicates that KITLG 
mutations are not a frequent cause of bilateral symmetric sensorineural HI. 
 KITLG-KIT signaling plays a role in proliferation, migration from the 
neural crest, and survival and differentiation of hematopoietic precursor cells, 
primordial germ cells and melanoblasts.25-28,39 In mouse, severe mutations in 
Kitl (Sl locus) and Kit (W locus) are embryonic lethal in the homozygous state 
but viable when compound heterozygous with less severe defects as are semi-
dominant mutations.40-42 Mice homozygous for the semi-dominant alleles Wv 
of kit and Sld of kitl are viable and display similar phenotypes i.e. macrocytic 
anemia, sterility, absence of coat pigmentation and abnormal pigmentation of the 
iris and of the stria vascularis in the inner ear.28,31,43-47 Absence or reduction of 
highly specialized melanocytes, the intermediate cells, in the stria vascularis leads 
to no or a reduced endocochlear potential (EP) and consequently to HL. This EP 
is the driving force for the transduction of sound via influx of K+ and other cations 
into hair cells.48,49 Steel et al. (1992)47 demonstrated that in Sld/Sld mice, both the 
survival and targeting of melanoblasts to the developing inner ear is affected but 
not early melanoblast differentiation and migration. At 11 days of gestation, lower 
numbers of melanoblasts could be detected near the otic vesicle in mutants than in 
control animals and these numbers further decreased during development.26,47
 In most of the studied inner ears of six days old Wv/Wv mice, no melanocytes 
could be detected in the stria vascularis which explains that no EP was measured. 
However, the penetrance of this phenotype was incomplete since in some ears, 
the EP was nearly normal and intermediate cells were present as in control 
mice.28 This variability in severity of the hearing impairment and affected ear is 
reminiscent of the phenotype in the presented families with KITLG mutations. 
In Wv/Wv mice, this variability in inner ear phenotype was found to reflect the 
number of melanocytes present and how far they migrated along each cochlea.28 
Also, a stria vascularis with structural anomalies was found to be capable of 
maintaining a normal EP50 which can contribute to the variable expressivity of 
the KITLG mutations in the presented families W09-1628 and 12-01744. Findings 
on secondary hair cell degeneration have been reported in Kit and Kitl mutant 
mice compound heterozygous for a null allele and an allele with the less severe 
mutations, Wv and Sld respectively.27, 51 We have no indications for secondary hair 
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cell loss in the presented families since the HL was found or reported to be stable. 
However, we cannot exclude progressive degeneration of hair cells in the prenatal 
stage, especially in those cases with severe to profound HL in one ear. 
 In family W09-1628 vestibular testing in six individuals with the mutation 
and with HL revealed abnormal, vestibular responses in four of the subjects. 
However, these subjects did not report vestibular symptoms during history taking. 
The only individual that complained about balance problems was not tested on 
vestibular function because of her high age. In conclusion, it seems that vestibular 
dysfunction could be part of the inner ear phenotype associated with KITLG 
mutations. However, this seems to lead to subclinical abnormal function, since 
the majority of individuals with the mutation did not report vestibular symptoms 
which suggests sufficient compensatory mechanisms.  
 In families W09-1628 and S1489, there are no indications for phenotypes of 
the tissues that are affected in the Kit and Kitl mutant mice, other than the 
inner ear i.e. hematopoietic tissues, gonads, eye, hair and skin. This suggests 
dominance of the wild-type KITLG allele over the mutant allele in those tissues. 
For the KITLG mutation in family 12-01744 this does not hold true for the iris 
and skin.
 Interestingly, activating KITLG mutations and variants in regulatory 
sequences of KITLG affect pigmentation of skin and hair. Firstly, missense 
mutations in KITLG are causative for familial progressive 2 hyperpigmentation 
and/or hypopigmentation syndromes (Figure 4D) (MIM 145250). Mutations 
underlying these syndromes are demonstrated (c.107A>G, p.Asn36Ser 
(NM_003994.5 and NM_000899.4)) or predicted (c.107A>G, p.(Val33Ala) 
and c.100A>C, p.(Thr34Pro)) to have an activating effect since all three are 
in the conserved VTNN motif.52,53 Protein modeling suggests that mutations 
in this domain may affect the affinity of KITLG for KIT.52 Secondly, SNPs 
in KITLG regulatory regions are associated with skin and hair pigmentation 
(rs642742 and rs12821256, MIM 611664).31 These data, together with the facts 
that KIT signaling regulates MITF function13,54,55 and that genes associated with 
hypopigmentation-deafness disorders function in the KIT-MITF pathway,8,56 
pinpointed KITLG as a candidate gene for WS II. Indeed, we have identified a 
missense mutation in KITLG to be associated with WS II in family 12-01744. 
The HL phenotype in this family is similar to that in families W09-1628 and 
S1489. The pigmentation abnormalities of skin and iris in this WSII family 
suggest a more severe effect of the p.Leu104Val substitution in these tissues, as 
compared to the p.Ser96Ter and the p.His67_Cys68delinsArg mutations which 
might be through a gain of function or dominant negative effect for either of 
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the transmembrane isoform of p.Leu104Val KITLG or the soluble isoform or 
both. To activate KIT, dimerization occurs for both isoforms.57,58 The p.Ser96Ter 
and the p.His67_Cys68delinsArg defects are likely to have a loss of function 
effect since the transmembrane isoform of p.His67_Cys68delinsArg KITLG is 
not detectably integrated into the membrane which will also be the case for 
the p.Ser96Ter KITLG since it lacks the transmembrane domain. Also, for both 
defects, the soluble isoform could not be detected in ELISA of the medium of 
cultured cells. 
 Our findings add KITLG to the family of genes associated with pigmentation-
deafness disorders i.e. KIT, PAX3 (MIM 606597), SOX10 (MIM 602229), EDN3 
(MIM 131242), EDNRB (MIM 131244), and MITF. As presented here for KITLG, 
the phenotypic variability of mutations in several of these hypopigmentation-
deafness genes depends on whether the effect of the mutation is loss of function 
(dosage), (presumably) dominant negative or activating. Loss of function 
mutations in MITF for example are dominant and cause WS II. Mutations in MITF 
that underlie Tietz syndrome are assumed to have a dominant negative effect. 
Tietz syndrome (MIM 103500) is more severe than WS II and characterized by 
fully penetrant bilateral, congenital and profound HL with fair and blond skin, 
so called “born as snow white”.59 
 In conclusion, we demonstrate that allelic mutations in KITLG can underlie 
different clinical conditions and these findings extend the set of genes known 
to be associated with hypopigmentation-deafness disorders as KITLG is now 
shown to be associated with WS II and with NS-UHL/AHL. Analogous to 
mouse, the severity of the human phenotype is likely to reflect the number 
of melanocytes that have reached the inner ear and skin and/or survived in 
these tissues. 
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SUppLeMeNtaL CLINICaL INFOrMatION, FIGUreS, 
taBLeS aND LeGeNDS
Supplemental Note 
Family W09-1628 
Individual V:7. Otoscopy revealed a fragile appearance of the malleus and an 
underdeveloped superior part of the auricle. These abnormalities were also seen 
in his brother (V:8) with normal hearing. CT imaging revealed no inner ear 
anomalies.
 A dip at 4 kHz in the right ear was observed in pure tone audiometry. Such a 
dip is specifically associated with noise exposure although no excessive noise 
exposure was reported by the affected individual. 
Individual III:6. The affection status of III:6 is indicated with a question mark in 
the pedigree (Figure 1) because his hearing loss (HL) might well be caused by 
other factors than the segregating genetic defect (Figure 1 and Figure S5). The 
HL in the left ear of individual III:6 had an onset between 45.56 and 46.46 years 
of age. Before the age of 45 years hearing was normal, as shown in Figure S3. 
Individual V:10. This individual has a symmetric, mild mixed HL which can be 
explained by his recurrent otitis media.
Individual III:2. This individual, indicated to have balance problems while 
walking on uneven ground and when walking on a straight line. He is a spouse 
and does not carry the genetic defect segregating in the family.
Individual III:5. With regard to hair and eye color, individual III:5 was lighter 
than all other family members. She heterozygously carries the rs12821256 G 
allele that is associated with blond hair (Figure S5).1 
Family S1489
Otoscopy did not reveal any abnormalities for the affected father and son (II:1 
and III:1, respectively) and there was no evidence of non-genetic causes of the 
HL. MRI did neither demonstrate inner ear abnormalities nor cerebellopontine 
angle pathology. Propositus III:1 indicated to have suffered from atopic 
dermatitis in the past.
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Figure S1. Expression of wild-type and aberrant soluble KITLG as detected by inmunofluorescence in 
transfected NIH3T3 cells used in the ELISA assays. 
Cells were permeablized and incubated with anti-KITLG and Alexa488 goat anti mouse (left column), 
GFP signal (middle column) and merged (right column). Nuclei were stained with Hoechst (in blue). 
“WT” means wild-type.
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5Figure S2. KITLG concentrations determined by ELISA. NIH3T3 cells transfected with a set of 
plasmids encoding FLAG-tagged wild-type and aberrant transmembrane KITLG were lysed and 10 
μl of cell extracts were analysed by ELISA. Expression of wild-type and aberrant KITLG was readily 
detected. Data are means ±SD. “WT” means wild-type.
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Figure S3. Pure tone air-conduction audiograms of individuals of family W09-1628 who have the KITLG 
c.286_303delinsT variant. Thresholds of the right (R) and left (L) ears are shown separately. Age is indicated in 
years between the audiograms of R and L ears. When available, longitudinal data are shown. The dashed lines 
in the audiograms represent the P95 thresholds related to the person’s sex and age at the last measurement. 
Audiograms of individuals with UHL (A), AHL (B), normal hearing (C) and questionable affection status (D) 
are indicated.
C
D
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Figure S4. Genome wide LOD scores as calculated using SuperLink online SNP 1.1 software. The Y axis 
represents LOD scores and the X axis genetic distance in centimorgans (cM), per chromosome. The blue 
lines mark a LOD score of 3.3 indicating genome wide significance and a LOD score of -2.0 indicating 
exclusion of linkage. In the calculations, windows of 10 SNPs were used; penetrance was set at 70% and 
the disease allele frequency at 0.001. There is only one region in chromosome 12q21.32-q23.1, delimited 
by rs10459171 and rs35723, (chr12:87,808,426-100,960,087; GRCh37, hg19) with a significant maximum 
LOD score of 4.27 for rs7132875 and rs7309222.
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Figure S5. Genotypes of VNTR markers and SNPs in regulatory sequences of KITLG. VNTR marker 
order is according to the Marshfield map. In brackets, the genotypes are indicated which were inferred 
from the pedigree information. For privacy reasons, the genotypes for the disease allele have not been 
indicated for unaffected individuals with the c.286_303delinsT mutation except for those with affected 
offspring. Recombination events in individuals IV:1 and IV:3 define the disease allele (in pink) flanked 
by D12S88 to D12S346. Only one individual of unclear affection status (III:6) and three symptomatic 
individuals with the mutation (III:9, IV:1, V:7) were heterozygous for the A allele of SNP rs6427402 
(allele frequency 92% in West Africans2). The G allele of rs12821256, which is associated with blond 
hair, is most prevalent in northern Europe.1 Only individual III:5 has a G allele for rs12821256. 
Her hair and eye color are lighter blond and blue, respectively, when compared to the other family 
members (Table S4). 
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Figure S6. A molecular modeling of the KITLG variants p.His67_Cys68delinsArg and p.Leu104Val 
using PDB files 1cfs and 2o26. The model for KITLG and KIT was constructed using the PDB files 
1scf and 2o26 as templates.3 The 1scf file contains the structure of human KITLG. In order to study 
the interaction of KITLG with the KIT receptor we constructed the Kit-Kitl complex using PDB-file 
2o26. The 2o26 file contains the structures for KITLG and KIT from mouse, which are 77% and 67% 
identical to respectively KITLG and KIT in humans. The generated human KIT model was superposed 
on the mouse KIT-KITLG complex. The YASARA4 and WHAT IF Twinset5 were employed (with 
default parameters) for model building and subsequent analyses.6 A) A close-up of the loop affected by 
the p.His67_Cys68delinsArg variant. In green, the intramolecular disulfide bond formed by Cys68 and 
Cys163 is presented. The inserted Arg and Cys163 that is left without a binding partner are presented 
in red. Loss of the Cys68-Cys163 intramolecular bond is predicted to affect the local structure of the 
loop and the overall active KITLG conformation. The wild- type protein is in grey, the substituted in 
moss-green. B) Overview of the KIT receptor in orange, the wild-type KITLG in blue, and the KITLG 
with p.His67_Cys68delinsArg in grey. The amino acid residue affected by the substitution is in red. 
C) A close-up of the α-helix affected by the p.Leu104Val variant. In green, the wild-type Leu104 
is shown and in red the variant Val104. Valine is smaller than leucine and it prefers β-sheets rather 
than α-helices. Therefore, p.Leu104Val might have a disruptive effect on the secondary structure of 
KITLG. D) Overview of the KIT receptor (orange) and the KITLG (grey) with the substituted Leu104, 
the side chain of this residue is shown as red balls.
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Figure S7
Figure S8
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Figure S7. KITLG detection on Western blot of NIH3T3 cells transfected with constructs encoding 
transmembrane wild-type, p.His67_Cys68delinsArg, p.Leu104Val and p.Ser96Ter KITLG. Transfected 
NIH3T3 cells were homogenized in lysis buffer (150 mM NaCl, 50 mM Tris HCl, pH 7.4, 5 mM EGTA, 
5 mM EDTA, 1% Triton X-100, 25 lg/ml leupeptin, and 1 mM phenylmethylsulphonylfluoride) and 
kept on ice for 30 min. After centrifugation at 10,000g (4ºC) for 5 min, 50 μg of protein were mixed 
1:1 with SDS-PAGE sample buffer (50 mM Tris–Cl, pH 6.8, 50 mM DTT, 2% SDS, 10% glycerol, 5% 
βME). Proteins were separated in a SDS-PAGE gel and transferred electrophoretically to nitrocellulose 
membranes. After blocking with 5% skimmed dry milk in 1% TBS (pH 7.6), 0.1% Tween 20 for 1 hr at 
RT, blots were incubated with the mouse anti-FLAG antibody (1:1000) (SIGMA, F1804)) overnight at 
4ºC. After washing, membranes were incubated with sheep anti-mouse IgG (1:10000) conjugated with 
HRP (Amersham Biosciences) for 1 hr at RT. Bands were visualized by enhanced chemiluminiscence 
(Clarity Western ECL substrate; Biorad) and exposed to X-ray film at different time points. Beta-actin 
was used as loading control. Arrows indicate bands of ~15, ~16, ~28 and ~68 kDa, respectively. Shown 
data is a representative of three independent experiments. Besides the ~28 kDa band corresponding to the 
expected size of FLAG-tagged KITLG, several other bands spanning a molecular weight range of about 
28-35 kDa were detected, indicating extensive and heterogeneous glycosylation.7,8 An additional band 
of 15 kDa was readily detected for the truncated p.Ser96Ter KITLG and was also present in the other 
samples, but with less intensity. This protein might represent the usage of an alternative ATG codon, 
downstream of the codon of Serine 96, and in frame with the three FLAG tags. A lighter second band 
of around 16 kDa was also detected in all samples which might be the result of proteolytic processing 
of the protein. Although the transmembrane isoform, expressed in this experiment, lacks the proteolytic 
cleavage site (encoded by exon 6), alternative proteolytic might have occurred as has been proposed 
for the murine Kitl.9 Finally, a band of ~68 kDa was detected which is more intense for the p.His67_
Cys68delinsArg mutation than for the other mutations and control suggesting an increased tendency to 
aggregate. The bands of about 16 and 15 kDa were not detected when we used the anti-KITLG antibody 
that is directed against the N-terminal region of the human KITLG (data not shown).
Figure S8. p.His67_Cys68delinsArg, p.Ser96Ter and p.Leu104Val aberrations do not lead to clear 
alterations of KITLG levels in blood. To analyze KITLG expression in human blood, 1 ml of blood 
was collected from individuals II:1 of family 12-01744, V:1 of family W09-1628 and II:1 of family 
S1489. Blood samples were centrifuged for 15 min at 15000 rpm at 4 ºC. One μl of supernatant was 
used for Western blot analysis with the anti-KITLG antibody (abcam, ab52603, anti-SCF) as primary 
antibody (1:1000) and the sheep anti-rabbit IgG (1:10000) conjugated with HRP (Amersham 
Biosciences) as secondary antibody. Western blot analysis was performed as described in the legend of 
Figure S7. Samples were analyzed on 12% SDS-PAGE followed by Western blotting with polyclonal 
anti-KITLG. No differences were observed between samples of control individuals and those of 
individuals with a KITLG mutation. There was no band visible that could expectedly represent the 
truncated p.Ser96Ter KITLG. 
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Figure S9. Kitl expression in mouse cochlea. Cochlea cDNA derived from cochlea RNA of postnatal 
(P) days P2 and P18 129sv wild-type mice was kindly provided by Prof. Guy Richardson (Sussex 
University, UK). PCR was performed with this cDNA as template and primers for Actb and Kitl and 
subsequently size-separated on 1% agarose gel according to standard protocols. To quantify Kitl 
expression, one µl of cDNA was used as template for quantitative PCR with SYBR Green (11066420, 
SYBR Green I Master, Roche Diagnostics). The gene for ribosomal 18S rRNA was employed as 
housekeeping gene for data normalization. The differences in expression were calculated by 
subtracting the obtained CT values of Kitlg and 18S rRNA, respectively, according to the following 
equation: ΔCT = CT (Kitlg) – CT (18S rRNA). A) Transcripts of Kitl in P2 and P28 mouse cochlea. 
Actb was employed as control. B) Quantitative PCR revealed changes of relative KITLG transcript 
levels during functional maturation of the mouse cochlea. For statistical evaluation the Student’s t-test 
was performed. Bars represent standard error of means.
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Target Primer Oligonucleotides
rs642742 Forward TGGGGTTTAAAGCATAGACTG
Reverse TGTGGTAATGGGTGAGTCTG
rs12821256 Forward AAGTATGCCCAAAGGATAAGG
Reverse GAGTGCTTTGTTCCAACTTAGTC
KITLG_mRNA_ 
NM_003994.5_BamHI_F
Forward CGCTGCGGATCCTTATGAAGAAGACA
KITLG_mRNA_ 
NM_003994.5_XhoI_R1
Reverse CGAAAGTAACAGTGTTGACTCGAGCCACAA
KITLG_mRNA_ 
NM_003994.5_XhoI_R2
Reverse ACAAGCCACTCGAGCACTTCTTGAAACTCTC
KITLG_intron ex3-4_
gateway_F
Forward GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGGAAGTTTGAGACAGCCTGG
KITLG_intron ex4-5_
gateway_R
Reverse GGGGACCACTTTGTACAAGAAAGCTGGGTCGCAGGACTGATTTTGCATTG
pCI-Neo-Rho-Insert Fw Forward CGGAGGTCAACAACGAGTCT
pCI-Neo-Rho-Insert Rev Reverse AGGTGTAGGGGATGGGAGAC
KITLG_Exon1 Forward GCTCCAGAACAGCTAAACGG
Reverse CAGCTGCAAGTCCCAGG
KITLG_Exon2 Forward GGTGAGCATAGCTTGAATGC
Reverse GCAGTGGTGTGCAACTAGC
KITLG_Exon3 Forward TGCTTTTCTCCAAAGCACTAC
Reverse CAATAAGCAAGCTCCTAAATAGC
KITLG_Exon4 Forward TGGCAGGCACTTGTAATCTG
Reverse CTTGTTTTCTTTGCTCATCTG
KITLG_Exon5 Forward CATACGTTAAAACAGCCATCTAAAAG
Reverse TCTTGCTACAGCTTAACACAGAGG
KITLG_Exon6 Forward AGACCTGGCAAGTAATCTGG
Reverse AGAAGACCATAAAAGGAATAACAG
KITLG_Exon7 Forward CTTGCAAAAGCAATATTCAGC
Reverse TCAGCTAGAGGGATTGTCTCC
KITLG_Exon8 Forward CAGCTTCTTTATTACTCTTTAGCCC
Reverse ATGGAGATGCAGCACTGAAG
KITLG_Exon9 Forward AGAAGGTAGGCTCCCCATTC
Reverse ACAATGGAGCCTGTCATGG
KITLG_control testing_p.
His67_Cys68delinsArg
Forward 6FAM CTCCGAGTTTTATGGCACTTAC 
Reverse  CTTGTTTTCTTTGCTCATCTG
KITLG_control testing_p.
Ser96Ter
Forward GACAGCTTGACTGATCTTCTGG
Reverse GAGTTTTCTTTCACGCACTCC
Kitl_qPCR_cochlea Forward TATGATAACCCTCAACTATGTCGC
Reverse TTGTCCAGAAGAGTAGTCAAGC
18S rRNA Forward CGGCTACCACATCCAAGGA
Reverse AATTACCGCGGCTGCTG 
Actb Forward GATGGTGGGCATGGGTCAGA
Reverse GGATGTCCACGTCACACTTCATGA
Kitl Forward CGGGAATCCTGTGACTGATAA
Reverse CCACTGTGCGAAGGTAACAA
table S1. Primer sequences.
For the primer design to amplify KITLG, NM_003994.5 and NM_000899.4 were used. For Actb, 
uc009ajk.1 was employed and for Kitl, uc007gxp.1.
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table S5. Filter steps applied on total CNV data from WES of individuals III:9 and IV:1 of family 
W09-1628.
Indicated is the number of CNVs, compared to reference genome GRCh37 (hg19), after every filter 
step. Total CNVs indicates the number of CNVs called in individuals III:9 and IV:1. The control 
dataset consisted of 721 genotypes of control individuals with Cytoscan HD arrays (Affymetrix) and 
1251 genotypes of control individuals with Affymetrix 6.0 arrays (Affymetrix). 
Filter steps # Variants
Total CNVs  26
CNVs  ≥ 5Kb 24
Exonic CNV 22
< 70% overlapping with control population 4
Linkage region 12q21.31-q23.1 0
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aBStraCt 
A combined strategy of linkage analysis and whole exome sequencing in a 
consanguineous family of Pakistani origin with a novel syndrome of progressive 
sensorineural hearing impairment, dystonia, regression of motor skills, signs 
of sensory neuropathy and ichthyosis-like features revealed a homozygous 
nonsense mutation, c.4G>T (p.Glu2*), in FITM2. FITM2 and its paralog FITM1 
constitute an evolutionary conserved protein family involved in partitioning of 
triglycerides into cellular lipid droplets. Despite the role of FITM2 in neutral lipid 
storage and metabolism, no indications for lipodystrophy were observed in the 
affected individuals. In order to obtain independent support of the involvement 
of FITM2 in the human pathology, downregulation of the single Fitm ortholog, 
CG10671, in Drosophila melanogaster was pursued by using RNA inter ference. 
Phenotypic characteristics of the syndrome were recapitulated in Drosophila 
by progressive locomotor impairment, hearing loss and morphological 
abnormalities of type IV sensory neurons as well as neuromuscular junctions. 
This confirms that the FITM2 mutation is indeed causative of the syndrome. 
The phenotypic characteristics of the affected individuals indicate that FITM2 
function in humans goes beyond neutral lipid storage and metabolism.
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INtrODUCtION 
Hearing is a complex process involving the inner ear for transformation of 
sound into an electrical signal that is further processed in the central nervous 
auditory pathway and cortex. Therefore it comes as no surprise that mutations in 
more than a hundred genes are causative of malfunction of the auditory system 
resulting in hearing impairment (See URL, Hereditary hearing loss homepage). 
Expression of these genes and the function of the encoded proteins are not 
private to the auditory system in most of the cases.1, 2 Defects in the proteins 
involved in hearing can give rise to hearing impairment only (non-syndromic 
hearing impairment) or can result in a multisystem disorder (syndromic hearing 
impairment) as it is described for more than 400 syndromes with hearing 
impairment in literature and Online Mendelian Inheritance in Man (See URL, 
OMIM).3
 Cells have the ability to store neutral lipids in specialized organelles, the 
lipid droplets (LDs) which thereby are important for energy storage and lipid 
metabolism.4 However, the role of LDs goes beyond this since functions 
in modulation of cellular signaling, transcription regulation and autophagy 
are emerging as well as functions in immunity.5 Defects in genes that have a 
role in LD formation and/or function can lead to hereditary lipodystrophies 
but also to motor neuropathies without obvious effects on lipid storage and 
metabolism.6 For example, Seipin, which is encoded by BSCL2 (MIM# 606158), 
is an endoplasmic reticulum (ER) resident protein involved in LD formation 
and maintenance as well as in adipocyte differentiation.7,8 Loss-of-function 
mutations in BSCL2 result in Berardinelli-Seip congenital lipodystrophy (MIM# 
269700) whereas gain-of-toxic-function mutations in BSCL2 cause a motor 
neuron disease (MIM# 600794) due to neuronal ER stress without metabolic 
implications.9-11 Spartin, encoded by SPG20 (MIM# 607111), is associated with 
LDs12 and functions in lipid droplet turnover. Loss of function mutations in 
SPG20 are causative of Troyer syndrome (MIM# 275900), a hereditary spastic 
paraplegia, which is not associated with defects in lipid metabolism.13 
 The Fat storage-Inducing TransMembrane (FITM) protein family is a novel 
two-member family of highly conserved proteins, FITM1 and FITM2, involved 
in LD partitioning and energy metabolism.14-17 FITM1 (MIM# 612028) is 
primarily expressed in skeletal muscle and, at lower levels, in heart. Expression 
of mouse Fit2 (MIM# 612029) is highest in brown and white adipose tissue and 
further ubiquitous at a low level in both humans and mouse.15 Expression in 
human adipose tissue has not been described yet. Deficiency of FIT2 in mouse 
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adipose tissue results in progressive lipodystrophy and postnatal whole body 
Fit2 knock-out in mouse is lethal.18, 19 So far, no phenotype in humans has been 
linked to mutations in either of the two FITM genes. However, FITM2 is part of 
the FITM2-R3HDML-HNF4A locus that is associated with type 2 diabetes. 
 In this study, we identified a homozygous truncating mutation in FITM2 in a 
consanguineous family of Pakistani origin with a characteristic constellation of 
clinical features of sensorineural hearing impairment, dystonia, regression of 
motor skills, signs of sensory neuropathy and an ichthyosis-like appearance of 
the skin. No indications for a lipodystrophy were present in the affected subjects. 
RNAi-induced gene ablations in Drosophila melanogaster recapitulated the 
human phenotype which supports the involvement of FITM2 in the presented 
novel human phenotype. 
MaterIaLS aND MethODS
patient evaluation
Written informed consent was obtained from individuals I-1 and I-2. The human 
subjects review boards of Biomedical and genetic Engineering, Islamabad, 
Pakistan, the medial ethics committee of the Radboud university medical center, 
Nijmegen, the Netherlands, and the Domain Specific Review Board for ethics of 
the National Healthcare Group Singapore approved the study protocol. 
 Patients of the presented family (W09-1008; Figure 1A) were evaluated by 
medical specialists in Pediatrics, Otorhinolaryngology, and Neurology. 
 Tmpanometry, pure-tone audiometry, Brainstem Evoked Response Audiometry 
(BERA), Magenetic Resonance Imaging (MRI) of the brain, measurements of 
fasting levels of glucose and triglycerides in serum and neurophysiological 
evaluations were performed according to standard protocols. Muscle tissue 
derived from a musculus vastus lateralis biopsy was embedded in paraffin and 
stained with hematoxilin-eosin according to standard protocols.
MrI of abdomen 
The abdominal MR images were acquired from a 3T MR scanner (Tim Trio 
Siemens) using two-point Dixon sequence (TR = 5.28 ms, TE1 = 2.45 ms, TE2 
= 3.68 ms, FA = 9 deg, bandwidth1 = 500 Hz/Px, bandwidth2 = 780 Hz/Px) after 
anatomical localization. For the parent (I-1), 80 axial slices with 3 mm thickness, 
0.6 mm interslice gap and in-plane resolution of 1.25 × 1.25 mm were acquired 
and 52 slices with in-plane resolution of 1.02 × 1.02 mm were acquired for two 
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affected children (II-5 and II-6). A fully automated segmentation technique was 
employed to segment and quantify the abdominal fat volumes between the first 
(L1) and fifth (L5) lumbar vertebrae.43 First, the fat tissues were separated from 
non-fat tissues by intensity thresholding. The extracted fat tissues were then 
classified into subcutaneous (SAT) and visceral (VAT) adipose tissues using 
graph theoretic segmentation.
Mr spectroscopy of the liver 
Fat content in the liver was determined using 1H magnetic resonance spectroscopy 
(MRS). The liver spectra were obtained from a 2 × 2 × 2 cm3 voxel from two 
locations (right and left lobes) using a point-resolved spectroscopy sequence 
(echo time (TE) = 30 ms, repetition time (TR) = 2000 ms) and a Siemens body 
matrix coil. The acquired spectra were fitted using the linear combination of 
model spectra (LCModel).43 The liver fat was determined from the concentration 
of methyl and methylene groups of lipids and the unsuppressed water signal and 
corrected for T2 losses.44
 
Genetic analyses
SNp Genotyping
Genomic DNA was isolated from peripheral-blood lymphocytes by 
standard procedures. All family members were genotyped employing the 
HumanOmniExpress BeadChip v1.1 (Illumina, Inc., San Diego, CA) arrays 
with 719,659 SNPs. Homozygosity mapping using 696,513 autosomal SNPs 
with genotype calls in all samples (364,151 polymorphic) using PLINK v1.07 
was performed.(45) Overlapping homozygous regions >5 Mb in size present 
in all affected and absent in the unaffected individuals were selected. Family 
relationships among genotyped individuals using identity-by-descent checks 
were performed. We further conducted a genome-wide linkage scan using 
MERLIN 1.1.2 on a subset of 53,028 independent SNPs, based on inheritance 
of the same ancestral mutant allele (0.001) from both parents (coded as first 
cousins) under a recessive model.46
Sequence analysis; Whole exome sequencing (WeS) and Sanger sequencing
In family W09-1008, WES was performed in the non-affected parents, I-1 and 
I-2, and in two affected siblings, II-5 and II-6 using the Nimblegen SeqCap 
EZ exome v3 kit and protocol (Roche). The captured libraries were barcoded, 
pooled and sequenced on a single lane in a multiplexed 2x101 base pair Illumina 
HiSeq 2000 sequencing run. Reads were mapped against the UCSC Genome 
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Browser Hg19 assembly (build 37) using BWA v1.7 and variants were called 
using the Genome Analysis Toolkit (GATK) v2 following the recommended 
guidelines. All four samples were sequenced to a mean depth of 79.5x with 
>96% of the exome covered by ≥10 reads. Identified variants were evaluated 
with the SIFT tool and checked against public databases of exomic or genomic 
variants (1000 genomes, HapMap and NHLBI exome variant server). 
 Primers for amplification of exons and exon-intron boundaries of FITM2 
(uc002xlr.1) were designed with ExonPrimer. Amplification by PCR was 
performed on 40 ng of genomic DNA with Taq DNA polymerase (Roche) or 
Amplitaq (Life Technologies). Primer sequences are provided in Table S1. PCR 
fragments were purified with NucleoFast 96 PCR plates (Clontech) in accordance 
with the manufacturer’s protocol. Sequence analysis was performed with the 
ABI PRISM BigDye Terminator Cycle Sequencing V2.0 Ready Reaction kit 
and analyzed with the ABI PRISM 3730 DNA analyzer (Applied Biosystems). 
Presence of the FITM2 c.4G>T transversion was determined in 137 ethnically 
matched healthy controls by restriction analysis of amplicons encompassing 
FITM2 exon 1 (primers as indicated in Table S1)which were purified as 
described above and digested with NspI (New England Biolabs) in accordance 
with the manufacturer’s protocol. Restriction fragments were analyzed on 2% 
agarose gels. The mutation removes a restriction site. The absence of the FITM2 
c.4G>T variant was also verified in the Nijmegen WES database (5031 exomes) 
and Exome Aggregation Consortium database (ExAC, 65,000 exomes).
expression analysis of FITM2 in heK293t cells
Wild-type and c.4G>T FITM2 cDNA were cloned in an expression vector 
containing a C-terminal Streptavidin-FLAG-tag (SF-TAP)47 using gateway 
technology (Life Technologies) according to the manufacturer’s instructions. 
HEK293T cells were cultured in high glucose DMEM AQmedia (Sigma 
Aldrich), supplemented with 10% FCS, 1% penicillin/streptomycin and 1 
mM sodium pyruvate. For DNA transfections, HEK293T cells were seeded in 
6-well plates, grown overnight, and transfected with 2 µg of plasmid using PEI 
transfection reagent (Merck Millipore). Twenty-four hours after transfection 
cells were washed with PBS and lysed on ice in lysis buffer (50 mM Tris-HCl 
pH 7.5, 150 mM NaCl, 0.5% Triton-X-100 supplemented with complete protease 
inhibitor cocktail (Roche). Affinity purification of SF-TAP-tagged proteins was 
performed on cleared lysates using anti-FLAG M2 affinity gel (Sigma Aldrich). 
Lysates were incubated for four hours at 4°C and subsequently precipitated 
by centrifugation and washed three times in lysis buffer. Protein lysates and 
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affinity purified samples were analyzed on Western blots of NuPAGE® Novex® 
12% Bis-Tris Protein Gels (Life technologies) and imaged by using the Odyssey 
Infrared Imaging System (LI-COR, USA). Tagged molecules were detected by 
anti-FLAG polyclonal antibodies (Sigma Aldrich) and IRDye800 goat-anti-
rabbit IgG (Licor) as described.48
rNai and phenotypic analyses in Drosophila melanogaster 
Drosophila melanogaster stocks and maintenance
Conditional RNA-mediated interference (RNAi) knockdown of Fitm (CG10671) 
was achieved with the UAS-GAL4 system.49 UAS-RNAi stocks against CG10671 
and their genetic background controls were obtained from the Vienna Drosophila 
RNAi Centre (VDRC).50 Experiments were replicated in multiple stocks, two 
from the GD RNAi library (v44433 and v44435; referred to as Fitm RNAi-1A 
and Fitm RNAi-1B, respectively) with the corresponding genetic background 
control (Control-1; v60000) and one from the KK RNAi library (v109895; 
Fitm RNAi-2) with the corresponding genetic background control (v60100; 
Control-2). The stocks are based on two independent RNAi constructs: GD3580 
(v44433 and v44435) and KK107999 (v109895).
 RNAi expression was induced by a variety of GAL4 driver lines, which carry 
a tissue-specific promoter driving the expression of GAL4. The w; C7-GAL4; 
UAS-Dcr-2 (fat body expression) was kindly provided by Marek Jindra.51 The 
GAL4 promoter driver lines, w;; αTub84B-GAL4/ TM6C, Sb1 Tb1 (5138) 
(ubiquitous expression) and w, UAS-Dcr-2; Mef2-GAL4 (25756) (skeletal 
muscle expression) were obtained from the Drosophila Bloomington Stock 
Center (BDSC). The w;; elav-GAL4 (8760) was obtained from the BDSC and 
combined with w; UAS-Dcr-2 (60009) from VDRC to create w; UAS-Dcr-2; 
elav-GAL4 (pan-neuronal expression). A copy of UAS-Dcr-2 was included to 
improve the efficiency of knockdown.50 The w; 477-GAL4, UAS-mCD8::GFP; 
+/ ppk-GAL4 driver (expression in class IV dendritic arborization (da) neurons) 
was assembled from yw, 477-GAL4, UAS-mCD8::GFP (8768) and w;; ppk-
GAL4 (32079), both from BDSC. Crosses were maintained according to standard 
procedures at 28°C.
Confirmation of Fitm knockdown by qrt-pCr
In order to evaluate the efficiency of RNAi-induced knockdown, Fitm RNAi-
1A, Fitm RNAi-1B and Fitm RNAi-2 lines were crossed to the αTub84B-GAL4 
driver (ubiquitious). One day old males of the appropriate genotype were 
selected for qRT-PCR. The extraction of mRNA, cDNA synthesis and qPCR were 
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performed as previously described.52 RNA polymerase II (RpII215) was used as 
a reference gene. Primer pairs for amplification of Fitm and RpII215 transcripts 
were designed using ExonPrimer software (http://ihg.gsf.de/ihg/ExonPrimer.
html). For each genotype, three biological and two technical replicates were 
performed. Differential gene expression was calculated using the 2ΔΔCt method.53 
For statistical analysis of the qRT-PCR data, p values were calculated with the 
two sided T-test in Excel 2007 (Microsoft). 
Island assay 
Fitm RNAi lines and the corresponding genetic background control lines 
were crossed to the αTub84B-GAL4 (ubiquitous), the Mef2-GAL4 (skeletal 
muscle) and the C7-GAL4 (fat body) driver lines, respectively. Progeny of the 
appropriate genotypes and age were subjected to the island assay.22 In brief, flies 
were thrown to a platform in the middle of a soap bath and their escape response 
was videotaped. Flies remaining on the platform after 10 seconds were manually 
counted. Flight ability, wing and leg movements were visually evaluated.21 If an 
abnormal locomotion behavior was found, at least one additional experiment 
was performed to confirm the observed behavioral defects. The SPSS statistics 
20 package (IBM) was used for the ANOVA statistical comparisons. 
 All behavioral experiments were performed at room temperature under 
standard light conditions. Aged flies were transferred to fresh food vials every 
three to four days. 
Drosophila neuromuscular junction (NMJ) morphology
The Fitm RNAi-1A and Fitm RNAi-2 lines and the corresponding control lines 
were crossed to the Mef2-GAL4 (skeletal muscle) driver line. Wandering L3 
male larvae were dissected and fixed in 3.7% paraformaldehyde in PBS for 30 
min. Type 1b NMJs of muscle 4 were co-labeled for bruchpilot (brp) and discs 
large 1 protein (dlg1). Brp was revealed using the primary antibody nc82 (1:125) 
(Developmental Studies Hybridoma Bank, University of Iowa) applied overnight 
at 4°C, and a secondary Alexa 488-labelled goat anti-mouse antibody (1:250; 
Invitrogen) for 2h. Discs large 1 was visualized using the primary antibody 
anti-dlg1 (1:25; Developmental Studies Hybridoma Bank) in combination with 
the Zenon Alexa Fluor 568 Mouse IgG1 labeling kit (Invitrogen) assembled 
according to the manufacturer’s protocol. Incubation times for antibodies was 
of 1.5hrs. Antibodies were diluted in PBS-Triton and each incubation period 
was followed by 5x 10min washing on PBS-T. NMJ images were obtained using 
an automated high-content Leica microscope (DMI6000B). Individual synapses 
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were imaged and the NMJ area, length, longest branching length, amount of 
active zones, branches and branching points were quantitatively assessed using 
an in-house developed macro for the Fiji image processing software. Data was 
collected from larvae selected from two independent experiments.
Dendritic morphology of class IV dendritic arborization neurons
Male L3-stage larvae were dissected following a ventral midline incision for 
imaging of the dorsal class IV dendritic arborization C (ddaC) neurons. The 
Fitm RNAi-1A and Fitm RNAi-2 lines and the corresponding controls were 
crossed to w; 477-GAL4, UAS-mCD8::GFP; +/ppk-GAL4 driver line. Dendritic 
neurons were stained with rat anti-mouse CD8a (1:100; Thermo Fisher 
Scientific MCD0800) and goat-anti-rat Alexa Fluor 488 (1:200; Thermo Fisher 
Scientific A-11006). Z-stack images were taken at a Zeiss LSM 510 confocal 
microscope with a 20x objective. Z-stacks were imported into NeuronStudio 
(version 0.9.92) for generation of neuronal reconstructions and Sholl analysis 
(10 μm interval).(54) Tracing files were analyzed with L-Measure (version v5.2 
(55)) and statistical significance was analyzed using the One-Sample T-Test in 
GraphPad Prism (version 5.00 for Windows, GraphPad Software). Data was 
collected from larvae selected from two independent experiments.
hearing test
To assess sound responses of the Drosophila Johnston’s organ (JO), antennal 
vibrations and ensuing antennal nerve potentials were measured in adult flies 
three days after eclosion as previously described.27 The Fitm RNAi-1A, Fitm 
RNAi-1B and Fitm RNAi-2 lines and the corresponding controls were crossed 
to the elav-GAL4 and αTub84B-GAL4 drivers. In brief, antennal vibrations 
were monitored at the tip of the antennal arista using a PSV-400 scanning laser 
Doppler vibrometer (LDV) with an OFV-500 close up unit (Polytec GmbH). 
Pure tones adjusted to the mechanical best frequency of the antenna were used 
as sound stimuli. The resulting sound particle velocity was measured with 
an Emkay NR3158 pressure gradient microphone (distributed by Knowles 
Electronics Inc.) at the position of the fly. In line with previous reports,27 the 
individual best frequency of each antenna was determined from the power 
spectrum of its mechanical free fluctuations in the absence of sound stimulation, 
and tone evoked antennal vibration amplitudes were measured as Fourier 
amplitudes at the frequency of sound stimulation. Ensuing nerve potentials were 
measured in the form of compound action potentials (CAPs) from the axonal 
projections of JO neurons in the antennal nerve via an electrolytically tapered 
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tungsten electrode inserted between the antenna and the head.28 A tungsten wire 
inserted into the thorax served as indifferent electrode. CAP amplitudes were 
plotted against the corresponding sound particle velocities. Hill fits were used 
to determine the sound particle velocity threshold of the CAPs, whereby the 
particle velocity corresponding to 10% of the maximum amplitude approached 
by the fit was used as the threshold criterion.10 To quantify the amplification 
gain exerted by motile responses of JO neurons, the antenna’s mechanical 
sensitivity, measured as antennal displacement amplitudes normalized to the 
corresponding sound particle velocities, was plotted against the particle velocity 
of the stimulus tones. The amplification gain was then measured as the ratio 
between the antenna’s mechanical sensitivity in the low and high intensity 
regimes.27, 28 Data analysis was performed using Polytec-VIB (Polytec GmbH), 
Spike 2 (Cambridge Electronic Design), Excel 2007 (Microsoft), SigmaPlot 10 
(Systat Software) and Prism (GraphPad Software) software.
Fat body analysis
Fitm RNAi lines and the corresponding controls were crossed to the C7-GAL4 
driver line (fat body). Progeny was transferred to vials with fresh food every two 
days. Fat bodies of female flies were dissected at the indicated adult age, fixed 
in PBS with 3.7% paraformaldehyde for 20 min, rinsed with PBS, stained with 
Bodipy (1:2000; C3922, Life technologies) for 20 min at room temperature, 
and mounted in Vectashield with DAPI (Vector Laboratories). Pictures were 
obtained using a Zeiss Axio Imager ZI fluorescence microscope (Zeiss). Data 
was collected from flies selected from two independent experiments. 
reSULtS
Clinical and paraclinical evaluation of the family
Clinical observations of affected individuals 
A consanguineous family (Figure 1A) was ascertained from the Punjab region 
in Pakistan with five sibs affected by syndromic hearing impairment and three 
healthy sibs and parents. All affected individuals had global developmental delay 
and subsequent neuro-regression. Sensorineural hearing impairment was the first 
symptom of the disease at the age of about six months which progressed until 
profound in about ten years (Figure 1B). Speech was limited to single words. No 
intervention was undertaken for the hearing impairment of the subjects. Delayed 
motor development was evident in all five affected subjects. Four of them only 
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walked independently at the age of three years and subject II-6 never walked 
independently. The three oldest subjects displayed regression in their motor 
skills from six years of age, with gradual loss of head control, ability to sit and 
walk by ten years. Fine motor skills were poor due to dystonic hand movements 
and finger deformities. Subjects were only able to feed themselves but needed 
assistance in other daily tasks such as dressing and toileting. Significant dystonic 
limb movements affected three subjects and truncal dystonia was observed in 
subjects II-5 and II-8. Contractures, including pes cavus deformities, were seen 
in all three dystonic individuals due to long-standing immobility and dystonia. 
There were no signs of spasticity. Muscle wasting of the lower limbs was 
observed, found to be more likely due to immobility and poor nutritional status 
rather than to myopathy or motor neuropathy. All affected subjects had sensory 
disturbances with two complaining of non-specific pain in their joints and the 
remaining three experiencing paraesthesia or ‘burning sensation’ in their limb 
peripheries, joints and trunk. Pain sensation was tested in subjects II-5 and II-6 
and found to be absent in the upper limbs and face but preserved in the trunk 
and lower limbs.
Figure 1. (A) Pedigree of family W09-1008 and segregation of the c.4G>T (p.Glu2*) mutation in 
FITM2 and (B) pure tone audiometry of individuals II:1, II:5 and II:6.
A
B
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All five affected individuals displayed ichthyosis-like whitish scaling of the 
skin with more prominent abnormalities on the shin and also scarring alopecia. 
Furthermore, they were poorly thrived and had low weights. Affected subjects 
did not display dysmorphic features and their daily life behaviour did not 
suggest severe cognitive dysfunction or visual abnormalities. The salient clinical 
features of the affected individuals are summarised in Table 1. 
Clinical examinations of affected individuals
Otological examination, tympanometry and pure-tone audiometry were performed 
in subjects II-1, II-5 and II-6 at the ages of 19, 10, and 8 years, respectively. 
No external or middle ear abnormalities were noticed and tympanograms were 
Characteristics II.1 II.3 II.5 II.6 II.8
Age (years) 26 22 13 9 6
Gender Female Female Male Male Male
Onset of HI 
(months)
6
Current speech Single words
Sensory 
disturbances
Frequent pain in joints Daily burning sensation in peripheries
Autonomic 
features
Urinary 
incontinence from 
12 years; daily 
diarrhea from 16 
years
Normal
Motor function Delayed walking at 
3 years; bedridden 
by 10 years
Delayed walking at 3 years; loss of 
ambulation by 10 years
Crawled 
at 2 years; 
never walked 
independently
Delayed walking 
at 3.5 years; 
unable to run
Dystonic 
movements
Dystonic limb 
movements from 
2 years
None Dystonic limb movements from 2 years None
Seizures Daily seizures from 
15 years
None
Skin features Ichthyosis-like features, most prominent at the shin
Height (m)/
weight (kg)/
BMI/age at 
measurement 
(yrs)
1.36/32.0/17.2/23 1.38/31.0/16.1/19 1.21/22.0/14.8/12 1.06/17.0/15.2/8 0.91/15.0/18.1/5
table 1. Clinical features of affected subjects with the homozygous c.4G>T (p.Glu2*) mutation in 
FITM2
For comparison, the BMI of two healthy sibs (II.2 and II.7) was 23.5 and 21.0 at the ages of 22 years 
and 12 years, respectively.
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normal for both ears. Pure-tone audiograms display bilateral, symmetric, severe 
or profound hearing impairment which is sensorineural since bone conduction 
thresholds were in accordance with air conduction thresholds (Figure 1B). 
BERA was performed for II-1 and II-5 and did not reveal any waveforms up 
to 90 dB, for both ears. There are no signs of muscle damage or liver or kidney 
dysfunction since serum levels of glutamic oxaloacetic transaminase (SGOT), 
creatine phosphokinase (CPK), lactate dehydrogenase (LDH) and aldolase 
were found to be within the normal range for both subjects II-1 and II-5 
(Table 2). Fasting glucose levels were determined to be normal for all three, 
II-1, II-5 and II-6. Also, fasting serum levels of triglycerides were normal 
(II-5 and II-6) (Table 2). 
Nerve conduction studies were performed for individual II-1 at the age of 14 
years. For the left tibial nerve, small Compound Muscle Action Potentials 
(CMAP) were measured with normal motor conduction velocity. Normal CMAP 
and motor conduction velocity were observed in the left Median and Ulnar 
nerves. Also, action potentials and conduction velocities in the left sensory 
Median and Ulnar nerves were found to be normal. Needle EMG was normal in 
table 2. Biochemical evaluation of serum and liver fat content of affected subjects.
SGOT, serum levels of glutamic oxaloacetic transaminase; CPK, creatine phosphokinase; LDH, 
lactate dehydrogenase; ND, not determined.
Measurements II.1 II.5 II.6 Control values
Fasting glucose 
(mg/dl)
101 110 94 60-110
SGOT (AST) (U/L) 27 (32) 25 (38) ND In brackets per 
indvidual
CPK (U/L) 136 (26-140) 150 (38-174) ND In brackets per 
individual
LDH (U/L) 263 397 ND 240-480
Aldolase (U/L) 4.5 (0.1-7.6) 3.0 (0.2-15.2) ND In brackets per 
indvidual
Urea (mg/dL) 30 45 ND 10-50
Creatinine (mg/dL) 0.8 0.7 ND 0.7-1.19
Triglycerides 
(mmol/L)
ND 1.31 1.21 <1.7
Liver fat (%) ND 3.63 ND <10%
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deltoid, anterior tibial and gastrocnemius muscles. Findings were interpreted as 
resulting from decreased muscle bulk. 
MRI of the abdomen of individuals II-5 and II-6, and of II-1 as a control did 
not demonstrate any signs of lipodystrophy. Values of liver fat content and 
subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) volumes 
were in the normal range. MRI of the brain was performed for individuals II-1 
and II-5 and showed no abnormalities, particularly not in the basal ganglia.
 A skeletal muscle biopsy of individual II-1 did not display myopathic or 
neurogenic changes.
 In summary, the syndrome in the family is characterized by progressive 
hearing impairment and delayed motor development followed by regression 
of motor function which can be accompanied by dystonia and signs of 
sensory neuropathy. The described evaluations did not provide insight in the 
primary defect or the pathogenic mechanisms underlying the syndrome.
Whole exome sequencing (WeS) identified a nonsense mutation in 
FITM2
Homozygosity mapping and linkage analysis of all family members revealed a 
single homozygous region of 8.4 Mb on chromosome 20q12-q13.2 (rs2903624-
rs6096425). LOD score calculations using 58,023 SNPs in linkage disequilibrium 
revealed a maximum LOD score of 4.00 (Figure S1). The only linkage region 
contained 125 genes (USCS, Ref Seq, hg19). WES was performed in the non-
affected parents, I.1 and I.2, and in two affected siblings, II.5 and II.6. The 
single homozygous region on chromosome 20q12-q13.2 was fully covered by 
Nimblegen SeqCap EZ exome v3. In the linkage region, only nonsynonymous 
exonic and canonical splice-site variants were selected, occurring with a 
frequency of less than 5% in the 1000 genomes and HapMap populations, and that 
were shared by both affected siblings homozygously and were heterozygously 
in the parents. This revealed a single homozygous nonsense mutation in the 
second codon, c.4G>T (p.Glu2*, NM_001080472.1; Figure S2A), of FITM2 that 
cosegregated with the disease in the family (Figure 1A). This FITM2 c.4G>T 
variant was neither present in 274 Pakistani control alleles nor in whole genome 
or exome databases (see ‘Subjects and Methods’). The variant was submitted to 
Leiden open variation database (LOVD, see URL) (variant ID #0000079006).
 Since postnatal whole-body Fit2 knock-out in mouse is lethal (19), we 
hypothesized that the present mutation might not lead to complete loss of 
FITM2 function due to usage of downstream alternative translation initiation 
sites. We expressed FLAG-tagged wild-type and p.Glu2* FITM2 in HEK293T 
189
6
Figure 2. Downregulation of Fitm impairs the locomotor abilities in Drosophila
The upper horizontal arrow represents the time points in days and developmental stage at which the 
flies were evaluated. Stacked bar graphs show the percentage of flightless flies (black bars) and flies 
that were able to clear the platform during the first 10 seconds (white bars). Fitm RNAi-1A and Fitm 
RNAi-2 flies with Fitm downregulated ubiquitously and in skeletal muscle with the αTub84B-GAL4 
(A) and Mef2-GAL4 (B) promoters, respectively, showed a severe locomotor impairment at 4 days 
after eclosion and thereafter. (C) Fitm knockdown in the fat body (C7-GAL4 driver) using the Fitm 
RNAi-1A and Fitm RNAi-2 lines revealed a progressive locomotor impairment starting at 12 days 
after eclosion as compared to corresponding age-matched control flies. Statistical significance was 
reached between knockdown flies and corresponding controls in all tests depicted (p=0.000). 
A
B
C
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cells to identify potential shorter FITM2 peptides. Even after FLAG-affinity 
purification, no indication for significant amounts of alternative FITM2 peptides 
were obtained (Figure S2B). Therefore, we conclude that the FITM2 mutation 
results in loss of FITM2 function. 
 To further address the involvement of FITM2 mutations in hearing impairment 
syndromes with characteristics overlapping those in the present family, FITM2 
was analyzed for the presence of mutations in six index patients with deafness 
and a sensory polyneuropathy. Also, four index cases were tested who were 
suspected of Mohr-Tranebjaerg syndrome, a dystonia-deafness syndrome, or 
with several characteristics of the syndrome and who did not carry TIMM8A 
mutations. This did not reveal any potentially pathogenic FITM2 variants.
Drosophila models of FITM2
To gain independent support for the role of FITM2 in the phenotype of the 
presented family and to dissect the underlying tissue-specific pathologies and 
mechanisms, we turned to an efficient genetic model organism, the fruit fly 
Drosophila melanogaster, that has already been successfully employed to 
study specific aspects of the observed human pathology.8, 20-23 The Drosophila 
genome harbors a single, so far uncharacterized gene representing the human 
FITM protein family (FITM1 and FITM2), CG10671. According to ModEncode 
and FlyAtlas systematic expression databases,24, 25 Fitm is widely expressed 
throughout developmental stages and tissues, with highest expression found in 
adult fat body, heart and carcass. From here on we will refer to CG10671 as 
Fitm. 
 We modeled loss of human FITM2 expression by conditional knockdown in 
Drosophila, employing two independent, inducible RNAi constructs (ID #3580 
and ID #107999) and the UAS-GAL4 system. The efficacy of downregulation 
of Fitm was determined by qRT-PCR after ubiquitous knockdown using the 
αTub84B-GAL4 driver. The relative mRNA expression upon Fitm knockdown 
was 14.67% (p=0.03) for Fitm RNAi-1A and 7.04% for Fitm RNAi-2 (p=3x10-
4) as compared to the respective control lines.
Knockdown of Drosophila Fitm causes locomotor impairment
To evaluate locomotor function, impaired in the presented Pakistani family, we 
first subjected Fitm knockdown models to the island assay. This revealed that 
ubiquitous Fitm knockdown leads to severe locomotor impairment, resulting in 
more than 86% of flightless flies at four and at 12 days after eclosion (Figure 
2A). Upon downregulation of Fitm in skeletal muscle more than 98% of the 
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flies displayed the flightless phenotype at 4 and at 12 days after eclosion 
(Figure 2B). The effect of fat body-specific Fitm knockdown on locomotion 
was evaluated, because of the evolutionary conserved role of FITM2 in lipid 
droplet formation in adipose tissue15, 18 and high Fitm expression in Drosophila 
fat body. A progressive locomotor impairment was observed from 49% at 12 
days after eclosion to more than 78% of flightless flies at 20 days after eclosion 
(Figure 2C).
 In addition to quantification of the flightless phenotype, we visually evaluated 
body and wing movements of the flightless flies, since sensory motor coordination 
is essential for flight initiation and a sensory neuropathy is part of the phenotype 
in the Pakistani family. At the initiation of flight, flies first raise their wings to 
a stable position that will be held for a few seconds before takeoff for flight.26 A 
Figure 3. Muscle-specific downregulation of Fitm leads to an increased number of active zones 
in NMJs
Synapse morphology was determined in muscle 4 of L3 larvae with Fitm downregulated in the skeletal 
muscle (Mef2-GAL4 driver) using the RNAi lines Fitm RNAi-1A and Fitm RNAi-2 and compared 
to the corresponding controls. Fitm RNAi flies demonstrated a significant increase in active zones 
without a significant change in NMJ area. Values for all parameters were normalized against values 
of the corresponding controls. Bar graphs represent the fold change of the knockdown condition 
compared to its corresponding control; error bars represent normalized standard error of the mean 
(SEM). P-values were determined using two-sided T-tests and are indicated in the graphs. The number 
of NMJ images is indicated with “n”.
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subset of Fitm knockdown flies displayed uncontrolled movements as compared 
to controls. The knockdown flies failed to upstroke their wings for take-off and 
instead displayed fast wing movements, and uncontrolled jumping and shaking 
of their corpus. This locomotion phenotype was highly consistent in both RNAi 
lines tested with all three ubiquitous, skeletal muscle and fat body promoters. In 
conclusion, loss of Fitm expression in Drosophila causes locomotor phenotypes 
and Fitm knockdown in either skeletal muscle or fat body suffices to induce 
these phenotypes. 
Fitm is required in muscle for normal development of NMJ synaptic 
terminals 
Since locomotor function and motor coordination require proper signal 
transduction in neuromuscular synapses, we investigated NMJ architecture in 
Drosophila L3 larvae upon muscle and pan-neuronal knockdown of Fitm by 
assessing various morphological parameters (Figure 3, Figure S3, Figure S4). 
While gross morphology and organization of NMJs were unaffected by muscle-
specific knockdown of Fitm (Figure S3), we observed a significant increase in 
the number of the so-called active zones, the microdomains of synaptic vesicle 
release within the presynaptic terminal (Figure 3). No consistent differences in 
other NMJ parameters were found upon pan-neuronal Fitm knockdown (Figure 
S4). Therefore, we conclude that reduced expression of Fitm in skeletal muscle 
of Drosophila L3 larvae positively affects active zone development in NMJs 
independent of NJM area.
Downregulation of Fitm causes abnormal dendrite branching and field 
coverage of Drosophila multi-dendritic sensory neurons 
Since a sensory neuropathy is part of the syndrome caused by a nonsensense 
mutation in FITM2, we evaluated the role for Fitm in sensory neuron development 
by imaging the ddaC class IV dendritic arborization neurons in Drosophila L3 
larvae. These nociceptive ddaC neurons have a complex, but rather stereotypic 
dendritic branching pattern with a large field of coverage (Figure 4A, C) that, 
together with other class IV dendritic arborization neurons, tile the larval body 
wall. We expressed RNAi transgenes in class IV dendritic arborization neurons 
using the 477-GAL4 and ppk-GAL4 drivers, simultaneously inducing expression 
of the fluorescent marker UAS-mCD8::GFP. Knockdown of Fitm in the independent 
RNAi lines Fitm RNAi-1A and Fitm RNAi-2, resulted in a strong dendrite field 
coverage defect in a subset of larvae, which was not observed in their respective 
controls (Figure 4A–D). The abnormal tiling phenotype was strongest in Fitm 
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Figure 4. Fitm knockdown in Drosophila interferes with nociceptive multi-dendritic sensory 
neuron morphology
 (A)–(D) Confocal projections of class IV da neurons within segment A3 of L3 larvae, visualized with 
the class IV da-specific drivers 477-GAL4 and ppk-GAL4 and UAS-mCD8::GFP. The ddaC neurons 
show abnormal dendritic morphology in a subset of Fitm RNAi larvae. (A) Control-1 shows contact to 
neighboring neurons. (B) Knockdown of Fitm RNAi-1A results in a severe outgrowth defect, observed 
in 5/18 larvae. (C) Representative Control-2, (D) Knockdown of Fitm RNAi-2 results in an abnormal 
phenotype in 1/11 larvae. As for Fitm RNAi-1A all contact to the neighboring sensory neurons is lost, 
but the outgrowth phenotype is less severe. With manual tracing and quantitative analysis the extent 
of the Fitm RNAi-2 phenotype was further analyzed (E–J). (E)–(H) Quantitative analysis of dendritic 
trees reveals that the affected Fitm RNAi-2 neuron has E) a reduced average branch path length 
(p=0.003), (F) a reduced accumulative branch path length (p=0.005), (G) an increased maximal branch 
order (p=0.02), and H) increased number of branches (p=0.02). (I)–(J) Sholl analysis reveals defects as 
a measure of the soma distance, to reveal spatial defects. (I) The dendritic length is increased between 
80–150 µm, but drops 200 µm from the soma. The field coverage is reduced by 100 µm. (J) The branch 
order is increased sharply from 80 µm and drops prematurely due to reduced field coverage. Dorsal is 
up in (A)–(D), scale bar is 100 μm, error bars in (E)–(J) indicate the SEM.
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Figure 5. Knockdown of Fitm impairs Drosophila hearing
Antennal vibrations and ensuing antennal nerve potentials were measured in the Fitm RNAi-1A, 
Fitm RNAi-1B and Fitm RNAi-2 lines and the corresponding controls (Control-1 and Control-2, 
respectively) crossed to the pan-neuronal elav-GAL4 and ubiquitous αTub84B-GAL4 drivers27 three 
days after eclosion. (A) Sound-evoked antennal displacement amplitudes (upper panels, log scale) and 
normalized compound action potential (CAP) amplitudes as functions of the sound particle velocity. 
Each circle indicates a single data point. Solid (upper panels) and dashed (lower panels) lines indicate 
linear auditory mechanics, as observed upon the loss of auditory sensory neuron motility and active 
mechanical amplification,28 and Hill fits to the pooled CAP responses of each strain, respectively. N 
= 5 flies per strain. (B) Respective CAP thresholds, deduced from Hill fits to the CAP amplitudes of 
each individual. (C) Respective mechanical amplification gains provided by auditory sensory neuron 
motility. Significances: **: p<0.01, *: p<0.05, and ns: not significant (Mann-Whitney U-tests).
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RNAi-1A (Figure 4B), but Fitm RNAi-2 also shows this same defect, were contact 
to the neighboring sensory neurons is completely absent (Figure 4D).
To gain more insight in the underlying defects of the abnormal field coverage, 
we performed manual tracing and quantitative analysis on the Fitm RNAi-2 
neuron (Figure S5). Analysis of the mutant and control dendritic trees revealed 
a reduced average branch path length (p=0.003, Figure 4E) and a reduced 
accumulative branch path length (p=0.005, Figure 4F), both in concordance 
with the reduced field of coverage. The maximal branch order and number of 
branches was not decreased, but displayed a slight increase with respect to the 
control panel (both p=0.02, Figure 4G, H). To test for space-constrained effects 
that would explain this result we performed Sholl analyses, where the length 
or branch order are plotted as a function of the distance from the soma. The 
analysis revealed that dendritic length was increased slightly between 80–150 
µm from the soma, but then decreased prematurely (Figure 4I). The branch 
order was strongly increased between 80–210 µm (Figure 4J), but prematurely 
dropped after 210 µm. The final field coverage of the neuron was reduced by 
100 µm. Taken together, our results demonstrate that Fitm is required for normal 
branching and dendritic field coverage of Drosophila ddaC nociceptive sensory 
neurons.
Fitm is required for normal hearing in Drosophila
Affected members of the presented family displayed postnatal sensorineural 
hearing impairment that progressed to profound. Therefore, we aimed at testing 
whether Fitm is implicated in Drosophila hearing. To do so, we analyzed sound-
evoked mechanical and electrical responses of the antennal hearing organ 
(Figure 5). Three RNAi lines, Fitm RNAi-1A, Fitm RNAi-1B and Fitm RNAi-2 
were tested, whereby Fitm expression was knocked down ubiquitously or pan-
neuronally. A third Fitm RNAi line was included, Fitm RNAi-1B, which harbors 
the same RNAi construct (ID #3580) as Fitm RNAi-1A but inserted in a different 
genomic position. This line was included to strengthen the phenotypic effect of 
Fitm knockdown on hearing, which was relatively mild in the RNAi-2 line. The 
relative mRNA expression upon Fitm RNAi-1B knockdown by using αTub84B-
GAL4 was of 17.64% (p=0.02). To evoke sound-responses, we exposed the flies 
to pure tones of different intensities at the individual mechanical best frequency 
of their antennal sound receiver27 and measured the resulting vibrations of this 
receiver as well as the ensuing compound action potentials (CAPs) propagated 
by the axonal projections of the fly’s auditory sensory neurons in the antennal 
nerve (Figure 5A). In genetic background controls, sound particle velocities 
197
6
exceeded ca. 0.05 mm/s evoked CAP responses (Figure 5B), consistent with 
published data on wild-type flies.28 As in wild-type flies, the sound-induced 
displacement of the antenna also scaled nonlinearly with the intensity of 
sound stimulation (Figure 5A), displaying a compressive nonlinearity that, 
arising from motile responses of auditory sensory neurons,28 actively amplifies 
the antennal displacement response to faint sounds with an amplification 
gain of approximately seven (Figure 5C). Both ubiquitous and pan-neuronal 
knockdown of Fitm using Fitm RNAi-1A significantly increased the threshold 
of the sound-evoked CAP responses (Figure 5B), documenting a reduced 
auditory sensitivity. The same trend, although not significant, was seen in flies 
expressing Fitm RNAi-1B, whereas auditory sensitivity seemed uncompromised 
in flies expressing Fitm RNAi-2 (Figure 5B). Significant hearing impairment 
was also detected in the latter flies when we examined the nonlinear scaling of 
their antennal vibrations, which provides a more sensitive measure of auditory 
sensory neuron integrity.28 Consistently, all three RNAi constructs significantly 
Figure 6. Lipid droplet size is altered by downregulation of Fitm
Lipid droplets labeled with Bodipy (red) in fat bodies of females of the Fitm RNAi-1A and Fitm 
RNAi-1B lines upon RNAi expression induced by the fat body (C7-GAL4) driver as compared to the 
corresponding female control flies. Nuclei were stained with DAPI (blue). RNAi expression leads 
progressive decrease of lipid droplet size as compared to that in controls evaluated at 4, 12 and 20 days 
after eclosion. The scale bar is 10 µm.  
4 days
Fitm RNAi-1A♀
Fitm RNAi-1B♀
Control 1♀
12 days 20 days after eclosion
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reduced this nonlinear scaling, as witnessed by significantly lowered mechanical 
amplification gains (Figure 5C). Only in flies with pan-neural Fitm RNAi-2 
expression, amplification gains resembled those of control flies, which already 
displayed severely reduced amplification gains. Together, these results document 
that Drosophila auditory sensory neurons require Fitm for normal mechanical 
amplification in hearing, which is linked to auditory stimulus transduction and 
auditory neuron integrity.28 
Fitm is important for lipid droplet size in the fat body of adult Drosophila
Having shown striking parallels between human and Drosophila phenotypes, 
we finally sought to evaluate whether Drosophila Fitm functions in lipid droplet 
formation, as previously reported in other organisms.15, 17, 18 For this, we knocked 
down Fitm expression in the fat body and evaluated lipid droplet size in female 
flies. Fitm RNAi-1A knockdown flies demonstrated a diminished lipid droplet 
size as compared to flies of the Control-1 background line at 2, 7 and 12 days 
after eclosion (Figure 6). The Fitm RNAi-2 line exhibited a strong variation in 
lipid droplet size and therefore was not suitable for the experiment (Figure S6). 
The lipid droplet phenotype as seen in fat bodies of Fitm RNAi-1A knockdown 
flies was reproduced in the Fitm RNAi-1B line (Figure 6). Therefore, we can 
conclude that Fitm function in lipid droplet formation is conserved in Drosophila. 
DISCUSSION
We have described a unique family with a novel homozygous truncating 
mutation, c.4G>T (p.Glu2*), in FITM2. Affected subjects display a syndrome 
characterized by progressive sensorineural hearing impairment, delayed motor 
development, dystonia and signs of sensory neuropathy and ichthyosis. The 
syndrome is further associated with reduced BMI. The chronic diarrhea of the 
oldest affected sib might also be associated with the symdrome as postnatal Fit2 
deletion in mouse results in a malabsorptive enteropathy.19 The combination of 
the disease characteristics is novel although observed phenotypic characteristics 
in the family are overlapping with several known monogenic neurological 
conditions such as, obviously, other dystonia-deafness syndromes including 
Mohr-Tranebjaerg syndrome (MIM #304700), and Megdel syndrome (MIM 
#614739, and also Troyer syndrome (MIM #275900). We propose to call the 
syndrome in the presented family “Siddiqi syndrome” after Dr. Saima Siddiqi, 
who initiated the research in this family. The causative association of the 
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syndrome with a loss-of-function mutation in FITM2 is supported by modeling 
of the disease in Drosophila melanogaster which has been proven to be a suitable 
model for studying conserved aspects of lipid metabolism and LD biology.8, 29 
RNAi knockdown of the single Drosohila FITM ortholog recapitulated hearing 
impairment , impaired locomotion, and abnormalities of the sensory system. 
 Affected subjects do not have signs of a lipodystrophy which is in contrast to the 
findings in mouse in which post-differentìation adipose-specific knockout of Fit2 
results in progressive reduction of white adipose tissue.18 Functional redundancy in 
human adipose tissue might exist for FITM2 through FITM1 which is apparently 
not the case in mouse. In the latter, FIT2 is prominently expressed in adipose tissue 
in which FIT1 was not detected.15 The relative expression of FITM1 and FITM2 in 
human adipose tissue is still elusive.
 Sensorineural hearing impairment is the first symptom of Siddiqi syndrome. 
The audiometric evaluations did not allow to discriminate whether the hearing 
impairment has a cochlear or retrocochlear neuronal origin. The hearing phenotype 
resulting from Fitm knockdown in Drosophila was reflecting impaired auditory 
stimulus transduction and auditory neuron function which might support a neuronal 
component in the human phenotype e.g. progressive loss of spiral ganglion cells as 
has been demonstrated in a patient with Mohr-Tranebjaerg syndrome.30 A cochlear 
component, however, might well contribute to progressive dysfunction of the auditory 
system in the patients. Interestingly, LDs are prominent constituents of Hensen 
cells which are highly specialized cells in the organ of Corti. Hensen cell LDs have 
been suggested to function in an anti-inflammatory response to prevent cochlear 
damage.31-34 Additionally, a mechanical function in modulating sound detection has 
been proposed for LDs in Hensen cells.31 Whether vestibular dysfunction is part of 
the inner ear phenotype could not be evaluated. Therefore, it remains undetermined 
whether impaired balance contributed to the delayed motor developments of the 
subjects. 
 Deafness-dystonia is clinically and etiologically heterogeneous and in many of 
the investigated cases the underlying cause remained elusive.35, 36 For part of the 
genetically solved cases, involvement of mitochondrial dysfunction is emerging as 
a common theme. This is obvious for Mohr-Tranebjaerg (MIM# 304700) syndrome 
with mutations in TIMM8A37 (MIM# 300356), for a number of rare mitochondrial 
disorders with mutations in mitochondrial genes as well as for SUCLA2-associated 
disease (MIM #612073), an atypical type of methylmalonic aciduria, as SUCLA2 
encodes the ATP-forming β subunit of mitochondrial succinyl-CoA ligase.38 
However, also for SERAC1 (MIM #614725) defects in patients with MEGDEL 
syndrome (MIM# 614739) impaired mitochondrial energy metabolism is part of the 
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pathogenic mechanisms. SERAC1 is associated with the endoplasmatic reticulum 
(ER) and suggested to localize at the ER-mitochondrial interface. It functions in 
remodeling of phosphatidylglycerol and cholesterol trafficking.39 TIMM8A is 
located in the mitochondrial intermembrane space and is important for maintenance 
of mitochondrial morphology.40 Interestingly, there is increasing data that suggest a 
functional connection between LDs, and thus FITM2, and other organelles including 
mitochondria.41 Based on these findings, it is tempting to speculate that impaired 
mitochondrial function or otherwise impaired energy supply in the affected tissues 
might be part of the disease mechanism in the present family with a defect in FITM2. 
In this light, it is interesting that overexpression of Fit2 in mouse skeletal muscle led 
to increased energy expenditure which indicated an unexpected function of FIT2 and 
thereby LDs in regulation of energy metabolism.14 The underlying mechanism of the 
latter is still elusive but might well be related to the expanding functions of LDs.5 
 Alternative and/or additional pathogenic mechanisms for the presented syndrome 
might be related to ER-stress analogous to the disease mechanism of specific gain 
of function mutations in BSCL2 that underlie motor neuropathies.9 Also impairment 
of other recently proposed roles of LDs e.g. in immunity, modulation of nuclear 
functions, protein degradation, autophagy, and lipid signaling should be considered 
to contribute to the phenotypic characteristics of the presented family.5, 42 Further 
studies are needed to elucidate the molecular mechanisms underlying the syndrome 
for which Drosophila melanogaster would be an excellent model as well as patient 
cells. 
 In conclusion, we have elucidated the genetic defect in FITM2 to underlie a novel 
dystonia-deafness syndrome which was modeled in Drosophila. The phenotype 
of the affected individuals suggests human FITM2 to be essential for biological 
processes other than neutral lipid storage and metabolism.
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Figure S1. Genome wide LOD scores as calculated using MerLIN 1.1.2
The Y axis represents LOD scores and the X axis genetic distance in centimorgans (cM), per 
chromosome. The dotted line mark a LOD score of 3.3 indicating genome wide significance and 
the dashed line mark a LOD score of -2.0 indicating exclusion of linkage. In the calculations, the 
disease allele frequency at 0.001. There is only one region in chromosome 20q12-q13.2, delimited 
by rs2903624 and rs6096425 (chr20:41,616,510-50,037,207; GRCh37, hg19) with a significant 
maximum LOD score of 4.
209
6Figure S2. identification of genetic defects underlying Siddiqi syndrome in family W09-1008 
and expression analysis of wild-type and p.Glu2* FITM2 fused to a flag TAG in HEK293T cells
(A) Partial sequences of FITM2 exon 1 are shown from an affected member, an unaffected heterozygous 
sib and an unaffected wild-type sib of family W09-1008. The predicted amino acid changes and the 
surrounding amino acids are indicated above the sequence. As reference sequence NM_001080472.1 
was employed. (B)The left panel shows a Western blot of a gel on which 10 % of the cell lysate 
was loaded (before affinity purification). The right panel shows a Western blot of a gel on which 10 
µl of the lysate after affinity purification (anti-FLAG) was loaded. Wildtype (WT) FITM2 migrates 
around 29kDa and it is absent upon transfection of the p.Glu2* FITM2 construct expressed. After 
affinity purification, a very weak band is observed at ~16kDa. However, the intensity of the 16 kDa 
band is about 2700 fold lower than the wild-type FITM2 band and therefore it is likely to have little 
or none biological impact. The gel was immunostained with an anti FLAG polyclonal antibody. Of 
four ATG-triplets in the original reading-frame, three (codon positions 94, 493 and 508) are predicted 
to be potential translation initiation sites by the Netstart 1.0 algorithm.1 Accordingly, alternative 
proteins would consist of 285 amino acids (aa) (26.2 kDa), 152 aa (11.2 kDa), and 147 aa (10.6 kDa), 
respectively. Expression constructs encode FITM2 fused to a C-terminal Strep-FLAG-tag (SF-TAP),2 
adding approximately 6 kDa to the proteins. Wild-type FITM2 was found to migrate according to 
molecular weight of ~29 kDa, which is lower as compared to the predicted mass of the complete 
protein (Figure S2). However, fragments of similar length are observed  with anti-FITM2 staining in 
the work of Duckert et al. and pro-peptide cleavage is predicted by the ProP algorithm.3 Marker size 
is indicated between the panels and given in kDa. 
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Figure S3. Downregulation of Fitm in the skeletal muscle has no effect on NMJ length, longest 
branch length, number of branches and number of branching points
Synapse morphology was determined in muscle 4 of L3 larvae with Fitm downregulated in the skeletal 
muscle by the Mef2-GAL4 driver in the RNAi lines Fitm RNAi-1A, and Fitm RNAi-2 and compared to 
the corresponding controls with no consistent differences in the presented parameters. All the parameter 
values were normalized with the respective control values. Bar graphs represent the fold change of 
the knockdown condition compared to its corresponding control, error bars represent normalized SEM. 
P-values were determined using two-sided T-tests. The number of NMJ images is indicated with “n”.
Figure S4. No consistent differences in NMJ parameters were found upon pan-neuronal Fitm 
knockdown
Synapse morphology was determined in muscle 4 of L3 larvae with Fitm downregulated pan-neurally 
using the elav-GAL4 driver in the RNAi lines Fitm RNAi-1A, and Fitm RNAi-2 and compared to the 
corresponding controls, no significant differences were found in any of the quantified NMJ parameters. All 
the parameter values were normalized with the respective control values. Bar graphs represent averages 
and error bars represent SEM. Significance was determined using two-sided T-test. The number of NMJ 
images is indicated with “n”.
#B
ra
nc
hi
ng
 p
oi
nt
s
Le
ng
th
Lo
ng
es
t b
ran
ch
 le
ng
th
#B
ra
nc
he
s
#B
ra
nc
hi
ng
 p
oi
nt
s
Le
ng
th
Lo
ng
es
t b
ran
ch
 le
ng
th
#B
ra
nc
he
s
#B
ra
nc
hi
ng
 p
oi
nt
s
#I
sla
nd
s
NM
J 
ar
ea
#A
ct
ive
 z
on
es
Le
ng
th
Lo
ng
es
t b
ran
ch
 le
ng
th
#B
ra
nc
he
s
#B
ra
nc
hi
ng
 p
oi
nt
s
#I
sla
nd
s
NM
J 
ar
ea
#A
ct
ive
 z
on
es
Le
ng
th
Lo
ng
es
t b
ran
ch
 le
ng
th
#B
ra
nc
he
s
Fo
ld
 c
ha
ng
e
Fo
ld
 c
ha
ng
e
Fo
ld
 c
ha
ng
e
Fo
ld
 c
ha
ng
e
211
6
Figure S5. Manual tracing representation of the type IV neurons of Drosophila
(A), (B) Control and Fitm RNAi-2 neuron with the manual tracing overlaid in cyan. (A’), (B’) Isolated 
manual tracing reconstruction. Scale bar 100 μm.
A
A’
B
B’
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Figure S6. Lipid droplet size in Drosophila after dowregulation of Fitm
Lipid droplets labeled with Bodipy (red) in fat bodies of females of the Fitm RNAi-2 upon RNAi 
expression induced by the C7-GAL4 driver as compared to Control-2 flies. Nuclei were stained with 
DAPI (blue). Differences in lipid droplet size between Fitm RNAi-2 females and controls at 4, 12 
and 20 days after eclosion were not detected because the size of lipid droplets of Control-2 was not 
uniform. The scale bar is 10 µm.
table S1. Primer sequences and PCR conditions for genomic PCR and Sanger sequence analysis of 
FITM2 (uc002xlr.1)
PCR amplicon Oligonucleotides (5` to 3`)
FITM2_Exon 1_forward agaggagacgagcgagttc
FITM2_Exon 1_reverse ctccaatgactcgtccacc
FITM2_Exon 2_forward cccctgacagtgtagagacc
FITM2_Exon 2_reverse aagtgcctaactgggaatgg
FITM2_Exon 1 _Digestion_forward ggcacggagaggaggac
FITM2_Exon 1_Digestion_reverse cactcacacgttgaggacg
Fitm_Exon1_forward cgtcatagccaccttcttctg
Fitm_Exon1-2_reverse gtcgcataaccctttgtgg
RpII215_Exon 3_forward ccgcgatacttctctccac
RpII215_Exon 4_reverse gaccagctaggcgacattc
4 days
Fitm RNAi-2♀
Control 2♀
12 days 20 days after eclosion
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aBStraCt
 
Purpose: Hearing impairment (HI) is genetically very heterogeneous, which 
hampers genetic counseling and molecular diagnosis. Testing of several known 
genes selected based on the type of HI, is laborious and expensive. In this study, 
we evaluate the diagnostic utility of whole exome sequencing (WES) targeting 
a panel of HI-related genes.
Methods: Two hundred index patients, mostly of Dutch origin, with presumed 
hereditary HI underwent WES targeting a HI gene panel. 
Results: We found causative variants underlying the HI in 58 of 200 patients 
(29%). Ten of these patients have a large homozygous deletion, which could 
only be identified by copy number variation detection in the WES data. Variants 
of uncertain significance were found in 26 patients (13%). In the remaining 116 
cases no potentially causative variants have been detected (58%). 
Conclusion: The diagnostic yield for HI using WES targeting a HI gene panel is 
higher than targeted sequencing of single genes. In our patient cohort, causative 
variants in GJB2, STRC, MYO15A, and USH2A, and in MYO6 were the leading 
causes for autosomal recessive and dominant HI, respectively. Segregation 
analysis of variants of uncertain significance in affected or unaffected relatives 
of index patients will further increase the diagnostic yield of WES.
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INtrODUCtION
DNA diagnostics of any genetically heterogeneous disease based on predictive 
gene testing is highly inefficient, laborious and expensive. High throughput 
sequencing technologies such as whole exome sequencing (WES) have coped 
with these disadvantages allowing the analysis of all protein-coding exons in a 
single cost-effective attempt.1
 Hearing impairment (HI) is the most common sensory disorder with an 
incidence of one in 750 newborns (> 40 dB) in developed countries.2 About half of 
the cases are attributed to genetic factors with more than a hundred genes known 
to date (http://hereditaryhearingloss.org/). HI is most frequently manifested as 
non-syndromic (NSHI) accounting for about 70% of the hereditary cases. About 
77% of NSHI cases exhibit autosomal recessive inheritance (arNSHI) with 61 
genes and 97 loci known to date, whereas it is dominant (adNSHI) in about 
22% of the cases with 33 genes and 67 loci known. The remaining 1% shows 
an X-linked, a Y-linked or a mitochondrial type of inheritance pattern with six 
loci and six genes known to date (http://hereditaryhearingloss.org/). NSHI is 
thus genetically very heterogeneous. Many genes have been described to be 
involved in only one or a few families with HI.3-5 Some exceptions are known, 
e.g. mutations in GJB2 followed by mutations in STRC and MYO15A are the 
most common causes for arNSHI worldwide.6-9 
 Since many genes contribute to hereditary HI, targeting all or a selection 
of protein-coding exons in a single experiment, like in WES, seems ideal and 
might ultimately be the only choice for a comprehensive genetic analysis of 
HI individuals. The implementation of WES in a diagnostic setting has been 
much slower than in scientific research due to the relatively low sensitivity 
of this method in detection of genetic variation in some exonic regions, e.g. 
extremely GC-rich regions, as compared to Sanger sequencing.10 Despite this 
fact, the diagnostic yield in hereditary HI obtained by WES is expected to be 
higher compared to the approach of phenotype-based pre-testing of one or two 
genes by Sanger sequencing.11 Therefore, the aim of this study is to evaluate the 
diagnostic utility of WES targeting a panel of HI-related genes in a group of 200 
Dutch index patients with presumed hereditary HI. 
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patIeNtS aND MethODS
patients
WES was performed in 200 patients with HI, mainly of Dutch origin. Non-
genetic causes of the HI were excluded by anamnesis. Thirty-seven patients 
have been previously reported.11,12 For 142 patients mutations in one or more 
genes involved in HI have been excluded before WES was performed. For all 
patients, written informed consent for WES was obtained after counseling by a 
clinical geneticist. 
WeS and bioinformatics
Prior to sequencing, genomic DNA fragments of all patients were enriched for 
exome sequences using the Agilent SureSelectXT Human All Exon 50Mb kit. For 
45 patients, WES was performed with a 5500xl machine (Life TechnologiesTM) 
at the department of Human Genetics, Radboudumc Nijmegen, and data were 
analyzed using LifeScopeTM software as previously reported.11 For the remaining 
patients (N=155) WES was performed at BGI-Europe (Copenhagen, Denmark), 
employing an Illumina HiSeq2000TM machine. For these samples, “read 
alignment” using BWA and “variant calling” with GATK were performed at BGI.13 
 For all patients, variants were annotated with an in-house developed annotation 
and prioritization pipeline.11 Variants in genes associated with HI were selected 
and analyzed. In the first 45 patients, a panel of 104 HI genes was analyzed.10 
The remaining 155 patients were analyzed with an updated list of 130 HI genes. 
Detailed information on both gene lists (DGD_181213 and DGD_200614) can 
be found at http://genomediagnosticsnijmegen.nl/services/exome-sequencing-
diagnostics. All reported variants have been verified by Sanger sequencing. 
 For all patients ‘copy number variant calling’ was carried out using CoNIFER 
0.2.0,14 and variant annotation was performed using an in-house developed 
strategy.15 
Interpretation and classification of variants 
To systematically predict their pathogenicity, variants were sorted based on existing 
guidelines for classification of variants (http://www.acgs.uk.com/media/774853/
evaluation_and_reporting_of_sequence_variants_bpgs_june_2013_-_finalpdf.
pdf). Patients were grouped based on the combination of (likely) pathogenic 
variants and associated phenotype known from literature. Three groups were 
distinguished: 1) patients with causative variants, 2) patients with variants of 
uncertain significance, and 3) patients without detected causative variants. 
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Validation of selected variants
All reported sequence variants have been validated by Sanger sequencing 
(primer sequences and PCR conditions are available upon request). Copy 
number variants were validated by MLPA (STRC, homemade MLPA kit s139; 
USH2A, MRC-Holland kits P361A1 and P362A2) or deletion-specific PCR 
(OTOA, kindly provided by Guney Bademci, MD).
MYO15A gene analysis
SNP genotyping was performed on genomic DNA samples isolated from 
peripheral blood of affected individuals using different single-nucleotide 
polymorphism (SNP) arrays (Affymetrix mapping 250K NspI, Affymetrix 
Genechip Genome-Wide Human Arrays 5.0 or Affymetrix Genechip Genome-
Wide Human Arrays 6.0) as described previously.16-18
 To determine the presence of the c.6787G>A transition in a panel of 102 index 
patients with presumed arNSHI, exon 32 of MYO15A (NM_016239.3) was 
amplified and digestion of PCR products with PvuII (New England Biolabs) 
was performed according to the manufacturer’s protocol. Restriction fragments 
were analyzed on 2% agarose gels; the variant introduces a restriction site. To 
determine the presence of the c.1137delC variant in the same patient panel, 
exon 2 was amplified using specific primers with an M13 tail. A second round 
of amplification was performed using an M13 forward and a fluophore-labeled 
M13 reverse primer. PCR products were subsequently separated on an ABI Prism 
3730 Genetic Analyzer, and analyzed with the GeneMapper software according 
to the manufacturer’s protocol (Life Sciences).
 For sequence analysis of MYO15A (NM_016239.3), all exons and exon-intron 
boundaries were amplified and Sanger sequence analysis was performed as 
described previously.16 Primer sequences for amplification of exons and exon-
intron boundaries of MYO15A are available upon request.
 
reSULtS
The exomes of 200 individuals with presumed hereditary HI, mostly of Dutch 
origin, were sequenced in this study. The inheritance pattern was suspected to 
be autosomal dominant in 65 cases, autosomal recessive in 33 cases, X-linked 
in one case and the remaining 101 cases were isolated. Subsequently, targeted 
analysis of WES data was performed for a panel of 104 (DGD181213, 45 cases) 
or 130 (DGD200614, 155 cases) genes associated with HI. The average coverage 
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per gene is available on our website (http://www.genomediagnosticsnijmegen.
nl/services/exome-sequencing-diagnostics).
Diagnostic yield with WeS in hI patients
We detected variants predicted to be pathogenic in 29% (58 cases) of the 
200 cases with presumed hereditary HI (Table 1, Supplementary Table S1, 
Supplementary Table S2). In 41 of these patients homozygous or compound 
heterozygous mutations in genes associated with autosomal recessive HI were 
detected, being large homozygous deletions of several exons or complete genes 
in 10 of these cases. GJB2 was found to be the most frequently mutated gene, 
followed by USH2A, MYO15A and STRC, together accounting for 41.4% of the 
positive cases (Figure 1a).
 In the remaining 17 cases heterozygous mutations in ten different genes 
associated with autosomal dominant were found (Supplementary Table S1, 
Figure 1b). In three cases, the heterozygous mutations were de novo. Mutations 
in MYO6 were the leading cause in this cohort of presumed adHI cases (Figure 
1b).
 The diagnostic yield was related to the type of inheritance of the HI in the 
patients. For patients with suspected autosomal recessive HI, the diagnostic 
yield was 54.5% (Table 1, Supplementary Table S2). In 27.7% of the cases 
without a (known) family history (isolated cases), the molecular etiology could 
be identified, the majority harboring causative variants in genes associated 
with arHI (Table 1, Supplementary Table S2). For adHI, presumed causative 
mutations were found in only 18.5% of the cases (Table 1, Supplementary Table 
S2). 
 We identified variants of uncertain significance in 26 cases (13%) 
(Supplementary Table S2, Supplementary Table S3). In 16 of these, co-segregation 
of the variant(s) with the disease in the family needs to be performed in order to 
classify these variants as the putative cause of the HI. In the remaining ten cases 
segregation analysis was performed. However, the variants could neither yet be 
classified as the cause of the HI, nor could they be discarded as not pathogenic. 
In two of these cases a variant has been identified which was previously 
described as causative for HI, but which does not segregate with the disease 
in the family (AD21 and ISO34). In one case (ISO31) compound heterozygous 
variants segregating with the HI were identified in two genes (SLC26A4 and 
USH1G). In two other cases the reported HI phenotype is different from the 
phenotype known to be associated with the mutation and/or gene (AD17 and 
AD23). In three cases, a combination of a missense and a nonsense variant 
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was found in LOXHD1 (AR19, ISO29 and ISO35). To date, mostly truncating 
mutations have been reported for this gene and only a single patient who carries 
a combination of a missense and a nonsense mutation.19-23 Finally, in two patients 
compound heterozygous variants were found in USH2A (AR20 and AR21). The 
significance of the (previously unreported) USH2A missense variants in these 
patients is unclear and they cannot be definitely classified as causative for the 
HI in these patients, although they are located in trans.
 In our study, 58% of the 200 exomes (116 cases) did not reveal causative 
variants. In the majority of them (92 cases) no putative causative variants were 
remaining after the data filtering procedure. In 19 cases, the variants were not 
segregating with the HI in the family. In four cases only a single variant was 
identified in a gene known to underlie autosomal recessive HI. In two of the 
Figure 1. Overview of HI genes and number of cases in which causative variants were identified in 
these genes. A. cases with arHI. B. cases with adHI.
A
B
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table 1. List of patients with presumed causal variants.
Patient Gene Variant 1 Variant 2 Segregating 
with HL
AD1# MYO6 NM_004999.3 c.1546+1G>T (p.?) - Yes
AD2 WFS1 NM_006005.3 c.2051C>T (p.(Ala684Val))# - ND
AD3 TECTA 
ENST00000392793.1
c.6002G>T (p.(Cys2001Phe)) - Yes
AD4 MYO7A NM_000260.3 c.1373A>T(p.(Asn458Ile))# - Yes
AD5# MYO6 NM_004999.3 c.1211del (p.(Gly404Glufs*4)) - Yes
AD6# MYH9 NM_002473.4 c.2507C>T (p.(Pro836Leu)) - Yes
AD7 POU4F3 NM_002700.2 c.828_829insT (p.(Lys277*)) - ND
AD8 MYO7A NM_000260.3 c.652G>A (p.(Asp218Asn)) - Yes
AD9 POU4F3 NM_002700.2 c.668T>C (p.(Leu223Pro))# - ND
AD10 MYO6 NM_004999.3 c.3395del 
(p.(Lys1132Serfs*12))
- Yes
AD11 SOX10 NM_006941.3 c.1195C>T (p.(Gln399*)) - ND
AD12 MYH14 
NM_001145809.1
c.394G>A (p.(Gly32Ser)) - Yes
AR1# USH2A NM_206933.2 c.9372-?_9570+? (p.?) c.9372-?_9570+? (p.?) ND
AR2 OTOA 
ENST00000388958
chr16(GRCh37):g.21581229-
21771715del#
chr16(GRCh37):g.21581229-
21771715del#
ND
AR3# CIB2 NM_006383.2 c.97C>T (p.(Arg33*)) c.196C>T (p.(Arg66Trp)) Yes
AR4 STRC NM_153700.2 c.-78-?_5327+?del(p.0?)# c.-78-?_5327+?del(p.0?)# Yes
AR5 USH2A NM_206933.2 c.8846-?_9371+?del(p.?) c.8846-?_9371+?del(p.?) ND
AR6 TMC1 NM_138691.2 c.646del (p.(Leu216Serfs*54)) c.790C>T (p.(Arg264*)) ND
AR7 CDH23 NM_022124.5 c.6442G>A (p.(Asp2148Asn))# c.1545_1547del (p.(Ile515del))# Yes
AR8 USH2A NM_206933.2 c.1606T>C (p.(Cys536Arg))# c.9815C>T (p.(Pro3272Leu))# Yes
AR9 GJB2 NM_004004.5 c.35del (p.(Gly12Valfs*2))# c.71G>A (p.Trp24*))# ND
AR10 GJB2 NM_004004.5 c.35del (p.(Gly12Valfs*2))# c.35del (p.(Gly12Valfs*2))# Yes
AR11 CDH23 NM_022124.5 c.2096A>G (p.(Asp699Gly)) c.4564A>G (p.(Asn1521Ser)) Yes
AR12 GJB2 NM_004004.5  c.-23+1G>A (p.?)# c.35del (p.(Gly12Valfs*2))# Yes
AR13 MYO7A NM_000260.3 c.3289C>T(p.(Gln1097*)) c.3862G>C(p.(Ala1288Pro))# 
c.5227C>T(p.(Arg1743Trp))#
ND
AR14 STRC NM_153700.2 c.-78-?_5327+?del(p.0?) c.-78-?_5327+?del(p.0?) ND
AR15 MITF NM_000248.3 c.649del (p.(Arg217Aspfs*4))# - ND
AR16 PCDH15 NM_033056.3 c.3374-2A>G (r.?) c.4127C>A (p.(Ala1376Asp)) Yes
AR17 STRC NM_153700.2 c.-78-?_5327+?del(p.0?)# c.-78-?_5327+?del(p.0?)# ND
AR18 STRC NM_153700.2 c.-78-?_5327+?del(p.0?)# c.-78-?_5327+?del(p.0?)# ND
ISO1#11 MYO15A NM_016239.3 c.625G>T (p.(Glu209*)) c.1137del (p.(Tyr380Metfs*64))# ND
ISO2# USH2A NM_206933.2 c.5385T>A (p.(Tyr1795*)) c.6850_6851insAATC 
(p.(His2284Glnfs*48))
ND
ISO3 CDH23 NM_022124.5 c.8480_8481del 
(p.(Leu2827Hisfs*23))
c.8480_8481del 
(p.(Leu2827Hisfs*23))
ND
ISO4# MYO15A NM_016239.3 c.6764+2T>A (p.?) c.3844C>T (p.(Arg1282Trp); 
c.5287C>T (p.(Arg1763Trp))
Yes
ISO5 GJB2 NM_004004.5 c.101T>C (p.(Met34Thr))# c.109G>A (p.(Val37Ile))# Yes
ISO6 WFS1 NM_006005.3 c.2051C>T (p.(Ala684Val))# - ND
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table 1. Continued.
Patient Gene Variant 1 Variant 2 Segregating 
with HL
ISO7 MYO15A NM_016239.3 c.6787G>A (p.(Gly2263Ser)) c.7893+1G>A (p.?) Yes
ISO8 TRIOBP 
NM_001039141.2
c.2653del 
(p.(Arg885Alafs*120))
c.5014G>T (p.(Gly1672*)) Yes
ISO9 USH2A NM_206933.2 c.2299del (p.(Glu767Serfs*21)) c.920_923dup 
(p.(His308Glnfs*16))
Yes
ISO10 MYO7A NM_000260.3 c.3476G>T (p.(Gly1159Val))# c.5560G>A (p.Val1854Met))# Yes
ISO11 GJB2 NM_004004.5 c.250G>C (p.(Val84Leu)) c.269T>C (p.(Leu90Pro))# Yes
ISO12 GJB2 NM_004004.5 c.109G>A (p.(Val37Ile))# c.109G>A (p.(Val37Ile))# ND
ISO13 TMPRSS3 
NM_024022.2
c.916G>A (p.(Ala306Thr))# c.1276G>A (p.(Ala426Thr))# ND
ISO14 STRC NM_153700.2 c.-78-?_5327+?del(p.0?)# c.-78-?_5327+?del(p.0?)# ND
ISO15 GJB2 NM_004004.5 c.35del (p.(Gly12Valfs*2))# c.101T>C (p.(Met34Thr))# Yes
ISO16 ACTG1 
NM_00199954.1
c.773C>T (p.(Pro258Leu)) - ND
ISO17 GJB2 NM_004004.5 c.35del (p.(Gly12Valfs*2))# c.508_511dup 
(p.(Ala171Glufs*40))#
ND
ISO18 MYO15A NM_016239.3 c.3311dup (p.(Glu1105*)) c.3311dup (p.(Glu1105*)) ND
ISO19 TRIOBP 
NM_001039141.2
c.3460_3461del 
(p.(Leu1154Alafs*29)) 
 c.3232dup 
(p.(Arg1078Profs*6))#
ND
ISO20 MYO7A NM_000260.3 c.5618G>A (p.(Arg1873Gln))# c.6028G>A (p.(Asp2010Asn))# Yes
ISO21 MYO6 NM_004999.3 c.3610C>T (p.(Arg1204Trp))# - ND
ISO22 SLC26A5 NM_198999.2 c.355C>T (p.(Pro119Ser)) c.355C>T (p.(Pro119Ser)) ND
ISO23 GJB2 NM_004004.5 c.101T>C (p.(Met34Thr))# c.109G>A (p.(Val37Ile))# ND
ISO24 SOX10 NM_006941.3 c.482G>A (p.(Arg161His))# - ND
ISO25 STRC NM_153700.2 c.-78-?_5327+?del(p.0?)# c.-78-?_5327+?del(p.0?)## ND
ISO26 MYO6 NM_004999.3 c.3335A>G (p.(Tyr1112Cys)) c.1897del(p.(Gln633Lysfs*19)) Yes
ISO27 LARS2 NM_015340.3 c.683G>A (p.(Arg228His)) c.880G>A (p.(Glu294Lys)) Yes
ISO28 OTOA 
ENST00000388958
chr16:21581229-21771715# chr16:21581229-21771715# ND
AR, autosomal recessive; AD, autosomal dominant; ISO, isolated; Y, yes; ND, not done; # 
mutations that have been described in literature before, the corresponding references are provided in 
Supplementary Table S1.
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patients the phenotype associated with the gene did not match the phenotype 
seen in the patient and the gene was not further analyzed. In the other patients 
the genes were analyzed with Sanger sequencing and/or MLPA which did not 
reveal a second variant. Finally, in one case a putatively pathogenic variant 
was identified in NLRP3, a gene known to underlie Muckle-Wells syndrome.24 
However, further clinical evaluation in the patient revealed no evidence for this 
syndrome and the variant was therefore considered not to be the cause of the HI. 
Diagnostic yield with targeted sequencing of single genes
To make a proper comparison of the diagnostic yield between single gene testing 
in DNA diagnostics and WES, an overview was made of all (in-house) gene 
analysis requests for HI in 2013-2014 and the diagnostic yield (Table 2). In total 
436 gene analyses were requested in 206 unique patients for 39 different genes; 
in 33 (7.6%) of the gene analyses pathogenic variants underlying the HI were 
identified in 16 different genes. The three genes with the highest diagnostic 
yield were GJB2, COCH and KCNQ4. For these three genes, founder or hotspot 
mutations occur in the Dutch population explaining the high incidence of 
mutations found in DNA diagnostics.25-27 
MYO15A mutations in the Dutch hI population
Recently, it has been reported that MYO15A mutations are a common cause of 
arNSHI.6 Analysis of this gene was not frequently requested for DNA diagnostics; 
only three times in two years (Table 2) and no causative variants were identified 
in these cases. However, in the current WES cohort MYO15A mutations were 
identified to underlie the HI in four cases. Therefore, involvement of MYO15A 
mutations in the Dutch arNSHI population was further determined in a panel of 
patients with arNSHI. First, we analyzed SNP genotyping data of 28 families 
with at least two individuals with presumed arNSHI. In eight families, affected 
siblings showed a shared genotype for MYO15A. All exons and exon-intron 
boundaries of MYO15A were subsequently screened in the index patient of these 
eight families. In five of these families causative variants segregating with the HI 
were identified (Supplementary Table S4). In a second approach, the presence of 
two mutations (c.1137delC and c.6787G>A) was investigated in a panel of 102 
additional index patients with presumed arNSHI. These mutations were selected 
since these were both identified in our arNSHI panel as well as in the WES 
cases (ISO1 and ISO7) at that time and we suspected that these might be founder 
mutations in the Dutch population. The c.1137delC mutation was present in 
five cases and the c.6787G>A mutation in two patients (homozygously in one). 
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table 2. Diagnostic yield for single gene testing in DNA diagnostics
Gene symbol # of requests # of positive* requests % of positive* request per gene
ACTG1 17 0 0
BSND 1 0 0
CLRN1 1 0 0
COCH 19 7 36.8
COL11A1 1 1 100
COL11A2 35 0 0
COL2A1 1 0 0
DFNA5 5 1 20
DFNB59 2 0 0
DIAPH1 8 0 0
EYA1 9 1 11.1
EYA4 22 0 0
GJB2 69 5 7.2
GRXCR1 1 0 0
HOXA2 1 0 0
KCNQ4 26 4 15.4
MITF 18 1 5.6
MYO15A 3 0 0
MYO6 16 0 0
MYO7A 3 1 33.3
NDP 1 1 100
OTOF 4 2 50
OTOG 3 0 0
OTOGL 3 0 0
PAX3 14 1 7.1
POU3F4 1 0 0
POU4F3 11 0 0
PTPRQ 1 0 0
SIX1 5 0 0
SIX5 5 0 0
SLC26A4 8 2 25
SNAI2 10 0 0
SOX10 2 0 0
TECTA 47 2 4.3
TMC1 2 0 0
TMPRSS3 36 2 5.6
TSHZ1 3 0 0
USH2A 5 1 20
WFS1 17 1 5.9
*positive indicates that causative variants were identified.
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All exons and exon-intron boundaries of MYO15A were subsequently screened 
in all patients carrying the c.1137delC or the c.6787G>A mutation. In two of 
these patients the gene could not be completely screened since the DNA was 
depleted. In total, sequence analysis of the MYO15A gene was performed in 
13 index patients. In eight of these homozygous or compound heterozygous 
putatively pathogenic variants were identified that segregated with the HI in the 
corresponding families (Supplementary Table S4). 
 To summarize, our targeted analysis of MYO15A revealed mutations in eight of 
131 families (6.1%). This number might well be higher since we did not screen 
the complete gene in 97 of the cases. All individuals with causative variants 
in MYO15A presented with congenital severe-to-profound HI (Supplementary 
Table S4).
DISCUSSION
In this study, we aimed to evaluate the diagnostic yield of WES-based targeted 
analysis of genes involved in HI. WES technology allowed the efficient 
identification of single nucleotide variants, indels and large deletions that affect 
the protein coding regions of HI genes in a single experiment.11 Our study 
underlines the great genetic heterogeneity for HI since causative variants were 
found in 25 different genes (Table 1). Our study also illustrates that there are 
still many genes to be discovered for HI since in 58% of the cases no putative 
causative variants were identified in the genes currently known to underlie HI. 
Part of these cases is likely to be explained by variants in known HI genes 
that cannot be identified by WES (e.g. deep intronic variants affecting splicing, 
variants in non-coding exons, repeat regions and regulatory regions). For the 
isolated cases, comprising about half of the subjects in this study, involvement 
of non-genetic causes cannot be fully excluded. Since de novo variants in 
known adNSHI genes were identified in three of the cases in our study, we 
hypothesize that novel genes for adNSHI can be identified by a de novo strategy 
(i.e. sequencing affected individuals and their unaffected parents). Variants 
of uncertain significance were mainly reported for patients with presumed 
autosomal dominant HI (Supplementary Table S2, Supplementary Table 
S3). Since no family members were available for segregation analysis, the 
pathogenicity of these variants remained unclear. This highlights the importance 
of sampling additional family members, and taking an accurate family history.
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A subset of the patients (36) in the present study was previously reported in 
the study by Neveling et al. In 16 out of these 36 cases they identified likely 
pathogenic variants which revealed a diagnostic yield of 44.4% for WES in 
HI.11 Segregation analysis was still needed, however, in nine of the families to 
confirm the genetic diagnosis. This analysis was performed in the current study 
and in seven families the variants did not segregate with the HI. This lowers 
the diagnostic yield of the cases included in the study by Neveling et al. to 
22%, which is comparable to the yield in our study and again underlines the 
importance of segregation analysis.
 The wide use of WES in routine diagnostics and research is producing large 
amounts of data on sequence variants in HI. Variants that have initially been 
reported as causative, based on the knowledge at that time, might be reclassified 
as benign due to increasing availability of allele frequency data.28 This 
highlights the importance of population-based allele frequency data to evaluate 
the causality of variants. However, rare variants can be still difficult to classify 
since we found that in two cases of our cohort (AD21 and ISO34) previously 
reported variants did not fully segregate with the HI in the corresponding 
families (Supplementary Table S3). This makes the causality of these rare 
variants questionable. Further examples are the novel missense variants that we 
identified in USH2A. We classified these as variants of uncertain significance, 
despite the facts that 1) they were predicted to be damaging 2) they were not 
reported in any public database so far, and 3) they segregated with the hearing 
loss in the corresponding families. However, without support from functional 
studies, the pathogenicity of these missense variants will remain uncertain 
since Petrovski et al. (2013) calculated a residual variation score of 4.18 for 
USH2A (75th percentile of scored genes, frequency data based on NHLBI 
Exome Sequencing Project) suggestive of a great tolerance of this gene to 
genetic variation.29 This is casting some doubt on the extensive variation in 
USH2A reported as likely pathogenic in public databases such as the Leiden 
Open Variant Database (LOVD). Importantly, these uncertainties are extremely 
difficult for genetic counseling, since parents have to be informed about the 
possible development of Usher syndrome in their children. 
 CNV detection in our cohort could identify large deletions in 5% of the 
cases, which is higher than the 2.6% presented in the literature.30,31 The most 
likely explanation for this difference is the relatively high frequency of 
STRC deletions in our population (3%). As has also been reported in other 
populations,8 deletions of STRC seem to be the second most frequent cause of 
arNSHI in the Netherlands. 
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We did not find causative variants in genes that are associated with identifiable 
phenotypes segregating with a recessive inheritance pattern, such as progressive 
HI with a downsloping audiogram caused by TMPRSS3 mutations,7,32 the stable 
HI with a cookie-bite audiogram configuration caused by mutations in TECTA7 
and SLC26A433 mutations associated with enlarged vestibular aqueducts and/or 
fluctuating HI. This is most likely due to the fact that these genes are generally 
tested for mutations in all patients with these identifiable phenotypes.
 The most important conclusion from our study is that the diagnostic yield 
of WES is much higher than that of single gene testing, 29% versus 7.6% 
(Table 2), respectively. In our cohort we found that mutations in GJB2, STRC, 
USH2A, MYO15A and MYO6 underlie HI in ~14% of the cases. This is in 
agreement with previously published studies on the involvement of HI genes 
in other populations.6-9,32,34 Moreover, additional targeted testing of MYO15A 
indicated that this gene is relatively frequently involved in prelingual congenital 
HI in the Dutch population. The main reason for the higher diagnostic yield 
in WES compared to that of single gene testing in our laboratory is the fact 
that either no genes have been pretested or the phenotypic variability does not 
allow successful pretesting by Sanger sequencing. Predictive gene testing is 
thus highly inefficient. We therefore suggest that for nonsyndromic childhood 
onset HI it would only be cost-effective to prescreen GJB2, STRC, USH2A and 
MYO15A. For recognizable phenotypes (such as Pendred syndrome, Waardenburg 
syndrome and Usher syndrome) prescreening of specific genes might still be 
useful. Novel cost-effective technologies, such as molecular inversion probes, 
will replace Sanger sequencing and allow testing of a panel of genes, such as the 
genes associated with Usher syndrome, in a single test.35,36 
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Patient Phenotype Previous single 
gene tests 
Gene Variant 1 Variant 2 Segregating 
with HL
AD11 MF/prog. TECTA, 
COL11A2, 
POU4F3
MYO6 NM_004999.3 c.1546+1G>T (p.?) - Yes
AD2 HI and optical 
atrophy
WFS1, OPA1 WFS1 NM_006005.3 c.2051C>T 
(p.(Ala684Val))2
- ND
AD3 NS - TECTA 
ENST00000392793.1
c.6002G>T 
(p.(Cys2001Phe))
- Yes
AD4 cong./HF/
profound
GJB2/GJB6 MYO7A NM_000260.3 c.1373A>T(p.
(Asn458Ile))3
- Yes
AD51 HF with a dip at 
4kHz/mixed HI
KCNQ4, WFS1, 
COL11A2, 
ACTG1, DFNA5
MYO6 NM_004999.3 c.1211del 
(p.(Gly404Glufs*4))
- Yes
AD61 HF/prog. KCNQ4 MYH9 NM_002473.4 c.2507C>T 
(p.(Pro836Leu))
- Yes
AD7 young age/
MF with dip at 
4kHz
TECTA, 
COL11A2
POU4F3 
NM_002700.2 
c.828_829insT 
(p.(Lys277*))
- ND
AD8 LF+MF/severe/
prog.
COCH, MYO6 MYO7A NM_000260.3 c.652G>A 
(p.(Asp218Asn))
- Yes
AD9 HF/prog. DFNA5, KCNQ4, 
ACTG1
POU4F3 
NM_002700.2 
c.668T>C 
(p.(Leu223Pro))4
- ND
AD10 preling./MF TECTA, 
COL11A2
MYO6 NM_004999.3 c.3395del 
(p.(Lys1132Serfs*12))
- Yes
AD11 cong./flat - SOX10 NM_006941.3 c.1195C>T 
(p.(Gln399*))
- ND
AD12 moderate/LF/ 
bowlshaped 
COL11A2, 
WFS1, TECTA
MYH14 
NM_001145809.1
c.394G>A 
(p.(Gly32Ser))
- Yes
AR11 Usher type 2 USH2A, RP-R USH2A NM_206933.2 c.9372-?_9570+? (p.?) c.9372-?_9570+? (p.?) ND
AR2 Cong./
moderate/ flat
GJB2/GJB6, 
SLC26A
OTOA 
ENST00000388958
chr16:21581229-
217717155
chr16:21581229-
217717155
AR36 cong./profound GJB2/GJB6, 
Asper array
CIB2 NM_006383.2 c.97C>T (p.(Arg33*)) c.196C>T 
(p.(Arg66Trp))
Yes
AR4 HF/prog. COCH, KCNQ4, 
WFS1, GJB2/
GJB6
STRC NM_153700.2 c.-78-
?_5327+?del(p.0?)7
c.-78-
?_5327+?del(p.0?)7
Yes
AR5 cong./HF/
severe/asym. 
mixed
GJB2/GJB6, 
SLC26A4, OTOF
USH2A NM_206933.2 c.8846-
?_9371+?del(p.?)
c.8846-
?_9371+?del(p.?)
ND
AR6 cong./severe GJB2/GJB6, 
TMPRSS3
TMC1 NM_138691.2 c.646del 
(p.(Leu216Serfs*54))
c.790C>T (p.(Arg264*)) ND
AR7 cong./severe GJB2/GJB6 CDH23 NM_022124.5 c.6442G>A 
(p.(Asp2148Asn))8
c.1545_1547del 
(p.(Ile515del))8
Yes
AR8 11y.o./HF/RP - USH2A NM_206933.2 c.1606T>C 
(p.(Cys536Arg))9
c.9815C>T 
(p.(Pro3272Leu))9
Yes
AR9 HF/moderate - GJB2 NM_004004.5 c.35del 
(p.(Gly12Valfs*2))10 
c.71G>A (p.Trp24*))11 ND
AR10 NS - GJB2 NM_004004.5 c.35del 
(p.(Gly12Valfs*2))10 
c.35del 
(p.(Gly12Valfs*2))10
Yes
AR11 profound GJB2/GJB6 CDH23 NM_022124.5 c.2096A>G 
(p.(Asp699Gly))
c.4564A>G 
(p.(Asn1521Ser))
Yes
table S1. Additional phenotype and single gene test information regarding patients with causative variants 
indicated in Table 1.
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AR12 cong. - GJB2 NM_004004.5 c.-23+1G>A (p.?)12 c.35del 
(p.(Gly12Valfs*2))10 
Yes
AR13 cong./HF - MYO7A NM_000260.3 c.3289C>T(p.
(Gln1097*))
c.3862G>C(p.
(Ala1288Pro))13 
c.5227C>T(p.
(Arg1743Trp))14
ND
AR14 4 y.o/ HF/
moderate
GJB2/GJB6 STRC NM_153700.2 c.-78-
?_5327+?del(p.0?)
c.-78-
?_5327+?del(p.0?)
ND
AR15 cong. GJB2/GJB6 MITF NM_000248.3 c.649del 
(p.(Arg217Aspfs*4))15
- ND
AR16 cong. GJB2/GJB6 PCDH15 
NM_033056.3
c.3374-2A>G (r.?) c.4127C>A 
(p.(Ala1376Asp))
Yes
AR17 HF - STRC NM_153700.2 c.-78-
?_5327+?del(p.0?) 7
c.-78-
?_5327+?del(p.0?) 7
ND
AR18 cong./ MF/
moderate
GJB2/GJB6, 
SLC26A4
STRC NM_153700.2 c.-78-
?_5327+?del(p.0?) 7
c.-78-
?_5327+?del(p.0?) 7
ND
ISO11 HF/prog. with 
RP
GJB2/GJB6, 
TMPRSS3
MYO15A 
NM_016239.3
c.625G>T 
(p.(Glu209*))
c.1137del 
(p.(Tyr380Metfs*64))16
ND
ISO21 cong./ HF/ 
severe/discant
GJB2/GJB6, 
TMPRSS3
USH2A NM_206933.2 c.5385T>A 
(p.(Tyr1795*))
c.6850_6851insAATC 
(p.(His2284Glnfs*48))
ND
ISO3 Usher 
syndrome
GJB2/GJB6, 
CDH23, MYO7A, 
USH1C, SANS, 
UH2A, VLGR1, 
USH3A
CDH23 NM_022124.5 c.8480_8481del 
(p.(Leu2827Hisfs*23))
c.8480_8481del 
(p.(Leu2827Hisfs*23))
ND
ISO41 cong./severe/
prog.
GJB2/GJB6 MYO15A 
NM_016239.3
c.6764+2T>A (p.?) c.3844C>T 
(p.(Arg1282Trp); 
c.5287C>T 
(p.(Arg1763Trp))
Yes
ISO5 HF/bowlshaped - GJB2 NM_004004.5 c.101T>C 
(p.(Met34Thr))17 
c.109G>A (p.(Val37Ile)) 
17
Yes
ISO6 cong./profound/
prog./optical 
atrophy
GJB2/GJB6, 
MITF
WFS1 NM_006005.3 c.2051C>T 
(p.(Ala684Val))2
- ND
ISO7 cong./severe GJB2/GJB6, 
MYO7A,KCNE1, 
KCNQ1, PTPRQ
MYO15A 
NM_016239.3 
c.6787G>A 
(p.(Gly2263Ser)) 
c.7893+1G>A (p.?) Yes
ISO8 HF/prog. COL11A2, EYA, 
TECTA
TRIOBP 
NM_001039141.2
c.2653del 
(p.(Arg885Alafs*120))
c.5014G>T 
(p.(Gly1672*))
Yes
ISO9 cong./flat GJB2/GJB6 USH2A NM_206933.2 c.2299del 
(p.(Glu767Serfs*21))
c.920_923dup 
(p.(His308Glnfs*16))
Yes
ISO10 HF/mild/prog./
night blindness
GJB2/GJB6, 
TMPRSS3, 
TMC1
MYO7A NM_000260.3 c.3476G>T 
(p.(Gly1159Val))18
c.5560G>A 
(p.Val1854Met))19
Yes
ISO11 cong. - GJB2 NM_004004.5 c.250G>C 
(p.(Val84Leu))
c.269T>C 
(p.(Leu90Pro))20
Yes
ISO12 LF/prog. - GJB2 NM_004004.5 c.109G>A 
(p.(Val37Ile))17
c.109G>A (p.(Val37Ile)) 
17
ND
ISO13 second decade/
HF/prog.
- TMPRSS3 
NM_024022.2
c.916G>A 
(p.(Ala306Thr))21 
c.1276G>A 
(p.(Ala426Thr))22
ND
ISO14 cong./ MF/
moderate
GJB2/GJB6 STRC NM_153700.2 c.-78-
?_5327+?del(p.0?)7 
c.-78-
?_5327+?del(p.0?)7 
ND
ISO15 MF - GJB2 NM_004004.5 c.35del 
(p.(Gly12Valfs*2))10 
c.101T>C 
(p.(Met34Thr))17
Yes
ISO16 cong./HF/
profound/ID
- ACTG1 
NM_00199954.1
c.773C>T 
(p.(Pro258Leu))
- ND
ISO17 cong./profound - GJB2 NM_004004.5 c.35del 
(p.(Gly12Valfs*2))10 
c.508_511dup 
(p.Ala171Glufs*40))23
ND
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AR12 cong. - GJB2 NM_004004.5 c.-23+1G>A (p.?)12 c.35del 
(p.(Gly12Valfs*2))10 
Yes
AR13 cong./HF - MYO7A NM_000260.3 c.3289C>T(p.
(Gln1097*))
c.3862G>C(p.
(Ala1288Pro))13 
c.5227C>T(p.
(Arg1743Trp))14
ND
AR14 4 y.o/ HF/
moderate
GJB2/GJB6 STRC NM_153700.2 c.-78-
?_5327+?del(p.0?)
c.-78-
?_5327+?del(p.0?)
ND
AR15 cong. GJB2/GJB6 MITF NM_000248.3 c.649del 
(p.(Arg217Aspfs*4))15
- ND
AR16 cong. GJB2/GJB6 PCDH15 
NM_033056.3
c.3374-2A>G (r.?) c.4127C>A 
(p.(Ala1376Asp))
Yes
AR17 HF - STRC NM_153700.2 c.-78-
?_5327+?del(p.0?) 7
c.-78-
?_5327+?del(p.0?) 7
ND
AR18 cong./ MF/
moderate
GJB2/GJB6, 
SLC26A4
STRC NM_153700.2 c.-78-
?_5327+?del(p.0?) 7
c.-78-
?_5327+?del(p.0?) 7
ND
ISO11 HF/prog. with 
RP
GJB2/GJB6, 
TMPRSS3
MYO15A 
NM_016239.3
c.625G>T 
(p.(Glu209*))
c.1137del 
(p.(Tyr380Metfs*64))16
ND
ISO21 cong./ HF/ 
severe/discant
GJB2/GJB6, 
TMPRSS3
USH2A NM_206933.2 c.5385T>A 
(p.(Tyr1795*))
c.6850_6851insAATC 
(p.(His2284Glnfs*48))
ND
ISO3 Usher 
syndrome
GJB2/GJB6, 
CDH23, MYO7A, 
USH1C, SANS, 
UH2A, VLGR1, 
USH3A
CDH23 NM_022124.5 c.8480_8481del 
(p.(Leu2827Hisfs*23))
c.8480_8481del 
(p.(Leu2827Hisfs*23))
ND
ISO41 cong./severe/
prog.
GJB2/GJB6 MYO15A 
NM_016239.3
c.6764+2T>A (p.?) c.3844C>T 
(p.(Arg1282Trp); 
c.5287C>T 
(p.(Arg1763Trp))
Yes
ISO5 HF/bowlshaped - GJB2 NM_004004.5 c.101T>C 
(p.(Met34Thr))17 
c.109G>A (p.(Val37Ile)) 
17
Yes
ISO6 cong./profound/
prog./optical 
atrophy
GJB2/GJB6, 
MITF
WFS1 NM_006005.3 c.2051C>T 
(p.(Ala684Val))2
- ND
ISO7 cong./severe GJB2/GJB6, 
MYO7A,KCNE1, 
KCNQ1, PTPRQ
MYO15A 
NM_016239.3 
c.6787G>A 
(p.(Gly2263Ser)) 
c.7893+1G>A (p.?) Yes
ISO8 HF/prog. COL11A2, EYA, 
TECTA
TRIOBP 
NM_001039141.2
c.2653del 
(p.(Arg885Alafs*120))
c.5014G>T 
(p.(Gly1672*))
Yes
ISO9 cong./flat GJB2/GJB6 USH2A NM_206933.2 c.2299del 
(p.(Glu767Serfs*21))
c.920_923dup 
(p.(His308Glnfs*16))
Yes
ISO10 HF/mild/prog./
night blindness
GJB2/GJB6, 
TMPRSS3, 
TMC1
MYO7A NM_000260.3 c.3476G>T 
(p.(Gly1159Val))18
c.5560G>A 
(p.Val1854Met))19
Yes
ISO11 cong. - GJB2 NM_004004.5 c.250G>C 
(p.(Val84Leu))
c.269T>C 
(p.(Leu90Pro))20
Yes
ISO12 LF/prog. - GJB2 NM_004004.5 c.109G>A 
(p.(Val37Ile))17
c.109G>A (p.(Val37Ile)) 
17
ND
ISO13 second decade/
HF/prog.
- TMPRSS3 
NM_024022.2
c.916G>A 
(p.(Ala306Thr))21 
c.1276G>A 
(p.(Ala426Thr))22
ND
ISO14 cong./ MF/
moderate
GJB2/GJB6 STRC NM_153700.2 c.-78-
?_5327+?del(p.0?)7 
c.-78-
?_5327+?del(p.0?)7 
ND
ISO15 MF - GJB2 NM_004004.5 c.35del 
(p.(Gly12Valfs*2))10 
c.101T>C 
(p.(Met34Thr))17
Yes
ISO16 cong./HF/
profound/ID
- ACTG1 
NM_00199954.1
c.773C>T 
(p.(Pro258Leu))
- ND
ISO17 cong./profound - GJB2 NM_004004.5 c.35del 
(p.(Gly12Valfs*2))10 
c.508_511dup 
(p.Ala171Glufs*40))23
ND
ISO18 cong./MF+HF/
severe/prog.
GJB2/GJB6 MYO15A 
NM_016239.3
c.3311dup 
(p.(Glu1105*))
c.3311dup 
(p.(Glu1105*))
ND
ISO19 cong./severe - TRIOBP 
NM_001039141.2
c.3460_3461del 
(p.(Leu1154Alafs*29)) 
 c.3232dup 
(p.(Arg1078Profs*6))24
ND
ISO20 HF/moderate/
prog./asym./
heterochromia 
iridis
GJB2/GJB6, 
TMPRSS3, 
MITF, PAX3
MYO7A NM_000260.3 c.5618G>A 
(p.(Arg1873Gln))25
c.6028G>A 
(p.(Asp2010Asn))26
Yes
ISO21 5 y.o./
moderate/prog.
GJB2/GJB6, 
TECTA, OTOF, 
MYO15A, TMC1
MYO6 NM_004999.3 c.3610C>T 
(p.(Arg1204Trp))27
- ND
ISO22 cong./ HF/
moderate
GJB2/GJB6, 
SLC26A4
SLC26A5 
NM_198999.2
c.355C>T 
(p.(Pro119Ser))
c.355C>T 
(p.(Pro119Ser))
ND
ISO23 6 y.o./HF/prog. - GJB2 NM_004004.5 c.101T>C 
(p.(Met34Thr))17
c.109G>A 
(p.(Val37Ile))17
ND
ISO24 cong./severe/
flat
- SOX10 NM_006941.3 c.482G>A 
(p.(Arg161His))28
- ND
ISO25 39 y.o./ MF+HF/
moderate/ prog.
- STRC NM_153700.2 c.-78-
?_5327+?del(p.0?)7
c.-78-
?_5327+?del(p.0?)7
ND
ISO26 HF/ moderate-
severe
GJB2/GJB6, 
SLC26A, Asper 
array
MYO6 NM_004999.3 c.3335A>G 
(p.(Tyr1112Cys))
c.1897del(p.
(Gln633Lysfs*19))
Yes
ISO27 cong./severe/
vestibular 
areflexia
GJB2/GJB6, 
USH2A, 
MYO7A, PTPRQ
LARS2 NM_015340.3 c.683G>A 
(p.(Arg228His))
c.880G>A 
(p.(Glu294Lys))
Yes
ISO28 HF/severe - OTOA 
ENST00000388958
chr16:21581229-
217717155
chr16:21581229-
217717155
AR, autosomal recessive; AD, autosomal dominant; ISO, isolated; Cong., congenital; LF, low frequencies; MF, 
mid frequencies; HF, high frequencies; prog., progressive; preling., prelingual; asym., asymmetric;y.o., years old; 
UHI, unilateral hearing impairment;ID, intellectual disability; ND, not done; NS, not specified.
Causative variant(s) ‘Uncertain’ variant No variant
Categories # total # cases % # cases % # cases % 
arHI 33 18.0 54.5 3.0 9.1 12.0 36.4
adHI 65 12.0 18.5 11.0 16.9 42.0 64.6
Isolated HI 101 28.0 27.7 11.0 10.9 62.0 61.4
Xlinked-HI 1 0.0 0.0 1.0 100.0 0.0 0.0
Total 200 58.0 29.0 26.0 13.0 116.0 58.0
table S2. Diagnostics rates of WES based on the type of inheritance of the HI.
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table S3. Information on inheritance pattern, phenotype pretested genes and of HI patients with variants of unknown 
significance identified by WES.
Patient Phenotype Previous 
single gene 
tests 
Gene Variant 1 Variant 2 Segregating 
with HL
AD13 HF/prog. POU4F3, 
MYO6
MYO7A NM_000260.4 c.6122T>A 
(p.(Ile2041Asn))
- ND
AD14 12y.o./
moderate/prog./
vest.
COCH SIX1 NM_005982.3 c.58G>C 
(p.(Val20Leu))
- ND
AD15 UHI PAX3, MITF MYO6 NM_004999.3 c.271G>A 
(p.(Ala91Thr))
- ND
AD16 HF/prog. MYO6 MYO7A NM_000260.3 c.2617C>T 
(p.(Arg873Trp))25
- No
AD17 cong./ HF/
moderate
GJB2, GJB6, 
KCNQ4
TECTA 
ENST00000392793.1
c.5794A>C 
(p.(Thr1932Pro))
- ND
AD18 cong./mild/flat - MYH14 
NM_001145809.1
c.5176C>T 
(p.(Arg1726Trp))
- ND
AD19 35 y.o./prog./
flat
EYA4, 
COL11A2, 
TECTA
COL11A1 
NM_001854.3 TECTA 
ENST00000392793.1
COL11A1:c.2799del 
(p.(Gly934Alafs*48))
TECTA: c.2128G>A(p.
(Glu710Lys))
ND
AD20 MF+flat/prog. EYA4, TECTA, 
COLL11A2
WFS1 NM_006005.3 c.941G>T 
(p.(Trp314Leu))
- ND
AD211 mid-life/
prog./Stickler 
syndrome
TECTA, 
ACTG1, 
POU4F3, 
COL11A2
COL11A1 
NM_001854.3
c.1630-2del (p.?) - Yes
AD22 LF/Turner 
syndrome
WFS1, DIAPH1 ESPN NM_031475.2 c.2239G>A 
(p.(Gly747Ser))
- ND
AD23 childhood/MF/
prog.
- WFS1 NM_006005.3 c.2032T>C 
(p.(Trp678Arg))
- Yes
AR19 cong./severe GJB2/GJB6, 
USH2A
LOXHD1 
NM_144612.6
c.1618dup 
(p.(Thr540Asnfs*24))
c.1730T>G (p.(Leu577Arg)) Yes
AR20 severe/flat GJB2/GJB6, 
SLC26A4
USH2A NM_206933.2 c.1772A>G 
(p.(Asp591Gly))
c.5018T>C 
(p.(Leu1673Pro))
Yes
AR21 moderate - USH2A NM_206933.2 c.5018T>C 
(p.(Leu1673Pro)) 
c.7871C>T 
(p.(Pro2624Leu))
c.2299del 
(p.(Glu767Serfs*21))
Yes
ISO29 cong./
moderate/flat
- LOXHD1 
NM_144612.6 
c.3061+1G>A (p.?) c.6353G>A 
(p.(Gly2118Glu))
ND
ISO30 5y.o./ MF/
moderate/
asym. 
- MYO6 NM_004999.3 c.584C>A 
(p.(Ala195Glu))
- ND
ISO31 cong./profound - SLC26A4 
NM_000441.1 USH1G 
NM_173477.4
SLC26A4:c.505del 
(p.(Thr169Leufs*3)) 
; USH1G: c.83C>T 
(p.(Pro28Leu))
SLC26A4:c.1334T>G 
(p.(Leu445Trp))29;USH1G: 
c.1258C>G (p.(Leu420Val))
Yes
ISO32 MF/moderate - TECTA 
ENST00000392793.1
c.5818G>A 
(p.(Ala1940Thr))
- ND
ISO33 MF+HF/prog. GJB2/GJB6, 
TECTA
MYO7A NM_000260.3 c.1846C>T 
(p.(Arg616Trp))
- ND
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ISO34 cong./ HF/
moderate
- TECTA 
ENST00000392793.1
c.5597C>T(p.
(Thr1866Met))30
- ND
ISO35 preling./prog. GJB2/GJB6, 
TMPRSS3
LOXHD1 
NM_144612.6 
c.3061C>T 
(p.(Arg1021*)) 
c.5885C>T 
(p.(Thr1962Met))
Yes
ISO36 asym. GJB2/GJB6 OTOGL NM_173591.3 c.2533T>C 
(p.(Phe845Leu))
c.4833G>A (p.?) ND
ISO37 Asperger 
syndrome
- TECTA 
ENST00000392793.1
c.2780A>G 
(p.(His927Arg))
- ND
ISO38 moderate/prog. GJB2/GJB6, 
MYO6
CEACAM16 
NM_001039213.3
c.859del 
(p.(Gln287Argfs*34))
- ND
ISO39 cong./ asym. GJB2/GJB6, 
TECTA, OTOF, 
MYO15A, 
TMC1
SLC26A4 
NM_000441.1
c.1246A>C(p.
(Thr416Pro))
- ND
XL11 Prog./flat GJB2/GJB6, 
KCNQ4, 
TMPRSS3
SMPX NM_014332.2 c.132G>A (p.?) - ND
AR, autosomal recessive; AD, autosomal dominant; ISO, isolated; Cong., congenital; LF, low frequencies; MF, mid 
frequencies; HF, high frequencies; prog., progressive; preling., prelingual; asym., asymmetric;y.o., years old; UHI, 
unilateral hearing impairment; ID, intellectual disability; ND, not done; vest. , vestibular complains.
table S4. Overview of the MYO15A mutations identified in Dutch HI patients in the present study.
* A) shared genotype B) DFNB panel# As a reference sequence NM_016239.3 was used.
Family Analysis* Allele 1 (cDNA)* Allele 1 (Protein) Allele 2 (cDNA)# Allele 2 (Protein)
1 A c.1137delC p.Thr380MetfsX64 c.6787G>A p.Gly2263Ser
2 A c.1137delC p.Thr380MetfsX64 c.4519C>T p.Arg1570X
3 A c.3963A>C p.Lys1321Asn c.6764+2T>A p.?
4 A c.4497G>T p.Glu1499Asp c.5506delC p.Leu1836CysfsX13
5 A c.6205C>T p.Pro2069Ser c.6764+2T>A p.?
6 B c.1137delC p.Thr380MetfsX64 c.10216+1G>A p.?
7 B c.1137delC p.Thr380MetfsX64 c.6764+2T>A p.?
8 B c.6787G>A p.Gly2263Ser c.6787G>A p.Gly2263Ser
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FUNCTIONS OF PROTEINS ENCODED BY NOVEL 
DEAFNESS GENES
The research described in this thesis has led to the discovery of novel deafness 
genes that, when mutated, cause hearing impairment (HI) which is the most 
common sensory disorder worldwide.47
 In chapters 2 and 3, two novel genes involved in autosomal recessive non-
syndromic HI (arNSHI) are reported. OTOGL encodes a member of the group of 
non-collageneous glycoproteins which, together with collagens, form the three 
acellular membranes of the inner ear: the tectorial membrane, the otoconial 
membrane and the cupula.2 These acellular membranes are inertial masses 
against which the stereocilia of the sensory epithelia in the organ of Corti and 
in the vestibular system can deflect.48 As a consequence, mechanotransduction 
occurs resulting in depolarization of hair cells. To date, the precise functions 
of the otoconial membrane and the cupula are still under investigation. 
However, the function of the tectorial membrane has been well studied in 
mice with mutations in tectorial membrane proteins.49 These studies revealed 
that the tectorial membrane has an important role in the tuning properties and 
sensitivity of the cochlea due to the tectorial membrane longitudinal stiffness 
gradients.49 These gradients are determined by the density of collagens and non-
collageneous glycoproteins. Among the latter, we find α-tectorin (TECTA), 
β-tectorin (TECTB), otogelin (OTOG), CEACAM16 and, as previously 
indicated, otogelin-like (OTOGL).2,50-53 Recessively inherited mutations in 
TECTA (DFNB21), OTOG (DFNB84B) and OTOGL (DFNB18B) (Chapter 2) 
result in a recognizable phenotype of non-progressive mid-frequency HI.2,51,54 
TECTA, OTOG and OTOGL share a similar protein structure with a stretch of 
von Willebrand (VW) factor and cysteine rich domains (C8) as seen in Figure 
1. OTOG and OTOGL lack the zona pellucida (ZP) domain present in TECTB 
and TECTA (Figure 1). It has been proposed that the ZP domain is a protein 
polymerization module that may enable TECTA and TECTB to form homo and 
heteropolymers.49,55 Therefore, TECTB could be considered as a candidate gene 
for mid-frequency HI as well, even though Tectb-/- mice display low-frequency 
HI.56 
 CEACAM16 is a cell-adhesion protein that is predicted to contain four 
immunoglobulin domains (Figure 1).57 CEACAM16 interacts with TECTA at 
the tectorial membrane-attached crown which connects stereocilia of outer 
hair cells with the tectorial membrane.57 Mutations in CEACAM16, as specific 
mutations in TECTA (DFNA8/12), cause postlingual adNSHI.52,54
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As presented in chapter 3, a homozygous nonsense mutation in CLIC5 is the 
underlying cause of the progressive HI accompanied by vestibular areflexia in 
two siblings of Turkish origin. The oldest sibling also presented an elevated 
albumin/creatinine ratio in urine and pre-hypertension which could be the first 
signs of a nephropathy. The proteinuria, progressive HI and vestibular areflexia 
phenotypes are all recapitulated in the Clic5 mutant mouse (jitterbug).58,59 CLIC5 
encodes the chloride intracellular channel 5 protein. However, as discussed 
in chapter 3, there are many lines of evidence supporting that CLIC5 could 
have a critical role in stereocilia integrity due to its role in the stabilization 
of actin filaments rather than in chloride homeostasis.1,58-60 Therefore, we 
categorized CLIC5 as a cytoskeleton-associated protein involved in stereocilia 
morphogenesis. 
 In chapter 4 mutations in CIB2, a gene known to be involved in Usher syndrome 
1J and DFNB4861 were functionally studied. CIB2 belongs to the family of 
calcium- and integrin- binding proteins. CIB2 contains three predicted EF hand 
domains of which the two N-terminal ones are predicted to bind calcium. All 
CIB2 mutations described to date, except for p.Ile123Thr that is located in EF 
hand 2, are hypothesized to affect the interaction with αIIβ integrin (Table 1).61 
Figure 1. Structural comparison between OTOGL, OTOG, TECTA, TECTB and CEACAM16, the 
non-collageneous proteins present in the tectorial membrane. The architecture of these proteins 
was modeled using SMART (http://smart.embl-heidelberg.de/). VWD, von Willebrand factor type 
D; VWC, von Willebrand factor type C;  C8, cysteine rich domain; NIDO, extracelullar domain 
of unknown function in nidogen; EGF-like, epidermal growth factor like; LC, low complexity; IG, 
immunoglobulin; CT: C terminal; ZP, zona pellucida.
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It was previously suggested that destabilization of the interaction with αIIβ 
integrin possibly disturbs the capacity of CIB2 to sequestrate calcium, as a result 
of changes in subcelullar localization.61 However, we demonstrated that neither 
the capacity of CIB2 to release calcium nor the subcellular localization of CIB2 
were affected by these mutations (Table 1). As previously reported, p.Glu64Asp 
is causative for Usher syndrome 1J.61 In the absence of αIIβ integrin, p.Glu64 
and p.Arg33 form a salt bridge. Nonetheless, p.Arg33Ter and p.Glu64Asp cause 
different phenotypes, arNSHI and Usher syndrome 1J, respectively.61 Therefore, 
we suggested in chapter 4 that p.Glu64Asp gained a different function in the 
retina that eventually led to the development of retinitis pigmentosa. Another 
possibility that cannot be completely ruled out is that p.Gly64Asp is not 
underlying the retinal phenotype in the presented Usher syndrome 1J family, 
whose ID is PKDF117.61 Ahmed et al. (2009) reported linkage to a region 
harboring CIB2 in family PKDF117.62 However, the VNTR markers flanking 
CIB2, D15S973 and D15S1027, were not fully informative and an unaffected 
individual carried the affected haplotype (V:13). Later, Riazuddin et al. (2012) 
reported the CIB2 p.Glu64Asp mutation underlying Usher syndrome 1J in the 
PKDF117 family. In this study, segregation analysis of the CIB2 p.Glu64Asp 
variant and whole exome sequencing (WES) in order to exclude other possible 
genetic causes within the linkage region, which for instance also harbours the 
NR2E2 gene that is known to be associated with both dominantly and recessively 
inherited retinitis pigmentosa,63 were not performed. These facts cast some 
doubt on the involvement of CIB2 in the retinal phenotype of the presented 
Usher syndrome 1J family. 
 In chapter 5 we demonstrated that loss of function mutations in KITLG are 
the cause of familial non-syndromic unilateral and asymmetric HI (NS-UHI/
AHI). Moreover, we identified a missense mutation in KITLG, with a possibly 
dominant negative or gain of function effect, underlying Waardenburg syndrome 
type II (WS II). The KITLG-KIT pathway functions in the proliferation, 
migration and survival of melanoblasts. Therefore mice that are homozygous 
for the semi-dominant alleles Wv of Kit and Sld of Kitl are important models to 
study the role of melanocytes in the hearing process.64,65 Both mouse models 
displayed HI due to a dysfunctional stria vascularis as a consequence of a lack 
of melanocytes. It has been postulated that melanocytes are important in the 
formation/function of the stria vascularis during development and/or that they 
play a role in the maintenance of the endocochlear potential.64,65 The localization 
of the K+ transporter, NKCC, and the K+ channel, Kir4.1, located at the apical 
membrane of intermediate cells (melanocytes) in the stria vascularis66 supports 
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this assumption. We demonstrated that KITLG is a novel gene associated with 
hypopigmentary and HI disorders due to a deficiency in neural crest cell-derived 
melanocyte development.67
 In chapter 6, a nonsense mutation in FITM2 is reported to be causative of a 
novel syndromic form of HI which is characterized by sensorineural HI, dystonia 
and sensory neuropathy. The FITM protein family is conserved throughout the 
evolutionary lineage down to Saccharomyces cerevisiae.13 FITM2 resides in the 
endoplasmic reticulum and participates in the partitioning of triacylglycerides 
into lipid droplets. Despite that FITM2 has a role in lipid droplet formation, 
lipodystrophy or disturbances of lipid storage and/or metabolism were not 
found to be part of the phenotype in this Pakistani family. This adds FITM2 
to the group of genes that encode proteins involved in lipid metabolism and 
neurological function and remarkably FITM2 is the first protein involved in 
lipid droplet formation whose dysfunction results in HI.68 
WHOLE EXOME SEQUENCING IN INDIVIDUALS WITH 
HEARING IMPAIRMENT
Although WES has proven to be successful in the identification of the genetic 
defects in genetically heterogeneous disorders,69 the lack of coverage of certain 
exons/genes and the interpretation of the numerous candidate variants obtained 
are still a challenge.
Table 1. Known mutations in CIB2 with their effect on calcium release, subcellular localization and 
predicted effect on integrin binding. In grey the variants that are part of the work performed in chapter 
4 are indicated. “USH1J” superscript indicates that this mutation is described to be causative for Usher 
syndrome type 1J.61 The ↑ means up-regulated and the ↓ means down-regulated.
Variants in CIB2 Calcium release Subcellular localization Integrin binding
p.Arg66Trp Not affected Not affected Impaired
p.Arg33Ter Nonsense mediated decay predicted
p.Phe91Ser Not affected Not affected Impaired
p.Glu64AspUsh1J Not affected Not affected Impaired
p.Cys99Trp ↑ Not affected Impaired
p.Ile123Trp ↓ Not affected Not affected
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Challenges 
Challenge 1: prediction of the functional effect of variants
Incorrect classification of genetic variants as being pathogenic or non-pathogenic 
is a systematic issue in HI as it is in human genetics in general. Due to a shared 
concern in the exponential increase of rare variants and their interpretation, 
guidelines for their classification have been formulated.69,70 In order to categorize 
a variant as clearly pathogenic, the gold standard is to perform a functional assay 
that supports its effect. However, this cannot be performed routinely due to the 
large amount of candidate variants that are identified by WES or whole genome 
sequencing (WGS) studies. Therefore, different computational tools have been 
developed to predict the effect of any type of mutation on protein structure or 
function and/or on transcript processing. 
 Evaluation of missense variants is especially challenging because most of 
the currently available prediction tools only model loss of function scenarios. 
However, missense variants can have dominant negative or gain of function 
effects. The most popular tools are SIFT,71 that is exclusively based on sequence 
conservation, and Polyphen 2,72 that is built upon sequence conservation but 
also considers the structural properties of the mutated amino acids. To obtain 
more accurate evaluations, on-line tools that combine the scores obtained by 
SIFT and Polyphen 2 and other prediction tools, are available. Some examples 
are Condel, that also includes Mutation Assessor,73 and combined annotation-
dependent depletion (CADD), that uses an algorithm to assess the pathogenicity 
of any kind of variation.74 Additionally, when the crystal structure of a protein 
or a protein domain has been generated and analysed by nuclear magnetic 
resonance, modelling the effect of missense variants on protein level can be 
performed by using on-line tools such as project HOPE (http://www.cmbi.ru.nl/
hope), YASARA75 and WHAT IF Twinset.76 With these tools, you can assess not 
only the effect of the variant on protein structure but also its impact on protein 
function in a certain context, e.g. effect on protein-protein interactions, as we 
showed for the mutations found in KITLG (chapter 5). 
 Effects on splicing, especially when they do not alter the canonical splice 
site sequences, are also difficult to predict because the mechanisms underlying 
the regulation of alternative splicing are only partially understood.77,78 Xiong et 
al. (2015) developed a tool that scores the impact of any kind of variation on 
splicing.79 Interestingly many of these variants predicted to alter splicing were 
located more than 30 nucleotides away from a splice site. Xiong et al. (2015) also 
reported that exonic variation (nonsense, synonymous and missense variants) 
are able to have an impact on splicing.79 These observations are very important 
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because the splicing effect of variants outside the canonical splice site regions 
is not addressed in guidelines that are routinely used in DNA diagnostics.69,70
 Truncating mutations do not always result in the production of a truncated 
protein. As indicated above, nonsense variations can result in effects on splicing, 
especially when located in in-frame exons, by a process named nonsense-
associated altered splicing.80 Alternatively this type of variants can alter splicing 
of the mutated exon or splicing of surrounding exons, e.g. the c.2299delG in 
USH2A exon 13, which is in-frame, results in a frameshift due to the mutation-
induced skipping of exons 12 and 13.81 When a nonsense mutation is located 
within the first exon an alternative in-frame start codon can be used, which 
might give rise to a (partially or fully) functional protein.82 Methods have been 
developed to predict whether this could occur.83 Finally, when a premature stop 
codon is created in the last 54 bp of the 3’-most intron or in the last exon, 
nonsense mediated decay might not occur, giving rise to a protein that is partially 
functional or it might gain other functions that are toxic to cell homeostasis (50-
bp rule).84 Rivas et al. (2015), who systematically characterized the effect of 
truncating variants in the transcriptome of a wide range of tissues, reported that 
the 50-bp rule has a high predictive value.85 
 An important aspect in the evaluation of variants is their frequency in the 
general and hearing impaired populations. For HI, Shearer A.E. et al. (2014) 
reported that 4.2% of variants described as being pathogenic turned out to be 
benign due to a relatively high allele frequency in an extensive control data 
set from different populations.86 Besides, finding the same or other mutations 
in a candidate gene in multiple families with a similar phenotype supports the 
involvement of a candidate gene in a phenotype, but not unequivocally. This 
assumption was made in many different studies.87 However, this association by 
itself is not decisive in assigning or excluding a candidate gene as a disease-
associated gene.88,89 Evidence from other resources like functional evaluation 
of the variants by analysing the impact of the variants on protein structure 
and function or animal models that recapitulate the human phenotype, should 
be taken into account. To date, over a hundred of genes have been associated 
with NSHI in humans. For about 10% of these genes, only a variant in a single 
family is reported to date. For most of these genes, supportive evidence for the 
pathogenicity of the genetic variant is obtained by in vitro cell studies or animal 
models, as we show in chapter 2 and chapter 6, which are indeed decisive to 
suggest the involvement of a particular gene in a phenotype when a second 
family with the same or other mutations in the gene of study is lacking.
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In conclusion, evaluation of the large numbers of genetic variants identified 
by WES and WGS is a challenge. The gold standard would be the functional 
evaluation of every variant, however this is not feasible. Therefore prediction 
of the effect of variants on the protein level, their frequencies in disease and 
control populations and all available information on protein structure and animal 
models are of critical importance.   
Challenge 2: coverage 
High quality coverage in WES studies is the most important requirement 
to reliably identify variants and it is also the main challenge behind the 
implementation of WES in a diagnostics setting which requires high sensitivity 
and specificity. Due to these requirements, other approaches that allow full 
coverage of a subset of genes, like molecular inversion probes (MIPs),90,91 
and targeted locus amplification (TLA),92 have been developed. In chapter 7, 
we find that mutations in four genes, GJB2, STRC, USH2A and MYO15A can 
explain 30.3% of arHI and 13.9% of sporadic cases with HI; and mutations in 
MYO6 explain 7.7% of adHI cases. Therefore, a pre-screening of a subset of 
genes using a targeted approach in large series of probands with arHL should be 
considered as a more cost- and time-effective approach than WES and WGS.91 
FUTURE PERSPECTIVES: WHOLE GENOME 
SEQUENCING AND TRANSCRIPTOMICS
Over a hundred proteins are known to play an essential role in the process of 
hearing since mutations in the corresponding genes are associated with HI in 
humans (http://hereditaryhearingloss.org/). In chapter 7, we report that 58% of 
patients, in whom all known genes involved in HI were evaluated by WES, and in 
40% of known DFN loci, a genetic causative variant has not yet been identified. 
This suggests that, despite the already known large genetic heterogeneity for 
HI, mutations in additional genes and/or mutations in non-coding regions are 
likely to underlie HI. Therefore, a step towards WGS and transcriptomics (RNA 
sequencing) of lymphoblasts or patient-derived pluripotent stem cells (iPSc) 
can uncover the hidden spectrum of mutations in HI.  In Figure 2, I present 
a diagram of the steps that could be taken to find the genetic cause of HI in 
suspected hereditary cases. As it is shown, collection of extensive and accurate 
clinical data and family history is the first step. Excluding environmental factors 
is essential since their contribution in congenital HI in developed countries is 
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estimated to be about 50% (chapter 1). Thus, the unknown environmental factors 
might be partially the reason behind the 61.4% of sporadic cases who remain 
unsolved in chapter 7. WES of sporadic cases with HI is extremely challenging 
due to different reasons: 1) the mode of inheritance is unknown, it could be 
recessive but also dominant with reduced penetrance or there could be a de novo 
dominant mutation. This implies that different filter protocols in analyzing WES 
data should be used giving rise to large numbers of candidate variants;  2) there 
is usually no DNA of other family members available to perform segregation or 
a trio analysis; therefore, a proper strategy such as pre-screening of a subset of 
genes relatively frequently involved in HI should be firstly considered. WES of 
isolated cases might follow when no potential variants are found. Although the 
availability of WES data of sporadic cases is definitely valuable e.g. to look for 
variants in candidate genes, when the budget is limited collection and WES of 
families with multiple affected individuals should be a priority.
 In families with multiple affected individuals with suspected arNSHI, adNSHI 
or X-linked HI, WGS should be considered after targeted gene pre-screening 
and WES. WGS is the most comprehensive genetic test developed to date.93 
The two major advantages of WGS over WES are: 1) WGS can robustly 
cover the exome because an enrichment step is not required; 2) WGS can 
identify intronic variants and complex rearrangements such as inversions and 
translocations.94 Therefore, in the near future, when the costs of WGS decrease, 
WGS will definitely substitute WES to explore the exome. Then the WES step 
in Figure 2 will disappear. WGS can generate more than three million variants 
per individual. Thus, the analysis and interpretation of how these variants 
can influence the disease manifestation, especially those in the non-coding 
sequences which account for 98% of the genome,95 will require a multiple 
step strategy. A combined strategy of WGS of multiple affected individuals 
with other genetic approaches such as linkage analysis or/and homozygosity 
mapping will already narrow the genomic region(s) of interest. Besides, WGS 
combined with transcriptomics, specifically with RNA sequencing, can reveal 
new (intronic) mutations and thus new disease mechanisms. However, only a 
subset of genes involved in audition are expressed in blood or other accessible 
tissues e.g. USH2A in nasal epithelium or skin fibroblasts.96,97 Therefore the 
generation of inner ear epithelium or inner ear hair-like cells from HI patient’s 
skin or blood cells to perform RNA sequencing will be required (Figure 2). 
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ANIMAL MODELS FOR STUDYING THE DISEASE 
MECHANISM UNDERLYING HEARING IMPAIRMENT
During the course of this thesis project, several animal models have been 
employed in order to study the function of proteins of interest in the auditory 
system. Recapitulation of the human phenotype in these mutant organisms gave 
us crucial information about the disease mechanism. Although mouse models 
are most frequently used for studying HI, the generation and maintenance is 
both cost- and labour- intensive. Therefore the fruit fly and zebrafish are being 
increasingly used.
 In chapter 2, downregulation of otogl in zebrafish was induced by using 
morpholinos. In chapters 3 and 5, evidence from mutant mouse models supported 
the involvement of CLIC5 and KITLG in HI. In chapter 6, conditional gene 
ablation via  RNAi of Fitm in Drosophila melanogaster could recapitulate the 
human phenotype.
Mus musculus - mouse model
The homology between the mouse and the human genome is about 80%.98 Many 
HI genes were identified in mutant mice before mutations in those genes were 
detected in humans.99 Many molecular pathways are conserved and a remarkable 
structural similarity between the human and mouse auditory systems has been 
reported.99 The human inner ear is located in the temporal bone and is therefore 
highly inaccessible. Mouse models allow histopathological and ultrastructural 
analyses of the inner ear tissues as well as electrophysiological measurements 
that can give more insight into the nature of the HI. Different from Danio rerio 
and Drosophila melanogaster, which do not have a cochlea per se, mice preserve 
independent organs for hearing, the cochlea, and equilibrium, the vestibular 
system. This allows the molecular study of both organs separately and also the 
investigation of structures specific to mammals, e.g. the tectorial membrane.100 
The results of these studies also contribute to the knowledge of inner ear biology 
in mammals. 
Danio rerio - zebrafish model
The zebrafish (Danio rerio) is an extensively used animal model in hearing 
research. Zebrafish do not have a cochlea as mammals do. In contrast, larval 
zebrafish have two otolith organs, the utricle and the saccule, that process both 
auditory and vestibular stimuli.101 Behavioral studies in fish models lacking 
either otolith organ revealed that the saccule is important for sound perception 
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Figure 2. Flowchart of the proposed steps that could be taken in order to find the genetic causes 
underlying HI (keeping in mind that WGS is still developing and costly). PPV means potentially 
pathogenic variant. The * indicates that PPVs in a subset of genes, as suggested in chapter 7, should be 
excluded before WES is performed. The ** indicates that mRNA of the gene in which a heterozygous 
PPV was found should be isolated from a stable cell line derived from patient tissue in order to seek 
for the second PPV required in arHI. The *** indicates that when parents are available a trio analysis 
should be considered to look for heterozygous de novo PPVs.
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and the utricle for the equilibrium (Figure 3).102,103 Another macular organ, the 
lagena, is present in juvenile stage104 (Figure 3). As it is shown in Figure 3, the 
otolith organs harbor hair cells, the ultimate sensory receptors with stereocilia 
on the apical surface which are embedded in a matrix, the otolith membrane.105 
After a sound or movement stimulus, the otolith organs are displaced relative to 
the hair cells due to the difference in inertia between them. This displacement 
evokes the opening of the mechanotranduction channels upon hair bundle 
deflection. The resulting depolarization of the hair cells initiates the release of 
neurotransmitters at the basal part of the cells.34 
 In addition to the two otolith organs, zebrafish also have a sensory system 
with hair cells  on the surface called the lateral line. The lateral line organ 
consists of interconnected neuromasts and allows the detection of low frequency 
waves such as those made by water movements (Figure 3).104 
 Due to the evolutionary conservation of the auditory process from zebrafish to 
humans, zebrafish is a suitable model to study human genes involved in HI. The 
main  advantages of using zebrafish in HI research are:
1.  Adult zebrafish produce lots of offspring on a weekly basis, facilitating 
large scale experiments.
2.  Eggs are fertilized ex vivo and therefore all embryonic developmental 
stages can be studied easily.
3.  Embryos are optically transparent thus different embryonic stages can 
be followed in vivo.
4.  Zebrafish can easily  be manipulated genetically.
Of the human genes 71.4% have at least one zebrafish orthologue. Due to a 
genome duplication event, approximately 30% of these genes have two zebrafish 
orthologs and the function of their encoded protein have likely been evolved 
differently, as is seen for for Kitla and Kitlb.106-108 Therefore, when zebrafish is 
used as a model, knockdown of the appropriate duplicate is essential in order to 
study the right molecular pathway.
Drosophila melanogaster – fruit fly model
Despite the evolutionary distance between Drosophila and humans, there are 
significant genetic and molecular similarities in the auditory system that make 
the fruit fly a good model organism for studying HI.31,109 The Drosophila antenna 
consists of three segments: the a1 (antennal segment) or scape, a2 or pedicelus 
and the a3 or funiculus and a feathery hair-like extension of the a3 segment 
called arista. The role of the a1 segment in hearing is not well understood yet. 
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Segment a3 and the arista together form the sound receiver. Segment a2 contains 
the Johnston’s organ that serves as a sensor of hearing and orientation. In the 
Johnston’s organ an array of about 250 scolopale cells (also called “chordotonal 
sensillia”) is present which are involved in signal transduction. Each scolopale 
cell is part of an entity called scalopidium. Each scolopidium is built up by 
a scolopale cell, a ligament and a cap cell which are in charge of the scolopidium 
basal and apical attachments, respectively (Figure 4). Besides the scolopidium 
also contains actin- and microtubule-rich scolopale rods (supporting cells) 
and ciliated sensory dendrites of two or three mechanosensory neurons 
(Figure 4).110,111 A near-field sound causes the deflection of the arista and 
consequently the rotation of the a2-a3 joint occurs making the scolopidium in 
the Johnston’s organ to stretch (Figure 4). Afterwards, an influx of potassium 
Figure 3. Organs of hearing and equilibrium in larval zebrafish. A. Drawing of a zebrafish larvae 
indicating the lateral line organ, the utricle and saccule. B. A schematic representation of the saccule 
and utricle in larval zebrafish. C. Diagram of the adult zebrafish ear in which the utricle, the saccule 
and the lagena are shown.
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occurs into the scolopidium triggering the depolarization of the mechanosensory 
neurons whose axons aggregate to form the antennal nerve to carry peripheral 
sound information to the auditory center of the brain (Figure 4).110,111 The 
depolarisation of the scolopidium is thus dependent on the potassium ion-rich 
fluid, the counterpart of the endolymph in humans, that embeds these sensory 
cells.112 The molecular details of the mechanotransduction channels involved in 
this process have not yet been fully elucidated. 
 Senthilan et al. (2012) employed an ato-based knockout strategy to compare 
gene expression profiles in the Drosophila Johnston’s organ. The ato gene 
encodes the atonal transcription factor. In Drosophila, ato is involved in the 
development of mechanosensitive neurons. In contrast, in vertebrates the Atoh1 
signaling pathway is not involved in the development of sensory neurons but 
in the development of the inner ear hair cells, the lateral line and the touch-
sensitive cells in the skin.113 Senthilan et al. (2012) reported that 89 of the 274 
genes expressed in the Johnston’s organ genes have vertebrate homologs and 
some of them are found to be expressed in vertebrate inner ears.31 Therefore, 
genes found to be relevant for the auditory function in Drosophila are to be 
considered good candidates for explaining HI in humans. 
 Finally, using Drosophila as a model organism has advantages such as fast 
generation time, low cost, high conservation of genes and pathways and an 
excellent genetic toolbox.
IMPACT OF MY RESEARCH ON SOCIETY
The primary aim of my PhD project was the identification of genes involved 
in HI and to provide insight into the molecular pathways and protein networks 
important in the process of hearing. The results obtained during my project 
have a significant impact on society both on the short and long terms. On the 
short term, the genes identified during my project were immediately translated 
into patient care in our DNA diagnostics division which is the main reference 
center for HI in the Netherlands. An enhanced knowledge on genetics, 
molecular mechanisms and phenotypes will allow a proper genetic diagnosis 
and subsequent counselling of the patients and their families.114 In the long 
term, most of the genetic therapies that are currently being developed have the 
prerequisite to know the underlying genetic defect. To apply genetic therapies, 
the HI in the patients should be progressive and starting after birth and not 
congenital profound suggesting a developmental defect in the auditory system. 
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Figure 4. Organ of hearing of Drosophila. A. Sketch of the fly’s antenna showing the three segments 
(a1, a2 and a3). The scalopidium in the Johnston’s organ is shown in red B. Sketch of a scolopidium 
depicting the different cell types. (Figure derived from and published with permission of Seol-hee).
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For the latter cases, cochlear implants and hearing aids are solutions that may 
improve the quality of life of the patients.114,115 Regarding genetic therapies, 
several attempts aiming at preventing or reversing HI have been undertaken in 
mouse models.116 Depending on both the type and the molecular mechanism of 
the mutated protein, the approaches are different: for loss of function (recessive) 
mutations, the genetic therapy should add a functional gene copy e.g. by viral 
delivery of the gene copy in the cochlea.117,118 Akil et al. (2012) delivered a wild 
type copy of Slc17a8 to the cochlea of knockout Slc17a8 mice by using AAV1 
and were able to restore the hearing in these mutant mice for more than a year.117 
In case of heterozygous (dominant) mutations the effect of which could also be 
gain of function or a dominant negative effect, the genetic therapy should aim 
at silencing the aberrant gene copy to enable the wild type allele to fulfil its 
function e.g. by silencing an allele by siRNA.119,120 Maeda et al. (2005) reported 
a successful attempt of hearing restoration in mice carrying the dominant 
negative mutation p.Arg75Trp in GJB2 by suppressing the expression of the 
mutant copy up to 70% by siRNA.121 Besides genetic therapies, regenerative 
therapies targeting hair cells are also being explored with so far less promising 
results.122 Most genes linked to HI are expressed in hair cells therefore these 
cells are the main target for regenerative therapies. One approach is to transplant 
embryonic stem cells or iPSCs into the inner ear to replace the lost hair cells; 
another approach is to express ATOH1 in the cochlea in order to induce the 
formation of hair cells. 
 In summary, unravelling the genetic defects underlying HI in humans improves 
the genetic diagnostics of HI families. Besides, knowing the genetic defect has 
a positive impact on their quality of life because (genetic) therapy or treatment 
possibilities can be assessed in the future (personalized medicine).123 Last but 
not least, genetic therapy attempts in mouse models are giving hope to prevent 
HI and restore hearing in humans in the near future. 
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Hearing impairment (HI) is the most common sensory disorder. In developed 
countries, approximately one in 750 newborns presents with HI at birth or 
develop HI shortly after birth. The factors that contribute to the development 
of HI are very diverse. Environmental factors such as viral infections during 
pregnancy, noise exposure and ototoxic medications, can explain about half 
of the cases. The other half can be explained by pathogenic genetic variants. 
Hereditary HI can be non-syndromic (NSHI) when only the hearing function is 
affected, occurring in 70% of the prelingual cases; or syndromic (SHI) when the 
HI is accompanied by other clinical phenotype(s) which occurs in the remaining 
30%. The most prevalent syndromes with HI are Usher syndrome, which is 
characterized by HI and retinitis pigmentosa, and Waardenburg syndrome (WS) 
which is characterized by HI and pigmentation abnormalities. Besides these, 
there are over 400 syndromes known in which HI is associated with a broad 
range of other clinical features, e.g. sensory neuropathy and dystonia as shown 
in chapter 6. 
To date, there are more than a hundred genes known to be involved in NSHI as 
presented in chapter 1. Despite this large genetic heterogeneity, in many of the 
patients the genetic defect underlying HI is still unknown. Therefore, during the 
course of this thesis project, we aimed at resolving the genetic etiology of HI to 
ultimately provide patients with an adequate genetic diagnosis and, in the long 
term, with an appropriate (genetic) therapy. 
 In chapter 1, a general introduction about the auditory system, the genetic 
heterogeneity of HI and the strategies for gene identification used in this thesis 
are described. 
Autosomal recessively inherited NSHI (arNSHI) is the most common form 
accounting for about 77% of hereditary prelingual cases with HI. SNP 
genotyping is a robust method to identify homozygous (homozygosity mapping) 
and compound heterozygous alleles (shared genotyping) in inbred and outbred 
populations. This strategy in combination with Sanger sequencing of the most 
promising candidate genes resulted in the identification of mutations in two 
novel arNSHI genes, OTOGL (chapter 2) and CLIC5 (chapter 3), and in 
mutations in a gene already known to be involved in arNSHI, CIB2 (chapter 4). 
In chapter 2, we described the identification of compound heterozygous 
mutations in OTOGL, c.547C>T (NM_173591.3; p.(Arg183Ter)) and 
c.5238+5G>A, in a Dutch family; and a homozygous truncating mutation, 
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c.1430delT (p.(Val477Glufs*25)), in a family of Turkish origin. These mutations 
were segregating with the congenital moderate mid-frequency HI present in each 
family. We demonstrate that Otogl was located in all the acellular membranes 
of the mouse inner ear and that knock down of Otogl expression in zebrafish 
resulted in reduced inner ear microphonic potentials, supporting the involvement 
of OTOGL mutations in the human phenotype. 
Chapter 3 is about the identification of a homozygous truncating mutation, 
c.96T>A (NM_016929.3; p.(Cys32Ter)), in CLIC5 underlying the progressive 
HI and vestibular areflexia in two sibs from Turkey. The orthologous mouse 
gene, Clic5, described to be mutated in the jitterbug (jbg) mouse, exhibited a 
similar phenotype as seen in the presented family: congenital progressive HI 
and vestibular dysfunction, due to progressive hair cell degeneration. One of the 
affected sibs also presented with very mild renal dysfunction. This might well 
be due to the CLIC5 mutations since the jbg mice have abnormalities in kidney 
podocytes leading to proteinuria. Therefore, renal function of the affected sibs 
will be monitored in future. 
In chapter 4, three different mutations in CIB2 are described that are causative 
for severe to profound arNSHI: 1) a homozygous founder mutation, c.272T>C 
(NM_006383.3; p.(Phe91Ser)), in two Pakistani families; 2) a homozygous 
mutation, c.196C>T (p.(Arg66Trp)) in a Dutch family and 3) compound 
heterozygous mutations, c.97C>T (p.(Arg33Ter)) and c.196C>T (p.(Arg66Trp)), 
in another Dutch family. We demonstrated that the missense mutations do 
neither affect either the subcellular localization of Cib2 in mouse vestibular 
hair cells nor the ATP-induced calcium responses in COS-7 cells. Mutations 
in CIB2 are also the underlying cause of Usher syndrome 1J, however, the 
patients described in chapter 4 did not show any signs of retinitis pigmentosa 
or vestibular dysfunction. Our results contribute to the insight in genotype-
phenotype correlations of CIB2 mutations.
Autosomal dominantly inherited NSHI (adNSHI) accounts for about 22% of the 
hereditary prelingual cases with HI. In chapter 5, we described a large family 
from the Netherlands with autosomal dominant non-syndromic unilateral and 
asymmetric hearing impairment (NS-UHI/AHI). By performing linkage analysis 
and whole-exome sequencing (WES) we identified a heterozygous nonsense 
mutation, c.286_303delinsT (NM_000899.4; p.Ser96Ter), in KITLG that was 
segregating with the disease with reduced penetrance. KITLG encodes the ligand 
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of the KIT receptor. KIT-KITLG interaction triggers a pathway involved in the 
development of melanocytes which seems to be ultimately connected to MITF. 
Mutations in MITF are associated with Waardenburg syndrome type II (WS II). 
Therefore, we screened two different panels of probands with NS-UHI/AHI and 
WS II for mutations in KITLG. We found a heterozygous mutation, c.200_202del 
(p.His67_Cys68delinsArg), in KITLG to be causative of NS-UHI/AHI in a family of 
Spanish origin and a heterozygous c.310C>G  (p.Leu104Val) mutation underlying 
WS II in a small family of Dutch origin. We evaluated the impact of these mutations 
on both protein isoforms of KITLG, the secreted soluble and the transmembrane 
isoforms. The p.His67_Cys68delinsArg transmembraneous KITLG could not reach 
the membrane as the wild type KITLG does and the secreted soluble p.His67_
Cys68delinsArg KITLG could not be detected in culture medium of transfected 
cells. In contrast, the p.Leu104Val transmembraneous KITLG was incorporated 
into the membrane but reduced levels of the p.Leu104Val soluble KITLG were 
secreted into the culture medium as compared to wild type. These data suggest 
that the p.Ser96Ter and p.His67_Cys68delinsArg mutations underlying NS-UHI/
AHI are loss-of-function mutations whereas the p.Leu104Val mutation possibly 
has a dominant negative or gain of function effect on KITLG. In conclusion, we 
demonstrated that KITLG is the first gene known to be mutated in NS-UHI/AHI 
and that allelic mutations in KITLG can also result in WS II adding KITLG to the 
group of genes associated with hypopigmentation-deafness disorders.
The auditory organ is very complex and many of the proteins encoded by HI genes 
also have a role in other organs. Therefore, it comes as no surprise that there are 
numerous syndromes with HI described to date. In chapter 6, we presented a novel 
syndrome characterized by a combination of HI, sensory neuropathy and dystonia. 
Homozygosity mapping and WES revealed a homozygous nonsense mutation, 
c.4G>T (NM_001080472.1; p.Glu2Ter), in FITM2, a member of a protein family 
involved in lipid storage and metabolism. By using conditional gene ablations by 
RNAi in Drosophila melanogaster, we demonstrated that the human phenotype is 
recapitulated in flies. By using the island test, it was demonstrated that locomotion 
of the flies was progressively impaired as it is in the patients. The sensory neural 
phenotype of the patients was recapitulated by the aberrant morphology of sensory 
type IV neurons in Drosophila. Moreover, we evaluated the hearing of flies upon 
RNAi which presented a loss of electrical responses and mechanical amplification 
in the Johnston’s organ indicative of sensorineural HI. Furthermore, lipid storage 
seems to be disturbed which is in line with a function of the human ortholog in 
lipid storage.
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In chapter 7, the efficacy of WES for the genetic diagnosis of 200 individuals 
with HI was investigated. The obtained diagnostic yield of WES was greater 
than that of predictive single gene testing based on the HI phenotype (29.5% vs 
7.6%). In our cohort we found that mutations in GJB2, STRC, USH2A, MYO15A 
and MYO6 underlined the HI in ~14% of the cases, therefore we suggested that it 
would be cost-effective, at least in our population, to pre-screen these genes by 
using novel cost-effective technologies, e.g. molecular inversion probes, before 
WES. 
In chapter 8, the findings, challenges and implications on health care described 
within this thesis are discussed. 
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Gehoorverlies is de meest voorkomende sensorische beperking. In ontwikkelde 
landen heeft één op de 750 pasgeborenen gehoorverlies of ontwikkelt zij of hij dit 
kort na de geboorte. De factoren die bijdragen aan het ontstaan van gehoorverlies zijn 
erg divers. Omgevingsfactoren, zoals virale infecties gedurende de zwangerschap 
en ototoxische medicatie, kunnen de helft van de gevallen verklaren. De andere helft 
kan verklaard worden door pathogene genetische varianten. Erfelijk gehoorverlies 
is niet-syndromaal wanneer alleen het gehoor is aangedaan en dit komt voor 
bij 70% van de prelinguale gevallen. Gehoorverlies is syndromaal wanneer het 
gepaard gaat met andere klinische kenmerken, wat voorkomt in de overige 30% 
van de gevallen. Twee van de meest voorkomende syndromen met gehoorverlies 
zijn Usher syndroom, gekenmerkt door gehoorverlies en retinitis pigmentosa, 
en Waardenburg syndroom, gekenmerkt door gehoorverlies en pigmentatie-
afwijkingen. Naast deze syndromen zijn er meer dan 400 syndromen bekend 
waarbij het gehoorverlies gepaard gaat met een breed scala aan andere klinische 
eigenschappen, zoals sensorische neuropathie en dystonie zoals beschreven in 
hoofdstuk 6.
Momenteel zijn er meer dan honderd genen bekend die betrokken zijn bij niet-
syndromaal gehoorverlies, zoals beschreven in hoofdstuk 1. Ondanks deze grote 
genetische heterogeniteit is in veel van de patiënten het onderliggend genetische 
defect nog onbekend. Daarom was het doel van deze thesis het ontrafelen van de 
genetische etiologie van gehoorverlies om uiteindelijk te komen tot een adequate 
genetische diagnose voor de patiënten en, op lange termijn, een toepasbare 
(genetische) therapie.
Hoofdstuk 1 omvat een algemene inleiding van het auditieve systeem, de 
genetische heterogeniteit van gehoorverlies en de strategieën die zijn gebruikt voor 
genidentificatie in dit proefschrift.
Autosomaal recessief overervend niet-syndromaal gehoorverlies (arNSHI) is de 
meest voorkomende vorm van gehoorverlies en omvat ongeveer 77% van de erfelijke 
prelinguale gevallen van niet-syndromaal gehoorverlies. SNP-genotypering 
is een robuuste methode om homozygote en compound heterozygote allelen te 
identificeren in consanguine en niet-consanguine populaties. Deze strategie in 
combinatie met sequentie-analyse van de meest veelbelovende kandidaatgenen 
hebben geresulteerd in de identificatie van mutaties in twee nieuwe genen voor 
arNSHI, OTOGL (hoofdstuk 2) en CLIC5 (hoofdstuk 3), en in mutaties in een gen 
dat al bekend was betrokken te zijn bij arNSHI, CIB2 (hoofdstuk 4).
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In hoofdstuk 2 wordt de identificatie van compound heterozygote mutaties 
in OTOGL beschreven. De c.547C>T (NM_173591.3; p.(Arg183Ter)) en 
c.5238+5G>A mutaties werden gevonden in een Nederlandse familie en een 
homozygote truncerende mutatie, c.1430delT (p.(Val477Glufs*25)) werd 
geïdentificeerd in een familie van Turkse afkomst. Deze mutaties erfden 
over met het aangeboren matige mid-frequentie gehoorverlies in de families. 
We tonen aan dat Otogl aanwezig is in alle acellulaire membranen van het 
binnenoor in de muis en dat verminderde expressie van Otogl in de zebravis 
resulteert in een afname van elektrische potentialen in het binnenoor. Deze 
resultaten ondersteunen de bevinding dat mutaties in OTOGL betrokken zijn bij 
het humane fenotype.
Hoofdstuk 3 beschrijft de identificatie van een homozygote truncerende 
mutatie, c.96T>A (NM_016929.3; p.(Cys32Ter)), in CLIC5 als oorzaak van 
progressief gehoorverlies en vestibulaire areflexie in een broer en zus van 
Turkse afkomst. Het orthologe gen in de muis, Clic5, is gemuteerd in de jitterbug 
(jbg) muis, die een vergelijkbaar fenotype vertoont als de beschreven familie: 
aangeboren progressief gehoorverlies en vestibulaire afwijkingen ten gevolge 
van progressief haarcelsterfte. Een van de aangedane personen had ook een zeer 
milde nierfunctiestoornis. Dit zou mogelijk veroorzaakt kunnen worden door 
de CLIC5 mutatie, omdat jbg muizen afwijkingen vertonen in de podocyten 
die leiden tot proteïnurie. Daarom zal in de toekomst de nierfunctie van de 
aangedane personen gevolgd worden.
In hoofdstuk 4, worden drie verschillende mutaties in CIB2 beschreven 
die  ernstig tot zeer ernstig autosomaal recessief overervend gehoorverlies 
veroorzaken: 1) een homozygote foundermutatie, c.272T>C (NM_006383.3; 
p.(Phe91Ser)), in twee Pakistaanse families; 2) een homozygote mutatie, 
c.196C>T (p.(Arg66Trp)), in een Nederlandse familie en 3) compound 
heterozygote mutaties, c.97C>T (p.(Arg33Ter)) en c.196C>T (p.(Arg66Trp)), 
in een tweede Nederlandse familie. We hebben aangetoond dat mutaties die 
leiden tot aminozuurveranderingen in CIB2 geen effect hebben op de cellulaire 
lokalisatie van het eiwit in vestibulaire haarcellen van de muis en ook niet op 
de door ATP geïnduceerde calciumreacties in COS-7 cellen. Mutaties in CIB2 
zijn ook beschreven als onderliggende oorzaak van Usher syndroom 1J, hoewel 
de patiënten beschreven in hoofdstuk 4 geen tekenen hadden van retinitis 
pigmentosa of vestibulaire problemen. Onze resultaten dragen bij aan inzicht in 
genotype-fenotype correlaties van CIB2 mutaties.
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Autosomaal dominant overervende niet-syndromale slechthorendheid is goed 
voor ongeveer 22% van de gevallen met erfelijk prelinguaal gehoorverlies. 
In hoofdstuk 5 is een grote Nederlandse familie beschreven met autosomaal 
dominant niet-syndromaal unilateraal en asymmetrisch gehoorverlies. Door 
linkage analyse te combineren met sequentie-analyse van het hele exoom 
(WES) hebben we een heterozygote truncerende mutatie, c.286_303delinsT 
(NM_000899.4; p.Ser96Ter), in KITLG gevonden die met een verminderde 
penetrantie segregeert met de ziekte binnen de familie. KITLG codeert voor 
de ligand van de KIT receptor. De interactie tussen KIT en KITLG activeert 
een cascade betrokken bij de ontwikkeling van melanocyten die uiteindelijk 
leidt naar MITF. Mutaties in MITF zijn geassocieerd met Waardenburg 
syndroom type II (WS II). Daarom, hebben we twee verschillende cohorten van 
indexpatiënten met niet-syndromaal unilateraal/asymmetrisch gehoorverlies en 
WS II onderzocht op mutaties in KITLG. We hebben hiermee een heterozygote 
mutatie, c.200_202del (p.His67_Cys68delinsArg), in KITLG geïdentificeerd 
als oorzaak van niet-syndromaal unilateraal/asymmetrisch gehoorverlies in 
een Spaanse familie en een heterozygote c.310C>G (p.Leu104Val) mutatie 
in een Nederlandse WS II familie. We hebben het effect onderzocht van deze 
mutaties op beide isovormen van KITLG, de uitgescheiden en oplosbare en de 
membraangebonden isovorm. Het membraangebonden p.His67_Cys68delinsArg 
KITLG kon, in tegenstelling tot het wildtype eiwit, het membraan niet bereiken 
en het uitgescheiden oplosbare p.His67_Cys68delinsArg KITLG kon niet 
worden gedetecteerd in het kweekmedium van getransfecteerde cellen. Het 
membraangebonden p.Leu104Val KITLG werd daarentegen wel aangetoond in 
het membraan, maar de concentratie van het p.Leu104Val oplosbare KITLG was 
lager in vergelijking met het wildtype eiwit in het kweekmedium. Resultaten 
laten zien dat de p.Ser96Ter en p.His67_Cys68delinsArg mutaties leiden tot 
een verlies van de normale functie van KITLG, terwijl de p.Leu104Val mutatie 
mogelijk een dominant negatief effect heeft op de werking van KITLG of leidt 
tot een anderszins veranderde functie van het eiwit. Concluderend kunnen we 
zeggen dat we hebben aangetoond dat KITLG het eerste gen is waarin mutaties 
leiden tot niet-syndromaal unilateraal/asymmetrisch gehoorverlies en dat 
mutaties in KITLG ook kunnen leiden tot WS II; dit voegt KITLG toe aan de 
groep genen geassocieerd met hypopigmentatie-doofheidsaandoeningen.
Het auditieve orgaan is zeer complex en veel van de eiwitten die gecodeerd 
worden door doofheidsgenen hebben ook een rol in andere organen. Daarom, is 
het geen verrassing dat er al talloze syndromen zijn beschreven met gehoorverlies 
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als een van de symptomen. In hoofdstuk 6 presenteren we een nieuw syndroom 
dat gekenmerkt wordt door een combinatie van gehoorverlies, sensorische 
neuropathie en dystonie. Het bepalen van de homozygote regio’s en WES 
toonden een homozygote mutatie aan, c.4G>T (NM_001080472.1; p.Glu2Ter), 
in FITM2, dat deel uitmaakt van een eiwitfamilie die betrokken is bij het 
opslaan van triacylglyceriden bij het lipidmetabolisme. Via RNAi in Drosophila 
melanogaster, hebben we aangetoond dat het humane fenotype en het fenotype 
van de fruitvlieg overlappen. Met behulp van de eilandtest werd aangetoond 
dat de motorische functie van de vliegen progressief vermindert zoals dit ook 
gezien wordt in de patiënten. Het sensorineurale fenotype van de patiënten zien 
we terug in de afwijkende morfologie van de type IV sensorische neuronen 
in Drosophila. Ook, hebben we het gehoor van de fruitvliegen onderzocht na 
RNAi waarbij een verlies van elektrische reacties en mechanische amplificatie 
in het Johnston’s orgaan werd gevonden wat indicatief is voor sensorineuraal 
gehoorverlies. Verder, lijkt de opslag van triacylglyceriden verstoord wat in lijn 
is met de functie van het FITM2 gen.
In hoofdstuk 7 werd de doelmatigheid van WES voor genetische diagnostiek 
onderzocht voor een cohort van 200 personen met gehoorverlies. De behaalde 
diagnostische opbrengst van WES was groter dan die van het testen van enkele 
genen die geselecteerd zijn op basis van het type gehoorverlies (29% versus 
7.6%). In het WES-cohort waren mutaties in GJB2, STRC, USH2A, MYO15A 
and MYO6 de oorzaak van het gehoorverlies in ~14% van de gevallen. Daarom 
concluderen we dat het kostenbesparend zou zijn, tenminste in onze populatie, 
om deze genen te analyseren met nieuwe kosteneffectieve technieken, zoals 
‘molecular inversion probes’, voordat wordt overgegaan tot WES.
In hoofdstuk 8, worden de resultaten van het onderzoek beschreven in deze 
thesis in een breder kader geplaatst en worden uitdagingen voor de toekomst en 
gevolgen voor de medische genetica besproken.
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